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5ABSTRACT
Background 
An elevated homocysteine level has been indicated as a risk factor for cardiovascular disease, 
cognitive decline, and fractures. Supplementation of vitamin B12 and folic acid in order to normalize 
homocysteine levels might be of substantial public health importance as this might reduce the risk 
for several age-related conditions. This thesis focuses on two health outcomes frequently associated 
with elevated homocysteine levels and low levels of vitamin B12 and folate: osteoporosis and cognitive 
decline later in life.
Methods 
Findings are presented in the context of a model which links dietary intake to biomarkers of nutritional 
status and subsequently to health outcomes. Two systematic reviews with meta-analyses investigated 
the current status of knowledge about the association of vitamin B12 intake and status with cognitive 
function, and the association of homocysteine, vitamin B12 and folate status with bone health. Baseline 
data of the B-PROOF study were used to assess 1) the association of vitamin B12 intake with status 
according to four biomarkers (vitamin B12, holotranscobalamin (holoTC), methylmalonic acid 
(MMA) and homocysteine), 2) the mutual association among these four vitamin B12 biomarkers and 
3) the association between homocysteine, vitamin B12 biomarkers, folate and cognitive function. The 
effect of 2-year daily vitamin B12 (500 μg) and folic acid (400 μg) supplementation on fracture risk was 
assessed in the B-PROOF study, a large (N=2919) randomized controlled trial in elderly people (aged 
≥65 years) with an elevated homocysteine level (≥12.0 µmol/L).
Results 
The systematic review of the literature showed no or inconsistent associations of vitamin B12 intake 
with cognitive function. Furthermore, serum vitamin B12 was not associated with risk of dementia, 
global cognition or memory. Studies on MMA and holoTC reported significant associations with risk 
of dementia, Alzheimer’s disease and global cognition. A meta-analysis showed that serum/plasma 
vitamin B12 per 50 pmol/L was borderline significantly associated with a lower fracture risk (RR=0.96, 
95% CI = 0.92-1.00) and that homocysteine was significantly associated with a higher fracture risk 
(RR=1.04, 95% CI = 1.02-1.07). Meta-analyses regarding vitamin B12, folate and homocysteine levels 
and BMD did not show significant associations.  
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In the B-PROOF study a doubling of vitamin B12 intake was associated with 9% higher levels of vitamin 
B12, 15% higher holoTC, 9% lower MMA and 2% lower homocysteine, saturation of biomarkers occurs 
with dietary intakes of >5 μg B12. Levels of MMA and homocysteine were higher when vitamin B12 
levels were below 330 pmol/L and when holoTC levels were below 100 pmol/L, with a steep elevation 
when levels of vitamin B12 and HoloTC were below 220 and 50 pmol/L respectively. At baseline, levels 
of vitamin B12 and holoTC were not associated with cognitive function in any cognitive domain. Levels 
of homocysteine (β= -0.009), folate (β= 0.002), MMA (β= -0.163) and the wellness score – a vitamin 
B12 biomarker combination score - (β= 0.048) were significantly associated with the domain of episodic 
memory. Additionally, homocysteine (β= -0.015) and the wellness score (β= 0.103) were significantly 
associated with the domain information processing speed. 
The B-PROOF intervention did not lower the risk of fracture in the total population (HR=0.84, 95% 
CI = 0.58-1.22).  Per protocol subgroup analysis of elderly aged >80 years, showed a lower risk of 
fracture in the intervention group (HR=0.28, 95% CI 0.10-0.74). We observed more cancer cases in 
the intervention group (HR=1.55, 95% CI = 1.04-2.30) compared to the placebo group. We cannot 
rule out the possibility of accelerated cancer progression as a possible negative side effect.
Conclusion 
Our literature reviews and observational data confirm an association of levels of homocysteine, vitamin 
B12 and folate with cognitive function and fracture risk in elderly. Supplementation with vitamin B12 
and folic acid did not lower the risk of fracture in the total study population. Though positive effects 
on fracture incidence emerged in elderly aged >80 years, these benefits should be weighed against 
potential risks. 
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The world population is ageing rapidly. The number of people aged 65 years or older in the Netherlands 
is expected to grow from 2.6 million in 2010 to 4.5 million in 2050 [1], and worldwide from about 810 
million in 2012 to more than 2 billion in 2050, or 22% of the total world population [2]. With ageing, 
the prevalence of age-related diseases and disabilities increases, together with the subsequent burden 
to individuals and society. Strategies to prevent or treat age-related disabilities are therefore important 
for public health. The maintenance of an optimal nutritional status and interventions to improve 
nutritional status may contribute to the health and well-being of the elderly and could therefore be 
included in these strategies. 
Elevated homocysteine levels are prevalent in 30-50% of Dutch elderly people [3-5], mainly due to 
low vitamin B12 and folate status. An elevated homocysteine level has been indicated as a risk factor for 
cardiovascular disease, cognitive decline, and fractures [6]. Supplementation of vitamin B12 and folic 
acid in order to normalize homocysteine levels might be of substantial public health importance as 
this could theoretically reduce the risk of several age-related conditions. In this thesis we focus on two 
health outcomes frequently associated with elevated homocysteine levels and low levels of vitamin B12 
and folate with great public health importance in elderly: osteoporosis and cognitive decline.
HoMoCySTeine MeTABoliSM And RelATed B-viTAMinS
Homocysteine
Homocysteine is a sulphur-containing amino acid which is formed during catabolism of the essential 
amino acid methionine as a product of numerous transmethylation reactions. Methionine is converted to 
S-adenosylmethionine (SAM), an important donor of methyl groups, which is subsequently demethylated 
to S-adenosylhomocysteine (SAH), which is then hydrolyzed to homocysteine (Figure 1). Homocysteine 
plays a central role in two metabolic pathways: remethylation and transsulfuration. In the remethylation 
pathway homocysteine is remethylated to methionine, a reaction catalyzed by methionine synthase, which 
uses vitamin B12 (cobalamin) as a co-factor and 5-methyl-tetrahydrofolate (5-MTHF) as a methyl donor. 
This remethylation takes place in most tissues. In the liver and kidneys, homocysteine is also remethylated 
by betaine-homocysteine methyl transferase which uses betaine as a methyl donor. In the transsulfuration 
pathway, limited to the liver and kidneys, homocysteine is irreversibly converted to cystathionine by 
cystathionine β-synthase, which requires vitamin B6 (pyridoxine) as a co-factor. Cystathionine is further 
hydrolysed by gamma-cystathionase to cysteine [6-8].
Levels of homocysteine are mainly determined by age, sex and renal function: homocysteine levels increase 
with age, men have higher levels than women and an impaired renal function raises homocysteine levels 
[9]. Furthermore, levels of homocysteine largely depend on the B-vitamins required in the homocysteine 
metabolism.  Dietary intake and status of vitamin B12 and folate, but also of vitamin B2 and B6 are inversely 
associated with homocysteine levels. The MTHFR 677C>T polymorphism is associated with reduced 
MTHFR enzyme activity [10], resulting in about 25% higher homocysteine levels in individuals with the TT 
genotype in comparison to individuals with the CC genotype [11].
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Figure 1. Schematic representation of the folate cycles and homocysteine metabolism. Hcy: homocysteine, 5-MTHF: 
5-methyl-tetrahydrofolate, 5,10 MTHF: 5,10-methylene-tetrahydrofolate, SAH: S-adenosylhomocysteine, SAM: 
S-adenosylmethionine, THF: tetrahydrofolate Enzymes: BHMT: betaine-homocysteine methyltransferase, 
CBS: cystathionine β-synthase, CTH: cystathionine γ-lyase,  MAT: methionine-adenosyltransferase, MS: 
methionine synthase, MT:  methyltransferases, MTHFR: methylenetetrahydrofolate reductase, SAHH: 
S-adenosylhomocysteine hydrolase, SHMT: serine-hydroxymethyltransferase, B-vitamins as co-factor: B2: 
riboflavin ( as FAD: flavin adenine dinucleotide), B6: pyridoxine, B12: cobalamin 
 
Homocysteine and cardiovascular disease 
Homocystinuria is a rare disease caused by inborn errors in the homocysteine metabolism, leading to 
severely elevated homocysteine levels. In the 1960s it was discovered that patients with homocystinuria 
suffered, among other symptoms, from arterial damage. Concluding from this observation, McCully 
postulated the ‘homocysteine theory’: the theory that homocysteine or one of its derivatives is toxic 
for the vascular wall [12]. 
In the following decades observational research indicated elevated homocysteine levels as an 
independent risk factor for cardiovascular diseases [13]. However, evidence from homocysteine-
lowering intervention studies with clinical endpoints was lacking for a long time, frustrating the 
discussion about the causal relation between homocysteine and cardiovascular disease. 
When finally, in the course of the first decade of the 21st century, the results of large intervention trials 
– predominantly secondary prevention trials – were published, they were somewhat disappointing, 
as none of the interventions showed an overall preventive effect of lowering homocysteine levels with 
B-vitamins on cardiovascular health outcomes [14-22].
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In addition, a meta-analysis of 12 randomized controlled trials, including the above mentioned trials, 
involving a total of 47,429 participants showed no effect of homocysteine lowering intervention on 
non-fatal myocardial infarction (pooled RR 1.02 (95% confidence interval 0.95;1.10), stroke (pooled 
RR 0.91, 95% CI 0.82;1.01) or death by any cause (pooled RR 1.01 (95% CI 0.96-1.07) [23]. Yet, 
the effect of folic acid on stroke is equivocal as some studies observed a protective effect of folic acid 
supplementation on stroke [24].
The failure of well-designed intervention studies to confirm homocysteine as a causal risk factor for 
cardiovascular disease destabilizes the homocysteine theory. To date, there is still no consensus whether 
elevated levels of homocysteine are the true cause of the observed negative health effects, or low levels 
of vitamin B12 or folate, renal insufficiency or another, yet unknown cause.  
Next to cardiovascular diseases, research was extended to other health outcomes. Associations of 
elevated homocysteine levels were observed with, among others, increased fracture risk, impaired 
cognitive function and Alzheimer’s disease in several observational studies [6, 25-28].
vitamin B12
Vitamin B12 is a water soluble vitamin, present mainly in foods of animal origin, such as meat, fish, 
eggs, liver, shellfish and dairy products. Vitamin B12 is essential for the development and myelination 
of the central nervous system and maintenance of its normal function. Besides its role as a cofactor for 
methionine synthase (Figure 1), vitamin B12 also acts as a cofactor for methylmalonyl coenzyme A 
(CoA) mutase, which catalyzes the conversion of methylmalonyl-CoA into succinyl CoA. In vitamin 
B12 deficiency the metabolites homocysteine and methylmalonic acid (MMA) accumulate. 
Vitamin B12 deficiency is common in elderly, with a prevalence of marginal vitamin B12 status around 
20% [29, 30]. Symptoms of vitamin B12 deficiency include haematological effects like megaloblastic 
anemia, gastrointestinal effects like glossitis and neurological manifestations such as peripheral 
neuropathy, myelopathy, subacute combined degeneration, delirium, depression, behavioural disorders 
and cognitive impairment [31-33]. The diagnosis of clinical vitamin B12 deficiency was originally based 
on the presence of severe megaloblastic anaemia combined with neuropsychological symptoms, 
but Lindenbaum et al. have showed that neurological symptoms such as cognitive impairment also 
occurred in the absence of haematological signs [34]. Currently, vitamin B12 deficiency is determined 
by measuring biomarkers of vitamin B12 status, although there is no consensus about the best biomarker 
or biomarkers and accompanying cut-off values [35-37].   
Vitamin B12 status can be evaluated by serum or plasma total vitamin B12 (total B12) levels, 
holotranscobalamin (holoTC) and the metabolites homocysteine and MMA [38]. Total B12 is most 
commonly used as a marker for vitamin B12 status, although MMA is considered a better marker, yet 
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more expensive and therefore not regularly measured [35, 38, 39]. HoloTC is the fraction of circulating 
vitamin B12 that can be taken up by the cells, and is considered as an early marker for vitamin B12 
deficiency [40]. HoloTC is a relatively new marker and currently not widely used in clinical practice 
[40, 41]. Homocysteine levels are, though a sensitive marker, not specific for vitamin B12 deficiency, 
since homocysteine levels are not only affected by vitamin B12 status, but also, among others, by folate 
status [38, 42]. 
folate and folic acid
Folate is a vitamin present in many food items, such as green leafy vegetables, fruits, meat and dairy 
products. Folate is a generic term for a family of compounds including folates naturally occurring in 
foods, and folic acid, a synthetic form used in food fortification and supplements. Folate accepts and 
donates one-carbon groups, which makes it important for DNA synthesis, DNA methylation and for 
the conversion of amino acids, such as in the homocysteine metabolism [7]. Folate from the diet is 
metabolized to 5-methyl-tetrahydrofolate (5-MTHF) which acts as a methyl donor in the homocysteine 
metabolism (Figure 1). In the conversion of 5,10-methylene-tetrahydrofolate (5,10-MTHF) to 
5-MTHF by the enzyme methylene tetrahydrofolate reductase (MTHFR), another B-vitamin, vitamin 
B2 (riboflavin), plays a role since flavin adenine dinucleotide (FAD), a metabolite of vitamin B2, serves 
as a cofactor for MTHFR [8]. 
High intakes of folic acid around the conception have been shown to reduce the risk of congenital neural 
tube defects [43, 44]. To ensure a sufficient folate status for women of childbearing age, the fortification 
of flour with folic acid is nowadays mandatory in over 60 countries worldwide [45]. In the Netherlands, 
there is up to now no mandatory fortification with folic acid, though several food products, such as 
breakfast cereals, are fortified. Women who have a wish to become pregnant are advised to take a daily 
supplement with 400 µg of folic acid periconceptionally [46].  
Folate status can be evaluated by measuring folate in serum or in erythrocytes. It is generally established 
that serum folate reflects short-term folate intake, and erythrocyte folate reflects long-term intake 
[47], but serum folate levels are nowadays acknowledged as an adequate marker for folate status in 
epidemiological studies [48].        
Supplementation with folic acid is highly effective in lowering homocysteine levels (25% decrease) 
[49], but the intake of high doses of folic acid alleviates vitamin B12-related anaemia and may therefore 
delay the diagnosis of vitamin B12 deficiency [50]. As vitamin B12 deficiency is common in elderly 
the addition of vitamin B12 next to folic acid supplementation could be recommended. Vitamin B12 
supplementation contributes further to the lowering of homocysteine levels with an additional 7% [49, 
51]. The addition of vitamin B6 next to folic acid and vitamin B12 supplementation does not contribute 
further to lowering homocysteine levels [49]. We therefore focus in this thesis on homocysteine, 
vitamin B12 and folate.
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Age-RelATed HeAlTH ouTCoMeS: oSTeopoRoSiS And 
CogniTive deCline
osteoporosis 
Osteoporosis is a chronic, multifactorial disorder which is characterized by low bone mass and 
micro- architectural deterioration of bone tissue [52]. A more pragmatic approach to the definition of 
osteoporosis is the occurrence of an osteoporotic fracture, since the occurrence of a fracture is in most 
cases the first clinical sign of the presence of osteoporosis. Fractures lead to pain, decreases in physical 
and social functioning, loss of quality of life and increased mortality in the case of hip fractures [53]. 
Osteoporotic fractures are a major cause of morbidity and disability in elderly. 
Risk factors for osteoporosis
The etiology of osteoporosis is complex and influenced by multiple risk factors, including non-
modifiable risk factors as well as lifestyle and dietary factors. 
Important non-modifiable factors for an increase in osteoporosis risk include: an increasing age; sex: 
women have a higher risk than men; a family history of fracture; the occurrence of a previous fracture; 
ethnicity: osteoporosis is more prevalent in Caucasian and Asian populations; the long-term use of 
glucocorticoids; and the presence of rheumatoid arthritis [54].
Lifestyle factors influencing osteoporosis risk include: high intakes of alcohol, smoking, low body 
mass index (BMI), sedentary lifestyle and frequent falls. Well established nutritional factors include 
low intakes of vitamin D, calcium, and protein [54]. A combination of vitamin D and calcium 
supplementation have been shown to decrease the incidence of fractures [55] and increased physical 
activity lowers the risk of osteoporosis [56-58]. Several observational studies showed that elevated 
homocysteine levels and low levels of vitamin B12 and folate are associated with higher fracture risk in 
elderly people [25, 26, 59-63]. 
Two randomized controlled trials (RCTs) investigated the effect of B-vitamin supplementation on 
fracture risk as a secondary outcome [64, 65]. These studies showed conflicting results and had a low 
generalizability to the older population. Sato et al. observed a large protective effect of 2-year daily 
supplementation of 1.5 mg vitamin B12 and 5 mg folic acid on hip fracture risk [64]. In the HOPE-2 trial 
no effect of 5-year daily supplementation of vitamin B12 (1 mg), folic acid (2.5 mg) and vitamin B6 (50 
mg) was observed on fracture incidence [65]. Evidence that B-vitamin supplementation may lower the 
risk of fracture is therefore still scarce: there is a need for well-designed RCTs to establish the possible 
role for B-vitamins in fracture prevention.
Mechanisms underlying the association between homocysteine, vitamin B12, folate and osteoporosis
There are several suggested mechanisms for the association between homocysteine, vitamin B12 and 
folate with bone health. Homocysteine may interfere with collagen cross-linking. Cross-links are 
important for the stability and strength of the collagen network and interference in cross-link formation 
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could cause an altered bone matrix, resulting in more fragile bones [66]. Vitamin B12 has been shown 
to stimulate osteoblast (bone forming cell) proliferation and alkaline phosphatase activity [67] and 
vitamin B12 deficiency has been associated with impaired functional maturation of osteoblasts [68, 69]. 
Other research shows evidence of osteoclast (bone resorption cell) stimulation in the presence of high 
homocysteine and low vitamin B12 concentrations [70, 71]. The role of folate in bone metabolism is 
likely to be indirectly related via elevated homocysteine levels [72].   
Cognitive decline and dementia 
Cognitive functioning is the process of receiving, processing, storing and using information. Cognitive 
functioning decreases with ageing. This decrease includes normal, age-related cognitive decline, but also 
more rapid cognitive decline, leading to cognitive impairment, and dementia or Alzheimer’s disease. 
Dementia is a syndrome due to disease of the brain, usually chronic, characterized by a progressive, 
global deterioration in intellect including memory, learning orientation, language, comprehension and 
judgment [73]. Alzheimer’s disease is the most common form of dementia and contributes to about 
60–70% of dementia cases. Other major contributors include vascular dementia, dementia with Lewy 
bodies, and a group of diseases that contribute to frontotemporal dementia. The total number of people 
with dementia worldwide is estimated at 35.6 million in 2010 and is projected to nearly double every 20 
years, to 65.7 million in 2030 and 115.4 million in 2050 [73]. 
Risk factors for cognitive decline and dementia
Multiple risk factors have been identified for cognitive decline and dementia. Major non-modifiable 
risk factors include: an increasing age; sex: women have a higher risk than men; carrying the 
apolipoprotein E4 allele; and the presence of vascular pathologies such as high blood pressure, diabetes 
and cardiovascular disease [74].
Lifestyle factors that affect cognitive decline and dementia include: education level: a higher education 
level seems protective against cognitive decline and dementia; marital status and a social network: 
being married or living together and having a large social network with a lot of activities seems to be 
protective [74]. Smoking, high alcohol consumption, a low physical activity level, a higher BMI in 
midlife and an accelerated decline in BMI in later life are risk factors [74]. Nutritional factors associated 
with a protective effect on the development of cognitive decline and dementia include high intakes of 
dietary vitamin E, omega-3 fatty acids and fatty fish [75]. Higher intakes of saturated fatty acids seem to 
increase the risk for cognitive decline and dementia [75]. Evidence however is primarily observational, 
intervention studies are lacking or show inconclusive results. Elevated levels of homocysteine and low 
levels of vitamin B12 and folate have been associated with cognitive impairment and an increased risk 
of dementia [75-77]. Here, the level of evidence is also mainly observational; intervention studies with 
vitamin B12 and folic acid supplementation are of miscellaneous quality and show inconclusive results 
[77].  
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Mechanisms underlying the association between homocysteine and cognitive decline
Several mechanisms have been postulated by which homocysteine, vitamin B12 and folate may affect 
cognitive function, the most important being: Hypomethylation as a result of low vitamin B12 and 
folate levels and elevated homocysteine levels causes myelin damage and disturbed neurotransmitter 
metabolism [78]; homocysteine is suggested to be neurotoxic [79]; in addition, high levels of 
homocysteine could cause structural vascular changes in the brain [80], leading to brain atrophy and 
white matter hyperintensities [81, 82]; high levels of MMA may also induce neurological damage [83]. 
RATionAle And ouTline of THiS THeSiS 
This thesis largely builds on the B-PROOF study and its related evidence base. The B-PROOF study 
is a large, multicenter RCT, initiated to investigate the effect of 2-year vitamin B12 and folic acid 
supplementation on fracture risk in elderly people (aged ≥65 years) with an elevated homocysteine 
level (≥12 µmol/L). At baseline, blood samples were obtained and participants (N=2919) filled 
out questionnaires about their health and lifestyle and underwent a broad screening including 
measurements of anthropometry, cognitive function and physical function. This resulted in an extensive 
dataset, which was used to describe several cross-sectional associations. Furthermore, we performed 
systematic literature reviews with meta-analyses to give an overview of the evidence available on the 
association of B-vitamins with bone health and cognitive function. These reviews were written within 
the context of the EURRECA network of excellence, which aimed at harmonizing the process of setting 
micronutrient recommendations across Europe with special focus on vulnerable population groups, 
including elderly people [84, 85].
Chapter 2 describes the design of the B-PROOF study. In Chapter 3 we explored the association of 
vitamin B12 intake with 4 biomarkers for vitamin B12 (total B12, holoTC, MMA and homocysteine) 
at baseline of the B-PROOF study. Two systematic reviews with meta-analyses investigate the 
association of vitamin B12 intake and status with cognitive function (Chapter 4), and the association 
of homocysteine, vitamin B12 and folate status with fracture incidence and BMD (Chapter 5). In 
Chapter 6 we analyzed the baseline association of vitamin B12 and folate status with cognitive function 
in the B-PROOF study population. Chapter 7 describes the effect of 2-year vitamin B12 and folic acid 
supplementation on fracture risk in elderly people: the main outcome of the B-PROOF study. In the 
final chapter, Chapter 8, we summarize the main findings of the research conducted for this thesis and 
reflect on our methodology and opportunities for future research. 
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ABSTRACT 
Background
Osteoporosis is a major health problem, and the economic burden is expected to rise due to an increase 
in life expectancy throughout the world. Current observational evidence suggests that an elevated 
homocysteine concentration and poor vitamin B12 and folate status are associated with an increased 
fracture risk. As vitamin B12 and folate intake and status play a large role in homocysteine metabolism, 
it is hypothesized that supplementation with these B-vitamins will reduce fracture incidence in elderly 
people with an elevated homocysteine concentration.
Methods
The B-PROOF (B-Vitamins for the PRevention Of Osteoporotic Fractures) study is a randomized 
double-blind placebo-controlled trial. The intervention comprises a period of two years, and includes 
2919 subjects, aged 65 years and older, independently living or institutionalized, with an elevated 
homocysteine concentration (≥12µmol/L). One group receives daily a tablet with 500 µg vitamin B12 
and 400 µg folic acid and the other group receives a placebo tablet. In both tablets 15 µg (600 IU) 
vitamin D is included. The primary outcome of the study is osteoporotic fractures. Measurements are 
performed at baseline and after two years and cover bone health i.e. bone mineral density and bone 
turnover markers, physical performance and physical activity including falls, nutritional intake and 
status, cognitive function, depression, genetics and quality of life. This large multi-center project is 
carried out by a consortium from the Erasmus MC (Rotterdam, the Netherlands), VUmc (Amsterdam, 
the Netherlands) and Wageningen University, (Wageningen, the Netherlands), the latter acting as 
coordinator.
discussion
To our best knowledge, the B-PROOF study is the first intervention study in which the effect of vitamin 
B12 and folic acid supplementation on osteoporotic fractures is studied in a general elderly population. 
We expect the first longitudinal results of the B-PROOF intervention in the second semester of 
2013. The results of this intervention will provide evidence on the efficacy of vitamin B12 and folate 
supplementation in the prevention of osteoporotic fractures. 
Trial Registration
The B-PROOF study is registered with the Netherlands Trial (NTR 1333) and with ClinicalTrials.gov 
(NCT00696514).
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Rationale and design of the B-PRoof study
BACkgRound 
Osteoporosis is a chronic, multifactorial disorder which is characterized by low bone mass and micro 
architectural deterioration of bone tissue [1]. Its major consequence is fractures, and especially hip 
fractures are associated with institutionalization and increased mortality. In 2000, approximately 
9 million fractures occurred worldwide, leading to a loss of 5.8 million disability adjusted life-years 
(DALYs) [2]. Due to a rise in life expectancy, the economic burden of osteoporotic fractures in Europe 
is expected to increase substantially in the coming decades: from €36.3 billion in 2000 to €76.8 billion 
in 2050 [3]. 
Pharmacological interventions may prevent 30-60% of fractures in patients with osteoporosis [4]. 
However, due to the high prevalence of osteoporosis and osteoporotic fractures, attention has been 
shifted towards preventive lifestyle interventions, such as vitamin D and calcium supplementation and 
promoting physical activity. Vitamin D and calcium supplementation has been shown to decrease the 
incidence of hip fractures and other non-vertebral fractures by 23-26% [5]. Increased physical activity 
is related to higher bone mineral density (BMD), bone structure and elasticity [6, 7] and is suggested 
to reduce the risk of hip fracture [8].
Besides those well-established factors,  it has been shown that elevated homocysteine concentrations 
and low vitamin B12 status are strongly associated with lower bone mass and higher fracture risk in 
independent living elderly [9-11] and frail elderly [12]. Vitamin B12 and folate deficiencies and elevated 
homocysteine concentrations have been associated with lower BMD [13-18]. 
An elevated plasma homocysteine concentration (≥15µmol/L) is prevalent in 30-50% of Dutch people 
older than 60 years, increases with age [19-21] and is multifactorial; age, sex and lifestyle factors, 
as well as environmental and genetic factors, nutritional intake of B-vitamins and hormonal factors 
affect homocysteine status [22]. B-vitamins play a central role in the homocysteine metabolism [23]. 
Treatment with vitamin B12 and folic acid supplements is effective in normalizing homocysteine 
concentrations [24, 25].
Evidence of a beneficial effect of supplementation with B-vitamins on fracture incidence has been 
signalled in Japan in elderly hemiplegic patients following stroke [26]. However, the generalizability of 
these findings is limited, since a highly selective patient population with a high percentage of vitamin D 
deficiency and a high fracture risk was studied. Moreover, pharmacological doses of folic acid (5 mg/
day) and vitamin B12 (1.5 mg/day) were given, which may increase the risk of adverse effects.
In vitro studies support the hypothesis of a beneficial effect of vitamin B12 supplementation. Vitamin 
B12 has been shown to stimulate osteoblast proliferation and alkaline phosphatase activity [27] and 
vitamin B12 deficiency has been associated with defective functional maturation of osteoblasts [28]. 
Recent publications indicate a shift to more evidence of osteoclast stimulation by high homocysteine 
and low vitamin B12 concentrations [29-31]. These mechanisms might be interrelated with another, 
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with subsequent interference of homocysteine with collagen cross-linking. Cross-links are important 
for stability and strength of the collagen network. Interference in cross-link formation would cause an 
altered bone matrix, further resulting in more fragile bone [32].
Accordingly, these mechanistic studies support the hypothesis of a beneficial effect of homocysteine 
reduction by B-vitamin supplementation on fracture incidence and related outcome measures. 
However, it remains unknown whether this relationship is causal as evidence from Randomized 
Controlled Trials (RCTs) is still limited. It would be most valuable to assess this relationship in a 
population consisting of generally healthy elderly people as deficiencies of vitamin B12 and folate are 
highly prevalent in this population and lead to elevated homocysteine concentrations.
The primary aim of our current intervention is therefore to assess the efficacy of oral supplementation 
with vitamin B12 and folic acid in the prevention of fractures in Dutch elderly people with elevated 
homocysteine concentrations. We will address potential pathways and phenotypes leading to 
fractures, osteoporosis measures, falls and physical performance. We will concurrently address other 
outcomes associated with elevated homocysteine concentrations, such as cognitive function [33] and 
cardiovascular disease [34]. The aim of this article is to describe the design of our intervention and to 
describe the baseline characteristics of the population enrolled.
MeTHodS
Study design
The B-PROOF study is a randomized, placebo-controlled, double-blind, parallel intervention study. 
B-PROOF is an acronym for ‘B-vitamins for the PRevention Of Osteoporotic Fractures’. This large 
multi-centre project is carried out in The Netherlands by a consortium from Erasmus MC (EMC, 
Rotterdam), VU University Medical Center (VUmc, Amsterdam) and Wageningen University (WU, 
Wageningen), the latter acting as coordinator. The study aimed to include 3000 subjects, aged 65 
years and older, with elevated plasma homocysteine concentrations (≥ 12µmol/L). The intervention 
period is 2 years. Participants were randomly allocated in a 1:1 ratio to the intervention group or to 
the control group. We stratified for study centre, sex, age (65-80 years, ≥ 80 years), and homocysteine 
concentration (12-18 μmol/L, ≥ 18 μmol/L). The intervention group receives a daily tablet with 500 
µg vitamin B12 and 400 µg folic acid and the control group receives a daily placebo tablet. Both tablets 
contain 15 µg (600 IU) of vitamin D3 to ensure a normal vitamin D status [35]. The intervention and 
placebo tablets, produced by Orthica, Almere, the Netherlands, are indistinguishable in taste, smell 
and appearance. The random allocation sequence and randomization were generated and performed 
using SAS 9.2 by an independent research dietician.
Recruitment took place from August 2008 until March 2011. The B-PROOF study has been registered 
with the Netherlands Trial Register (www.trialregister.nl) under identifier NTR 1333 since June 1, 
2008 and with ClinicalTrials.gov under identifier NCT00696514 since June 9, 2008. The WU Medical 
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Ethics Committee approved the study protocol, and the Medical Ethics committees of EMC and VUmc 
gave approval for local feasibility. 
Sample size
Sample size calculation was based on the primary outcome measure of the intervention, i.e. osteoporotic 
fractures. The fracture rate in the non-treated group was estimated to be 5-6% in a period of two years, 
based on osteoporotic fracture incidence in both independently living and institutionalized elderly. 
Elderly in the highest quartile of homocysteine concentrations have been shown to have a doubled 
risk of fracture [10], we expected that the fracture rate in the treated group would be reduced by 34%. 
With a power of 80%, a significance level (α) of 0.05, one tail, 1500 participants were required for both 
intervention and placebo group. To compensate for the expected drop-out rate of 15%, we extended the 
intervention period with one year for the first 600 participants of the study.
Subjects
Most participants were recruited via the registries of municipalities in the area of the research centres 
by inviting all inhabitants aged 65 years and older by mail. Furthermore, inhabitants of elderly homes 
in the area of Rotterdam, Amsterdam and Wageningen were invited to participate, after providing 
information brochures and information meetings. In addition, elderly who participated in previous 
studies of the research centres were approached. All participants gave written informed consent before 
the start of the intervention.
A total of 2919 subjects were included in the intervention (Figure 1). Inclusion and exclusion criteria 
are listed in Table 1. 
Changes to inclusion criteria after trial commencement
The inclusion criteria regarding cut-off values for plasma homocysteine concentrations and age 
were adapted during the first phase of the intervention. The initial eligibility criterion for plasma 
homocysteine concentrations has been adjusted from ≥ 15 µmol/L to ≥ 12 µmol/L before the start of 
the study. Extended data analyses (unpublished data), based on Van Meurs et al., 2004, showed that a 
relation between homocysteine status and fracture incidence is also present at a lower homocysteine 
concentration (~14 µmol/L). Furthermore, cross-calibration between different local homocysteine 
methods used in the current study (Architect Analyser, HPLC and LC-MS) and the methods used in 
the previous leading studies [9, 10] showed that a homocysteine concentration of 14 μmol/L in these 
studies corresponded with a concentration of 12 μmol/L when using the current methods. 
It was decided to adapt the criterion for age from 70 years and older to 65 years and older after the first 
year of recruitment, because the association between homocysteine and fractures is also present in 
people aged 65-70 years [9, 10].  
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Figure 1. Recruitment and baseline measurements in participants of the B-PROOF study
Table 1. Inclusion and exclusion criteria for the B-PROOF study 
Inclusion criteria Exclusion criteria
- Men and women, aged 65 years and older - Immobilization: being bedridden or wheelchair bound
- Compliance for tablet intake of >85% 4-6 weeks 
prior to start of the trial
- Cancer diagnosis within the last 5 year, except skin cancer 
as basal cell carcinoma and squamous cell carcinoma
- Competent to make own decisions - Serum creatinine level >150 µmol/L 
- Elevated homocysteine level (≥ 12 µmol/L and 
≤ 50 µmol/L)
- Current or recent (<4 months) use of supplements with 
very high doses of vitamin B12 (intramuscular injections) or 
folic acid (>300 µg)
- Participation in other intervention studies
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Screening and run-in period
Blood samples were obtained from participants in the morning at the research centres or at an external 
location in the living area of the participants. Participants were in a fasted state, or had taken a light 
breakfast. Venous blood was drawn by a skilled nurse to obtain plasma, serum and buffy coats. For 
homocysteine analysis, a plasma EDTA tube was stored on ice immediately after blood drawing and 
samples were processed within 4 hours after blood drawing, to prevent a temperature- and time-
dependent increase in plasma homocysteine [36]. Plasma homocysteine was measured using the 
Architect i2000 RS analyser (VUmc, intra assay CV=2%, inter assay CV=4%), HPLC method [37] 
(WU, intra assay CV=3.1%, inter assay CV=5.9%) and LC-MS/MS (EMC, CV=3.1%). According 
to a cross-calibration, outcomes of the three centres did not differ significantly. Serum creatinine was 
measured with the enzymatic colorimetric Roche CREA plus assay (CV=2%). The remaining plasma, 
serum and buffy coats samples were kept frozen at -80 °C until further analysis. 
After blood sampling participants started with a six-week run-in period, in which the participants took 
placebo tablets and were asked to daily fill out their study supplement intake on a research calendar. 
Subsequently, participants were informed whether they could further participate in the study or not, 
as an elevated plasma homocysteine concentration was an inclusion criterion, and an elevated serum 
creatinine concentration was an exclusion criterion. In case of laboratory results outside the reference 
range set for homocysteine (>50 μmol/L) or creatinine (>150 μmol/L) participants were referred to 
their general practitioner. 
Measurements
Eligible participants were invited for baseline measurements, which were performed during a 1.5-2 
hour session at one of the study centres or at the participant’s home. The 2-year intervention period 
started after these baseline measurements. Adherence was assessed by recordings on the research 
calendar, counts of bi-annually returned tablets, and periodical phone calls with the participants. After 
two years of intervention, participants are invited for follow-up measurements, in which the baseline 
measurements are repeated.
primary outcome
The primary outcome of the trial is time to first osteoporotic fracture. Participants recorded fractures 
on the research calendar, which was returned every 3 months. Incomplete or unclear data were further 
inquired by telephone. Furthermore, the research team verified reported fractures with the participants’ 
general practitioner, hospital physician and/or by radiographs. All fractures are considered osteoporotic, 
except for head/ hand/ finger/ foot/ toe fractures and fractures caused by traffic accidents [38]. The 
time to fracture is the difference between starting date and date of fracture reported on the calendar or 
by the general practitioner.
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Secondary outcomes
Falls 
Falls were recorded weekly on the research calendar. A fall was defined as an unintentional change in 
position resulting in coming to rest at a lower level or on the ground [39]. Recurrent falling was defined 
as at least two falls of a participant within six months during the two years of follow-up [40].
Dual Energy X-ray Assessment (DXA)
In two out of three study centres Dual Energy X-ray Assessment (DXA) was performed to measure 
bone mineral density (BMD) and lean body mass and to assess vertebral fractures, using the Hologic 
QDR 4500 Delphi device (VUmc, Hologic Inc., USA, CV=0.45%) or the GE Lunar Prodigy device 
(EMC, GE Healthcare, USA, CV= 0.08%). The two devices were cross-calibrated. DXA was performed 
under standard protocols within four weeks after the participant’s start of the intervention. 
Total hip, femoral neck and lumbar spine BMD (g/cm2) were measured. Total hip BMD was measured 
at the left femur, while in case of a hip prosthesis at the left side, the right side was measured. Instant 
vertebral assessment (IVA) was performed to detect clinical and non-clinical vertebral fractures. Results 
were independently evaluated by two researchers, and inconsistencies were discussed.
Furthermore, total body composition was measured. The amount of fat-free soft tissue (i.e. lean mass 
minus bone mineral content) of the extremities can be used as an indicator of skeletal muscle mass and 
has been validated in older persons [41].
Quantitative Ultrasound (QUS)
Quantitative ultrasound (QUS) measurements of the calcaneus were performed using a Hologic 
Sahara bone densitometer (Hologic Inc., USA). Broadband ultrasound attenuation (BUA, dB/MHz, 
CV=3.7%) and speed of sound (SOS, m/s, CV=0.22%) were measured in duplicate in both the right 
and the left calcaneus. From these parameters, the quantitative ultrasound index (QUI, CV=2.6%) and 
estimated BMD (eBMD) were calculated. 
Bone turnover markers
After completion of the study, bone turnover markers will be determined in a subsample in order to 
obtain better insight in the mechanism underlying the effect of B-vitamin supplementation on bone 
health. Standard assays will be performed in baseline and follow-up blood samples to measure markers 
of bone formation and bone resorption, such as procollagen type 1 N-extension peptide (P1NP) and 
cross-linked carboxyterminal telopeptide of type 1 collagen (CTx). 
Physical performance and handgrip strength
Physical performance was measured using three tests; a walking test, a chair stands test, and a balance 
test. These performance tests are commonly used in elderly people [42-44]. During the timed walking 
test, participants were asked to walk 3 meters, turn around, and walk back as quickly as possible. During 
the timed chair stands test the participants rose from and sat down in a chair as quickly as possible for 
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five consecutive times without the use of their arms. Standing balance was assessed with the modified 
Romberg test in which the participants were asked to maintain balance for 10 seconds in four different 
positions with increasing difficulty. Each position was performed with eyes open and eyes closed. 
Hand grip strength (kg) was measured using a strain-gauged dynamometer (Takei, TKK 5401, Takei 
Scientific Instruments Co. Ltd., Japan, inter observer CV= 5%). Participants were asked to perform 
two maximum hand grip trials with each hand in standing position with their arms along their body. 
Maximal hand grip strength was defined as the average of the highest score of the left and right hand.
Vascular parameters
Blood pressure measurements were performed using an Omron M1 plus blood pressure device 
(Omron Healthcare Europe). In two of the centres vascular structure and function was assessed non-
invasively in a subsample by measuring blood pressure, intima-media-thickness (IMT) of the carotid 
artery, carotid distensibility (DC), aortic pulse wave velocity (PWV) and augmentation index (AIx). 
Carotid B-mode ultrasonography is performed using the L105 40mm 7.5 MHz array transducer (Picus, 
Pie Medical Equipment, Maastricht, the Netherlands) on the right carotid artery. IMT is evaluated as 
the distance luminal-intimal interference and the media-adventitial interface (Art.Lab, Esoate Europe, 
Maastricht, the Netherlands). The vessel wall movement–detector system has been described in detail 
previously [45]. The system consists of a wall track system and data-acquisition system (Art.Lab, Esoate 
Europe, Maastricht, the Netherlands). AIx is calculated using arterial tonometry obtained from the 
right radial, carotid and femoral artery using the Sphygmocor device (Sphygmocor version 7.1, AtCor 
Medical, Sydney, Australia). PWV is measured with simultaneously three channel ECG recording and 
recording of the right carotid and femoral artery pulse waveforms. Twenty-four hour ambulatory blood 
pressure recording was performed using Oscar 2 ambulatory 24 hour blood pressure monitor (SunTech 
Medical, North Carolina, USA).
Biomarkers of cardiovascular disease and cardiovascular events
Cardiovascular events were defined as cardiovascular mortality, myocardial infarction and stroke. 
Participants were requested to fill out a questionnaire regarding their cardiovascular history. After 
completion of the study cardiovascular and inflammatory biomarkers, such as amino-terminal B-type 
natriuretic peptide (NT-proBNP) and high-sensitivity hsC-reactive protein (hs-CRP) will be measured 
in baseline and follow-up blood samples. 
Cognitive function
We used the Mini-Mental State Examination (MMSE) for a description of global cognitive performance 
in our study population [46]. In a subsample, i.e. all participants of WU, domain specific cognitive 
function was assessed using six standardized tests; the Symbol Digit Modalities Test, the Letter Fluency 
test, the Trail Making Test, the Digit Span Test, the Word Learning Test and the Stroop Colour Word 
Test. These tests were used to construct the following cognitive domains: attention, working memory, 
executive function, information processing speed and episodic memory [47]. 
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Depression and Quality of Life
The Geriatric Depression Scale (GDS) was used to measure depressive symptoms [48]. To determine 
quality of life the EuroQoL EQ-5D [49] and Short Form Health Survey (SF-12) [50] questionnaires 
were used.
Measurement of covariates
General self-reported health and medication usage
Self-reported medical history, ethnicity, use of medication and of nutritional supplements, current 
alcohol intake and smoking habits and history of falls and fractures were determined using a 
questionnaire. 
Medication use during the study period was also retrieved from pharmacies. Data included the 
prescription period, the total amount of drug units per prescription, the prescribed daily number of 
units, product name, and the Anatomical Therapeutic Chemical (ATC) code.
Physical Activity
Physical activity was measured using the LASA Physical Activity Questionnaire (LAPAQ), which is 
a validated questionnaire to measure physical activity in elderly people [51]. The activities included 
walking, cycling, gardening, participation in sports and light and heavy household activities. Frequency 
and duration of each activity during the last two weeks were assessed. Physical activity was calculated 
in minutes/day and kcal/day.
Nutritional status and food intake 
The Mini Nutritional Assessment (MNA) [52] and the Simplified Nutritional Appetite Questionnaire 
(SNAQ) [53] were used to screen for malnutrition and appetite loss. Standing height was measured 
in duplicate to the nearest 0.1 cm with the person standing erect and wearing no shoes. Weight was 
measured to the nearest 0.5 kg with the person wearing light garments without shoes and empty 
pockets. In a subsample, i.e. all participants of WU, we estimated dietary intake by a Food Frequency 
Questionnaire (FFQ) with its main focus on macronutrients, vitamin B12, folate, vitamin D, and calcium. 
The FFQ was developed by the dietetics group at the department of Human Nutrition, Wageningen 
University and was derived from an FFQ which was validated for energy, fat, cholesterol, folate and 
vitamin B12 intake [54, 55]. 
Genotyping
From the blood samples drawn at baseline, DNA was isolated for genotyping. Subsequently, all 
samples were genotyped for approximately 700.000 single nucleotide polymorphisms (SNPs) using 
the Illumina Omni-express array, which has >90% coverage of all common variation in the genome. 
If known functional SNPs were not tagged well by the array, they were genotyped separately using 
TaqMan allelic discrimination assays on the ABI Prism 9700 HT sequence detection system. The data 
will be used in a hypothesis-free genome-wide association study (GWAS) as well as in analyses of 
genetic variation in known candidate genes.
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data analysis
The data analyses will be performed by following the intention-to-treat procedure (effectiveness study) 
and the per-protocol-procedure (efficacy study). If necessary, data will be transformed and analyses will 
be adjusted for the presence of covariates. Time to first fracture will be analysed using Cox Proportional 
Hazard Models. Differences in mean change between groups will be analysed with independent sample 
Student’s t-test, ANOVA or other similar tests. Two-sided P values will be calculated and a significance 
level of 0.05 will be applied. 
We did not perform an interim analysis because we did not expect and observe negative side effects of 
the supplementation and because of the relatively long recruitment period, with most of the participants 
included in the last year of recruitment. We keep track of any serious adverse events (SAEs) occurring 
during the duration of the study.
inclusion and baseline characteristics of the participants
Baseline characteristics of participants in the B-PROOF study are shown in Table 2. During the 
recruitment, we addressed approximately 69.000 people (Figure 1). This resulted in the screening of 
6242 interested persons, of which 3027 were eligible to participate. One hundred and eight participants 
withdrew consent before start of the intervention resulting in 2919 participants who completed baseline 
measurements. The mean age of participants at the start of the intervention was 74.1 years (SD: 6.5) 
and 50% was female. Median plasma homocysteine concentration was 14.1 µmol/L (IQR: 13.0-16.6). 
diSCuSSion 
To our best knowledge, the B-PROOF study is the first intervention study in which the effect of vitamin 
B12 and folic acid supplementation on osteoporotic fractures is studied in a general elderly population. 
Currently, folic acid fortification is not mandatory in the Netherlands, and it is only applied on small 
scale in bread substitutes. This intervention is therefore an excellent opportunity to investigate the 
effect of folic acid and vitamin B12 supplementation in a non-fortified population. Positive evidence 
emerging from this intervention might enable elderly to live into an advanced age with lower fracture 
risk. Implementation of vitamin B12 and folic acid supplementation might therefore reduce the costs of 
national health services for osteoporosis in the elderly.
Elevated homocysteine concentrations are associated with various health outcomes, but until now there 
are no large interventions investigating the effect of homocysteine lowering treatment on, for example, 
physical performance. Therefore, the wide range of secondary outcomes studied in the B-PROOF 
study is unique. The possibility to perform a GWAS in such a large general elderly population will 
provide us with relevant data on the underlying mechanisms and genes involved in age-related diseases 
as osteoporosis and cognitive decline. In addition, DNA analysis gives us the opportunity to focus on 
the effect of B-vitamins on epigenetic changes.
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Table 2. Baseline characteristics of the B-PROOF study participants 
Total
(n=2919)
Male
(n=1456)
Female
(n=1463)
Study location (n)
- WU 
- VUmc
- Erasmus MC
856
778
1285
499
301
656
357
477
629
Age (years)* 74.1 (6.5) 73.4 (6.1) 74.9 (6.8)
Plasma homocysteine (µmol/L)# 14.4
 [13.0-16.6]
14.6 
[13.1-16.8]
14.1 
[12.9-16.3]
Serum creatinine (µmol/L)# 82.0 
[71-94]
90.0 
[81.0-101.0]
73.0 
[65.0-84.0]
Weight (kg)# 77.9 (13.3) 83.1 (11.9) 72.7 (12.5)
Height (cm) # 169.3 (9.3) 175.9 (6.6) 162.7 (6.6)
Physical activity (min/day)# 130.0 
[84.0-192.9]
116.3 
[72.5-177.0]
142.9 
[96.0-205.7]
Years of education* 10.1 (4.0) 10.9 (4.1) 9.2 (3.6)
Smoking (%)
- Current
- Former
- Never
9.6
56.5
33.9
10.8
69.1
20.1
8.5
44.0
47.6
*Results are presented in mean (standard deviation); #Results are presented in median [interquartile range].
We have some remarks on the expected outcomes of this study. We expect the effect of folic acid 
and vitamin B12 supplementation to be most beneficial in people with an elevated homocysteine 
concentration. We therefore only included elderly people with elevated homocysteine concentrations 
(≥12 µmol/L), but as a consequence, we cannot extrapolate the results to elderly with low to normal 
homocysteine concentrations (<12 µmol/L). However, 49% of the elderly screened in our study had 
an elevated homocysteine concentration. This percentage might be higher in the general Dutch elderly 
population, since people interested in nutrition and health, with a subsequent healthier lifestyle are 
probably more willing to participate in a long term intervention study. Therefore, the B-PROOF study 
covers a large segment of the general Dutch elderly population.
Because we supply both folic acid and vitamin B12, it will not be possible to indicate whether the effects 
of the intervention will be the consequence of folic acid or vitamin B12 supplementation or lowering 
homocysteine concentrations in general. However, since both vitamins play a significant role in 
homocysteine metabolism, and folic acid supplementation alone might mask a possible vitamin B12 
deficiency [56], it is the most efficient and safest to supplement both vitamins. 
The first longitudinal results of the B-PROOF study will become available in the second semester of 
2013.
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ABSTRACT
Background
 Vitamin B12 status is measured by four plasma/ serum biomarkers: total vitamin B12, holotranscobalamin 
(holoTC), methylmalonic acid (MMA) and homocysteine (tHcy). Associations of B12 intake with 
holoTC and tHcy and associations between all four biomarkers have not been extensively studied. This 
study therefore investigates associations between B12 intake and biomarkers and associations between 
biomarkers. 
Methods
Levels of total B12, HoloTC, MMA and tHcy  were determined in 2919 elderly people (≥65 years) with 
elevated tHcy levels (≥12 µmol/L). B12 intake was assessed in a subsample. Multivariate regression 
analysis assessed the association between intake and status. With restricted cubic spline plots we 
explored the dose-response association between B12 intake and biomarkers, and the association of total 
B12 and holoTC with  tHcy and MMA. 
Results
A doubling of  B12 intake was associated with 9% higher total B12, 15% higher HoloTC, 9% lower MMA 
and 2% lower tHcy. Saturation of biomarkers occurs with dietary intakes of >5 μg B12. Spline regression 
showed that levels of MMA and tHcy started to rise when vitamin B12 levels fall below 330 pmol/L and 
with HoloTC levels below 100 pmol/L, with a sharp increase with levels of B12 and HoloTC below 220 
and 50 pmol/L respectively. 
Conclusion
In this study we observed a significant association between vitamin B12 intake and vitamin B12 
biomarkers and between the biomarkers. The observed inflections for total B12 and holoTC with MMA 
and tHcy could indicate cut-off levels for further testing for B12 deficiency and determining subclinical 
B12 deficiency.  
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inTRoduCTion
Vitamin B12 is water-soluble vitamin, essential for neurological functioning and the production of cells, 
and is present in foods of animal origin. Vitamin B12 status is of concern in the elderly population, as it 
is estimated that about 20% of the elderly have a suboptimal vitamin B12 status [1-3].
Vitamin B12 status can be evaluated by serum or plasma total vitamin B12 (total B12) levels, 
holotranscobalamin (holoTC) and the metabolites homocysteine (tHcy) and methylmalonic acid 
(MMA) [4]. HoloTC is the fraction of circulating vitamin B12 that can be taken up by the cells [5]; 
the metabolites homocysteine (tHcy) and MMA accumulate with vitamin B12 deficiency, due to a 
lack of vitamin B12 as cofactor for the enzymes methionine synthase and methylmalonyl-CoA mutase, 
respectively. Methionine synthase remethylates homocysteine to methionine and methylmalonyl-
CoA mutase converts methylmalonyl-Coa to succinyl CoA. 
Total B12 is most commonly used as a marker for vitamin B12 status, although MMA is considered a 
better marker, yet more expensive and therefore not regularly measured [4, 6, 7]. HoloTC is a relatively 
new marker and currently not widely used in clinical practice [5, 8]. As tHcy level is not only affected by 
vitamin B12 status, but, among others, also by folate status, elevated tHcy levels are, though a sensitive 
marker, not specific for vitamin B12 deficiency, but also for folate deficiency [4, 9]. 
Levels of biomarkers for vitamin B12 status depend on vitamin B12 intake from food and supplements 
and on body stores. Until now, research on the association of daily vitamin B12 intake with biomarker 
status focused mainly on total B12 and MMA as a biomarker for vitamin B12 status[10-15]. Less is 
known about the association between vitamin B12 intake and levels of HoloTC and tHcy. Furthermore, 
studies investigating associations between biomarkers of vitamin B12 generally focus on only two or 
three of the biomarkers [16, 17].  In this study, we explored: 1) the association between vitamin B12 
intake and four biomarkers of vitamin B12 status (total B12, HoloTC, MMA and tHcy), and 2) the 
mutual association among the four biomarkers for vitamin B12 status in elderly people participating in 
the B-PROOF study. We furthermore assessed the prevalence of atrophic gastritis, as this condition is 
postulated as an important cause for vitamin B12 deficiency in elderly [2]. 
MATeRiAlS And MeTHodS
Subjects  
In this cross-sectional study, baseline data of the B-PROOF study were used. The B-PROOF study 
is a randomized controlled double blind intervention study investigating the effect of daily vitamin 
B12 and folic acid supplementation on fracture risk in a general elderly population (≥65 years) with 
elevated homocysteine levels (≥12 µmol/l). The study population and the design of the study have 
been described in detail elsewhere [18]. 
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The study was carried out in three study centers in The Netherlands; Erasmus MC (EMC, Rotterdam), 
VU University Medical Center (VUmc, Amsterdam) and Wageningen University (WU, Wageningen). 
A total number of 2919 people were included in the intervention. In this paper we report dietary intake 
data from the Wageningen subsample and biomarker data for the whole population. All participants 
gave written informed consent before the start of the study. The Medical Ethics committee of WU 
approved the study protocol, and the Medical Ethics committees of EMC and VUmc gave approval 
for local feasibility.
dietary intake
Habitual dietary intake was estimated by a Food Frequency Questionnaire (FFQ), which was 
developed to assess the intake of energy, macronutrients, type of fat, vitamin B12, folate, vitamin D, 
and calcium. This FFQ was based on a questionnaire which was developed and validated for the 
assessment of energy, total fat, fatty acids and cholesterol [19]. This basic FFQ was updated using 
the Dutch National Food Consumption Survey of 1998 and extended with questions  to estimate 
folate, vitamin B12, calcium, and vitamin D intake [20]. In addition, new foods on the market relevant 
for the purpose of the FFQ  were included. Finally, the FFQ consisted of 190 food items and which 
covers at least 90% of energy and nutrient intake [21]. Furthermore, use of vitamin B12, folic acid and 
vitamin D supplements apart from the study supplements was registered as well. The FFQ was sent to 
all participants at the WU (n=856). 
Biochemical markers: laboratory analysis
Blood samples were obtained from participants in a standardized way in a fasted state or after a light 
breakfast. Plasma tHcy was measured using the Architect i2000 RS analyser (VUmc, intra assay 
CV=2%, inter assay CV=4%), HPLC method (WU, intra assay CV=3.1%, inter assay CV=5.9%) 
and LC-MS/MS (EMC, intra assay CV=5.5% at 14.1 μmol/L, inter assay CV=1.4% at 13.7 μmol/L). 
According to cross-calibration, outcomes of the three centres did not differ significantly (results not 
shown). Serum vitamin B12 and folate were measured using immunoelectrochemiluminescence assay 
(Elecsys 2010, Roche, Almere, The Netherlands) (intra assay CV vitamin B12 5.1% at 125 pmol/L and 
2.9% at 753 pmol/L; intra assay CV folate: 5.9% at 5.7 nmol/L and 2.8% at 23.4 nmol/L) [22]. Serum 
HoloTC was determined by the AxSYM analyser (Abbott Diagnostics, Hoofddorp, The Netherlands) 
(intra assay CV<8%) and serum MMA was measured by LC-MS/MS (intra assay CV=8.1% at 
0.18 μmol/L, inter assay CV=1.6% at 0.24 μmol/L) [23]. Serum creatinine was measured with the 
enzymatic colorimetric Roche CREA plus assay (intra assay CV=2%). DNA was isolated from buffy 
coats to determine MTHFR C677T genotype using the Illumina Omni-express array.
Serum pepsinogen I (PGI) and II (PGII) concentrations were measured at WU in a subsample 
(n=762), by ELISA technique (Epitope Diagnostics, San Diego, CA, USA) (intra assay CV<10%). 
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other variables
Smoking (never, former, and current smoker) and alcohol consumption (none, light, moderate, and 
excessive) were based on self-report. Classification of alcohol use was based on the number of days per 
week alcohol was consumed and the number of drinks per time.
Statistical analysis 
Data are presented as mean with SD or median with interquartile range. Associations between 
vitamin B12 intake and status and between status markers were examined using Spearman’s correlation 
coefficient, because biomarker data were not normally distributed. As levels of tHcy are also influenced 
by levels of folate [24], the correlation between vitamin B12 and tHcy was adjusted for serum folate level. 
Both intake and status markers were transformed to their natural-log as we assumed a dose response 
association between vitamin B12 intake and status with a saturation of biomarkers at higher levels of 
intakes [15]. With the log-transformed variables we performed multivariate regression analysis. Based 
on their biological relevance and their contribution to a change in the regression coefficient of the 
variable of interest of at least 10%, age, sex, smoking status, alcohol intake and supplement use were 
included as covariates in the multivariate linear regression analysis. Betas are interpreted as follows: 
when vitamin B12 intake was e-times higher, biomarker status was (eβ -1)*100% higher, consequently, 
a doubling of vitamin B12 intake was associated with a higher total B12 status of approximately (2β-
1)*100%.
We used restricted cubic spline plots to explore the dose-response association between vitamin B12 
intake and status markers, and the association among serum vitamin B12 and tHcy, MMA and holoTC. 
With these splines we were able to estimate visually an optimal vitamin B12 intake per biomarker status 
and to estimate a breakpoint in the association between total B12 status, HoloTC, MMA and tHcy. 
Following the analyses of Vogiatzoglou et al. we excluded the lowest and highest 2.5 percentiles of 
total B12 and HoloTC in the status-status spline to smoothen the spline [17].  Cubic spline functions 
were tested in regression models at three, four and five knots using spline plots and likelihood ratio 
tests [25]. 
All analyses were performed using SAS statistical software, version 9.2 (SAS institute Inc, Cary, NC), 
except the restricted cubic splines, which were performed using R statistical software version 2.12.2 
(www.R-project.org). Significance was accepted at p<0.05. 
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ReSulTS
The study population comprises 2919 participants, with a mean age of 74 ± 7 years and 50% were men 
(Table 1). 
Table 1. Characteristics of the study population
Characteristic Valuea
Demographic measures (n=2919)
Age (y) 74.1 ± 6.5
Male 1459 (50%)
Education:  
 -low
 -middle
 -high
53%
21%
26%
Current smoker 10%
BMI (kg/m²) 27.1 ± 4.0
MTHFR genotype 
 677 CC 46%
 677 CT 41%
 677 TT 13%
Biochemical measures (n=2919)
Plasma tHcy (µmol/L) 14.4 (13.0 - 16.6)
Serum holoTC (pmol/L) 64.0 (46.0 -85.0)
Serum total B12 (pmol/L) 266.4 (208.6-342.5)
Serum MMA (µmol/L) 0.23 (0.18 - 0.30)
Serum folate (nmol/L) 18.7 (14.8 - 24.0)
Serum creatinine (µmol/L) 84.0 ± 18.3
Pepsinogen (n=720):
pepsinogen I (ng/ml) 205.8 ± 102.5
pepsinogen II (ng/ml) 15.5 ± 10.6
PGI/PGII (ratio) 15.3 ± 7.7
% atrophic gastritis (ratio <1.6) 3%
Dietary intake (n=603)
Dietary vitamin B12 intake (µg/day) 4.1 ± 2.0
Dietary folate intake (µg/day) 192 ±54
Energy intake (kcal/day) 2006 ± 473
BMI, Body Mass Index; MTHFR, Methylenetetrahydrofolate Reductase; tHcy, total homocysteine; holoTC, 
holotranscobalamin; MMA, methylmalonic acid  
a Values are presented as mean ± SD, number (%) or median (IQR) 
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vitamin B12 intake 
Six hundred sixty four (664) participants (78%) returned their FFQ; after excluding data from 61 
participants with unrealistically high or low energy intake as defined by Goldberg [26] valid intake 
data of 603 participants were available. Mean dietary intake of vitamin B12 was 4.1 µg/day, 9% of the 
participants used a dietary supplement containing vitamin B12 (median 0.85 µg/day) (Table 1).  Six per 
cent of the participants had a vitamin B12 intake lower than the Dutch estimated average requirement 
(EAR) of 2.0 µg/day. 
Association between vitamin B12 intake and vitamin B12 status markers
Dietary vitamin B12 intake was significantly correlated with total B12 (r= 0.13), holoTC (r= 0.11) 
and MMA (r= -0.12), all p<0.01, but not with tHcy (r= -0.06, p=0.12). Correlations did not alter 
substantially when total vitamin B12 intake was taken into account (dietary intake plus additional 
supplement intake). 
The association between dietary vitamin B12 intake and B12 status was further analysed with multivariate 
regression analysis. Vitamin B12 intake was significantly associated with all biomarkers (Table 2). A 
doubling of vitamin B12 intake was associated with an approximately 9% higher total B12, 15% higher 
HoloTC, 9% lower MMA and 2% lower tHcy status (Table 2).
Figures 1a-d show the association between vitamin B12 intake and B12 status markers, adjusted for 
age, sex, smoking, alcohol intake and supplement use, as visualised with restricted cubic splines with 
3 knots. These figures suggest a saturation of the biomarkers around an intake of approximately 5 μg 
vitamin B12/day.
Table 2. Multivariate regression analysis for the association between loge dietary vitamin B12 intake  and loge 
biomarker (n=603) 
Biomarker Model β (SE) 95% CI p-value Change for doubling 
B12 intakea 
Loge total B12 Crude 0.12 (0.04) 0.05 to 0.19 0.001
Adjustedb 0.13 (0.04) 0.06 to 0.20 0.000 9%
Loge HoloTC Crude 0.16 (0.05) 0.06 to 0.25 0.001
Adjustedb 0.20 (0.05) 0.10 to 0.30 <0.0001 15%
Loge MMA Crude -0.14 (0.04) -0.22 to -0.06 0.001
Adjustedb -0.13 (0.04) -0.21 to -0.05 0.003 -9%
Loge tHcy Crude -0.03 (0.02) -0.07 to 0.00 0.066
Adjustedc -0.04 (0.02) -0.07 to -0.00 0.037 -2%
Hcy, total homocysteine; holoTC, holotranscobalamin; MMA, methylmalonic acid
a a doubling of vitamin B12 intake is associated with a % change in biomarker status
b models were adjusted for age, sex, smoking, alcohol intake and supplement use
c tHcy model was adjusted for age, sex, serum levels of folic acid, smoking, alcohol intake and supplement use
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Figure 1. 
a: Association between vitamin B12 intake and total vitamin B12, adjusted for age, sex, smoking, alcohol intake and 
supplement use, b: Association between vitamin B12 intake and HoloTC, adjusted for age, sex, smoking, alcohol 
intake and supplement use.
 
a.
b.
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c.
d.
Figure 1. Continued 
c: Association between vitamin B12 intake and MMA, adjusted for age, sex, smoking, alcohol intake and 
supplement use, d: Association between vitamin B12 intake and tHcy, adjusted for age, sex, smoking, alcohol 
intake and supplement use.
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Association between the different biomarkers for vitamin B12 status
Correlation coefficients of the four biomarkers of vitamin B12 status are shown in Figure 2. B12 status 
markers were correlated with each other (p<0.0001), the correlation between total B12 and tHcy 
was adjusted for folate status.  Adjustment for MTHFR genotype (CC, CT or TT) did not alter the 
correlations.
Figure 2. Spearman’s correlations between biomarkers of vitamin B12 status (all p<0.0001)
 apartial correlation, 
adjusted for serum folic acid level. 
Figures 3a-d show the association of total B12 with MMA and tHcy and of holoTC with MMA and tHcy, 
visualized with restricted cubic splines with 5 knots, without the lowest and highest 2.5 percentiles of 
total B12 and HoloTC. With total B12 and holoTC levels below approximately 330 and 100 pmol/L 
respectively, levels of tHcy and MMA start to rise, and rise steeper with total B12 and holoTC levels 
below approximately 220  and 50 pmol/L.  Adjustment for serum folate did not alter the association 
between tHcy and total B12 (data not shown). The association between HoloTC and total B12 was 
linear across the whole range of measurements (data not shown).  
Atrophic gastritis
We observed a prevalence of 3% for atrophic gastritis in the subsample of the B-PROOF study (n=720) 
when using the cut-off value of PGI/PGII ratio <1.6 as suggested by Van Asselt [2]. When using a less 
strict cut off value for PGI/PGII ratio of 5.0 [27], 8% of our population was diagnosed with atrophic 
gastritis. Participants with atrophic gastritis (PGI/PGII ratio <5.0, n=55) had significant higher levels 
of tHcy (mean 16.2 vs. 15.1 µmol/L, p=0.04) and MMA (mean 0.60 vs. 0.26 µmol/L, p<0.0001), 
lower levels of total B12 (mean 231 vs. 283 pmol/L, p=0.0003) and HoloTC (mean 68.4 vs. 44.3 
pmol/L, p= 0.0001) and were older (mean 74.2 vs 72.5 years, p=0.0009) than participants without 
atrophic gastritis (n=655).
associations of vitamin B12 intake and related Biomarkers
 51 
3
Figure 3.
a: Association between total B12 and MMA, adjusted for age, sex and creatinine levels. The highest and lowest 2.5% 
of total B12 are not included, b: Association between total B12 and homocysteine, adjusted for age, sex and creatinine 
levels. The highest and lowest 2.5% of total B12 are not included. 
a.
b.
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c.
d.
Figure 3. Continued  
c: Association between holoTC and MMA, adjusted for age, sex and creatinine levels. The highest and lowest 
2.5% of holoTC are not included, d: Association between holoTC and homocysteine, adjusted for age, sex and 
creatinine levels. The highest and lowest 2.5% of holoTC are not included.
associations of vitamin B12 intake and related Biomarkers
 53 
3
diSCuSSion
In this study we showed that vitamin B12 intake was associated with all 4 biomarkers of vitamin B12 
status. Saturation of biomarkers occurred with a habitual daily dietary intake of >5 μg of vitamin B12. 
Spline regression showed that MMA and tHcy levels started to rise with total B12 levels below 330 
pmol/L and HoloTC levels below 100 pmol/L.
These observations were made in a population with an adequate vitamin B12 intake, as 94% of the 
population measured reached the Estimated Average Requirements (EAR) of 2.0 μg/day. The 
observed median dietary vitamin B12 intake of 4.1 μg/day corresponds to the median intake 4.2 μg/
day of the Dutch adult population, as measured in the Dutch National Food Consumption Survey of 
2007-2010 [28]. 
The strength of the association between vitamin B12 intake and total B12 and MMA status is similar 
to that observed in other studies. A recent meta-analysis of 19 observational studies regarding the 
association between vitamin B12 intake and serum/plasma total B12 status generated an overall β of 
0.10 (95% CI: 0.06-0.14) on the loge loge scale for adults and elderly, and a slightly higher overall β of 
0.13 (95% CI: 0.04-0.21) for elderly only. For MMA the overall β was -0.11, based on 9 studies. These 
βs are similar to the βs we observed: β=0.13 for serum B12 and β=-0.13 for MMA. Less is published 
about the association of dietary vitamin B12 intake with holoTC and tHcy. Two studies of Bor et al., 
one in a healthy young population (n= 299) and one in postmenopausal women (n=98) investigated 
the association between vitamin B12 intake and biomarker status, including HoloTC and tHcy [10, 11]. 
Bor et al. observed higher HoloTC levels and lower tHcy levels in the upper three quintiles of vitamin 
B12 intake, although not significant for all data points. Howard et al. did not observe an association 
between vitamin B12 intake and tHcy levels in subjects with low vitamin B12 status [14]. Furthermore, 
Bor et al. observed a saturation of biomarker status of vitamin B12 intake between 4-7 µg/day comparing 
quintiles of vitamin B12 intake  [10, 11]. In our study we observed a similar saturation level of around 5 
µg/day, that is, above the current Dutch Recommended Daily Allowance (RDA) of 2.8 µg/day. These 
findings might indicate that the current RDA is too low to guarantee an optimal biomarker status in 
elderly people. Regarding the association between vitamin B12 intake and biomarker levels, our study 
clearly provides new information, as we show a continuous dose-response association between vitamin 
B12 intake and tHcy and HoloTC in a considerably large elderly population. 
We visually explored the association of total B12 levels with tHcy and MMA with restricted cubic splines. 
We observed that below total B12 levels of approximately 330 pmol/L both tHcy and MMA levels 
started to rise, with a steep rise when total B12 levels fall below 220 pmol/L. This is in line with other 
studies, which observed inflections between 200 and 500 pmol/L [17, 24, 29, 30].  We furthermore 
explored the association of HoloTC with tHcy and MMA and observed that below HoloTC levels of 
approximately 100 pmol/L both tHcy and MMA levels started to rise, with a steep rise when HoloTC 
levels fall below 50 pmol/L.  To our knowledge, such a visual representation of the continuous 
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association of HoloTC with MMA and tHcy has not been shown before. Important to note is that we 
corrected our analyses for creatinine levels, as creatinine is a marker for renal insufficiency and affects 
levels of tHcy and MMA [31].
The rise in MMA and tHcy below total B12 and HoloTC levels of 330 and 100 pmol/L respectively 
indicates that the enzymes methylmalonyl-CoA mutase and methionine synthase are no longer 
saturated by their co-factors, in other words, a state of metabolic insufficiency. This state occurs long 
before classical clinical vitamin B12 deficiency is determined (Figure 3), as traditional clinical cut-off 
values for total B12 range from 148 to 200 pmol/L[32], but corresponds well with the occurrence 
of subclinical vitamin B12 deficiency, or the presence of mild abnormal vitamin B12 biomarker levels 
without clinical signs or symptoms [31], usually defined by total B12 levels of <258 - 300 pmol/L [1, 
33]. 
Cut-off values for vitamin B12 deficiency as suggested for HoloTC are distinctly lower, <20 pmol/L 
[8] or <32-35 pmol/L [23, 34], than the inflections shown in our data, confirming the sensitivity of 
HoloTC as an early marker for vitamin B12 deficiency [5]. This finding might suggest that cut-off levels 
for HoloTC should be raised to 50 pmol/L, but further research regarding the specificity of higher 
HoloTC cut-off values is desirable. 
There is an active debate about the best biomarker or combination of biomarkers and cut-off values for 
vitamin B12 deficiency, and consensus has not yet been reached [4, 7, 16, 31-33, 35, 36].  Traditionally, 
total B12 is used as a marker for clinical vitamin B12 deficiency, with a cut-off value of ≤148 or ≤200 
pmol/L [32]. Nowadays, the general idea is to combine values of at least two biomarkers, preferably a 
circulation biomarker (total B12 or HoloTC) and a metabolic biomarker (MMA, as tHcy is not specific 
for vitamin B12 deficiency) [16, 35]. For instance, current clinical practice in the Netherlands includes a 
cut-off value for total B12 of 300 pmol/L or HoloTC of 32 pmol/L for further testing of MMA levels. As 
subsequently measured MMA levels are >0.45 µmol/L, clinical vitamin B12 deficiency is diagnosed [23]. 
As mentioned, a distinction is made between clinical and subclinical vitamin B12 deficiency. There 
is a plea for treating people with subclinical vitamin B12 deficiency, as results from observational 
studies indicate that various health outcomes such as neural tube defects, cognitive functioning, 
depression, brain atrophy and bone health are already worsening at low-normal levels of vitamin B12 
and normalizing levels of vitamin B12 biomarkers could theoretically improve health outcomes [33]. 
However, results from intervention studies are not univocal. Further research should focus on the 
effect of treating suboptimal vitamin B12 biomarker levels with vitamin B12, through supplementation 
or food fortification, on suspected health outcomes. 
Results of the B-PROOF intervention study will contribute to the evidence in this research field, as 
the effect of 2 year vitamin B12 (and folic acid) supplementation on several health outcomes, including 
fracture risk and cognitive function, will be investigated.
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Our current results give insight in the levels of the four biomarkers and their mutual association in 
a large Dutch elderly population and contributes therefore to the general understanding of the 
distribution of vitamin B12 biomarkers. The inflections for total B12 and HoloTC as observed in our 
study, could be of use clinical practice and scientific research : 1) the inflections suggest a cut-off value 
for levels of total B12 and HoloTC indicating further testing of levels of MMA to determine clinical 
vitamin B12 deficiency with optimal sensitivity and specificity, 2)  The inflections contribute to the 
determination of a cut-off value for subclinical vitamin B12 deficiency. This cut-off value could be used 
in research investigating the effect of treating subclinical vitamin B12 deficiency on health outcomes 
such as osteoporosis and cognitive function.
According to an earlier observation in Dutch elderly people  [2] and other populations [37, 38] we 
expected atrophic gastritis to be a substantial problem in our study population, but on the contrary, we 
observed a low prevalence of atrophic gastritis, 3%, and 8% with a less strict cut-off value. Participants 
with atrophic gastritis had significantly worse outcomes on all four biomarkers.  We do not have an 
explanation for the large difference in the observed prevalence in comparison with van Asselt et al. 
A study in New Zealand in elderly with comparable characteristics also observed a low prevalence of 
atrophic gastritis, about 7% [39]. Although measuring levels of pepsinogen I and II and addressing the 
ratio between these levels is a generally established method for the diagnosis of atrophic gastritis [27], 
the addition of serum gastrin levels or measurement of Helicobacter pylori antibodies and antibodies 
to parietal cells and intrinsic factor [40] might have added to our understanding of the state of atrophic 
gastritis in our population, but due to practical reasons this was not feasible. 
This study has also some limitations. As this study population is part of an intervention study with 
one of the inclusion criteria being an elevated tHcy level (≥12 μmol/L), biomarker status of this 
population may not totally represent the biomarker status of a general elderly population. One of the 
four biomarkers for vitamin B12 deficiency is already elevated, biomarker profiles might therefore be 
less favourable than in the general elderly population. The use of cross-sectional data prevents us from 
determining causal relations.
To summarize, our study covers a large study population with data available on four biomarkers for 
vitamin B12 status, plus on vitamin B12 intake in a subsample of the population. The availability of data 
on four biomarkers is exceptional and the results of this study add to the understanding of the mutual 
association between the biomarkers; the inflections observed in the association of total B12 and holoTC 
with MMA and tHcy could indicate cut-off levels for further testing for B12 deficiency and determining 
subclinical B12 deficiency.
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ABSTRACT
Current recommendations on vitamin B12 intake vary from 1.4-3.0 μg per day and are based on the 
amount needed for maintenance of hematological status or on the amount needed to compensate 
obligatory losses. This systematic review evaluates whether the relation between vitamin B12 intake 
and cognitive function should be considered for underpinning vitamin B12 recommendations in the 
future. The authors summarized dose-response evidence from randomized controlled trials (RCTs) 
and prospective cohort studies on the relation of vitamin B12 intake and status with cognitive function 
in adults and elderly people. Two RCTs and 6 cohort studies showed no or inconsistent associations 
between vitamin B12 intake and cognitive function. Random effects meta-analysis showed that serum 
vitamin B12 (50 pmol/l) was not associated with risk of dementia (4 cohort studies), global cognition 
z-scores (4 cohort studies) or memory z-scores (4 cohort studies). Although dose-response evidence 
on sensitive markers of vitamin B12 status (methylmalonic acid and holotranscobalamin) was scarce, 4 
out of 5 cohort studies reported significant associations with risk of dementia or Alzheimer’s disease 
or global cognition.
Current evidence on the relation between vitamin B12 intake or status and cognitive function does not 
suffice for being considered in deriving vitamin B12 recommendations. Further studies should consider 
the selection of the sensitive markers of vitamin B12 status.
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inTRoduCTion
Dietary recommendations provide guidance on nutrient intakes that should be sufficient to fulfil 
requirements of nearly all apparently healthy people in a specified population. Traditionally, these 
recommendations were intended to prevent deficiency disorders, but today the focus is slowly changing 
towards optimal health also including relations between diet and prevention of chronic diseases [1, 2]. 
Current recommendations on vitamin B12 intake are similar for adults and elderly people and vary from 
1.4-3.0 μg per day in Europe. They are based on the amount needed for the maintenance of hematological 
status and on the amount needed to compensate obligatory losses [3-5]. Relations between vitamin B12 
intake and health related outcomes, e.g. cardiovascular diseases, cognitive function, and osteoporosis, are 
not yet taken into account when deriving vitamin B12 recommendations. To support transparent decision-
making on whether these relations should be considered for setting vitamin B12 recommendations in the 
future, systematic reviews and meta-analyses are needed to objectively evaluate and integrate the available 
evidence [6]. Previously, 5 systematic reviews addressed the relation between vitamin B12 intake or 
status and cognitive function in a qualitative manner [7-11]. The aim of this review was to summarize 
dose-response evidence from randomized controlled trials (RCTs) and prospective cohort studies on the 
relation of vitamin B12 intake and status with cognitive function in adults and elderly people and to identify 
research gaps relevant for deriving vitamin B12 recommendations.
MeTHodS
This systematic review with dose-response meta-analyses was conducted according to standardized 
methodology as developed within the scope of the EURRECA (EURopean micronutrient 
RECommendations Aligned) Network of Excellence, which is shortly described below.
Search
We conducted a systematic literature search in the databases MEDLINE, EMBASE and Cochrane library 
Central through February 17, 2009, using search terms on study designs in humans AND vitamin B12 AND 
(intake OR status). The search terms both included MeSH terms and words to be found in title or abstract. 
The strategy was adapted for each database to fit database specific features. To be able to use the same 
search to identify publications on other health related outcomes both in adults and elderly and in younger 
population groups, no terms were added to limit the search to health outcome or study population. 
Moreover, by using a broad search we expected a more complete retrieval of relevant publications. The 
search was not limited by language. Web appendix 1 shows the full MEDLINE search strategy (available 
online). The initial search yielded 5,219 references after exclusion of duplicates using Endnote XII. In 
addition, we reviewed reference lists of 10 review articles reporting on the relation between vitamin B12 
intake or status and cognitive function to identify potentially relevant references that were not yet collected 
on basis of the database search (n=134). We updated the searches on February 11, 2010 (n=560) and from 
February 2010 to January 2012  we checked database alerts. 
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Selection of studies
For the selection of relevant publications for our systematic review, we used predefined in- and 
exclusion criteria. In general, studies were eligible for inclusion if they were conducted in apparently 
healthy human subjects aged ≥18 y, and addressed cognitive function as a health outcome. We defined 
4 categories of cognitive function: incident dementia, incident Alzheimer’s disease (AD), global 
cognition, and domain-specific cognition. The specific domains of cognitive function used in this review 
were based on the classification of cognitive tests proposed by Wald et al. 2010 [12]: memory, speed, 
language and executive function. Global cognition comprised assessment methods addressing different 
domains of cognition e.g. a compound z-score combining z-scores of different cognitive performance 
tests or the mini-mental state examination (MMSE) combining aspects of orientation, memory and 
attention into one questionnaire [13]. Domain-specific cognition includes cognitive performance tests 
assessing a single domain of cognitive function.
Observational studies were included if they 1) had a prospective cohort or nested case-control design, 
and 2) addressed exposure by either validated dietary assessment methods or by serum/plasma 
concentration of markers indicating vitamin B12 status (vitamin B12, methylmalonic acid (MMA) or 
holotranscobalamin (holo-TC)). Serum/plasma vitamin B12 is most commonly used as a marker of 
vitamin B12 status, however, the functional markers of vitamin B12, holo-TC and MMA, have been 
suggested as more sensitive and specific. Holo-TC represents the fraction of vitamin B12 that is delivered 
to body cells and MMA is the substrate for the vitamin B12 dependent enzyme methylmalonyl CoA 
mutase, so in case of vitamin B12 deficiency MMA levels will increase [14-17].
Intervention studies were included if they 1) had a randomized controlled trial design, 2) studied the 
effects of supplements, fortified foods or micronutrient intake from natural food sources and included a 
placebo or untreated comparison group, and 3) had minimum intervention duration of 2 weeks. Studies 
were excluded if they only included patients with pre-existing disease because relations of vitamin B12 
intake or status with cognitive function in such study populations may not be representative for the 
general apparently healthy population. 
First, 2 reviewers (ED, SB) screened titles and abstracts of all references identified with the searches 
according to the in- and exclusion criteria. Secondly, 4 reviewers (ED, JvW, AS, MP) evaluated full 
texts of the remaining references against the same criteria. For the purpose of alignment and quality 
control, each reviewer screened and evaluated 10 percent of the total number of references in duplicate 
with another reviewer. The rare discrepancies were resolved by group consultation among all reviewers 
until consensus was reached. During the selection process all reasons for exclusion were registered and 
details are shown in Figure 1.
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Figure 1. Study selection process for systematic review RCT, Randomized controlled trial; MMA, methylmalonic 
acid, holo-TC, holotranscobalamin
data extraction
Data extraction was performed by a single reviewer (ED, JvW, or AS) using standardized data extraction 
forms in an Access database. A second reviewer verified the data. Disagreements were discussed and 
settled, if needed in consultation with a third reviewer. Data extracted included general characteristics 
of the study design and study population; details on measures of intake, status and cognitive function; 
details on data analysis and results. In addition, we extracted information concerning the validity of 
studies including sequence allocation (RCT), blinding (RCT), compliance (RCT), reproducibility and 
between-population comparability of intake, status and cognitive measures, control for confounders (at 
least age, sex, education, vascular disease, ApoE-4) and other forms of bias. We assessed the overall 
risk of bias of each individual study using standardized procedures largely based on guidance from the 
Cochrane Collaboration [18], resulting in one of the following judgments: low, moderate or high risk 
of bias.
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data-synthesis
Opportunities for meta-analysis were evaluated for comparability with regard to cognitive outcome, 
intake or status marker and the study population. If less than 3 comparable studies were available, 
results were qualitatively described. If 3 or more comparable studies were available, we carried out a 
dose-response meta-analysis that pools the relative risk (RR) per change in unit of exposure (binary 
outcomes) or the regression coefficient (β) (continuous outcomes) from multiple adjusted models. 
For serum/plasma vitamin B12 we chose to express association measures per 50 pmol/l. Hazard ratios 
(HR) and odds ratios (OR) were considered as RR because the outcome was relatively rare. If articles 
reported insufficient data (missing data, inconsistencies or any other uncertainties), we requested 
corresponding authors for additional information. 
None of the studies on incidence of dementia or AD provided data in the desired format, but rather 
presented the risk of dementia or AD comparing subjects with high versus low vitamin B12 intake [19-
21], low versus normal vitamin B12 status  [22-25] or the number of cases and controls among subjects 
with and without vitamin B12 deficiency [26]. One author provided us with the log (RR) and its 
standard error (SE) upon request [22] and for 6 other studies we were able to derive the log (RR) (SE) 
based on reported data [19-21, 23] and data provided by the authors [25] as described in detail in web 
appendix 2 (available online). One author did not respond to our requests, and data were insufficient 
to derive the log (RR) (SE) [24].
All studies on global cognition included repeated measures of global cognition scores. Two studies 
did not report details on the association with vitamin B12 intake or status [27, 28]. We requested 
the authors to provide us with the missing data, but they were not able to respond to our request in 
time. Associations with vitamin B12 status were most frequently assessed by the use of linear mixed 
models including serum/plasma concentrations of a vitamin B12 status marker, a time variable and the 
interaction term of vitamin B12 status and time [29-31]. In such models, the regression coefficient for the 
interaction term represents the rate of change in global cognition attributable to an increase in vitamin 
B12 status additional to the deterioration in global cognition as a result of aging. Other studies presented 
associations between baseline serum vitamin B12 and serial [32] or follow-up [33] global cognition 
scores, associations between baseline plasma vitamin B12 and changes in cognitive decline during follow-
up [34, 35], Spearman rank correlations between changes in plasma vitamin B12 and MMSE-scores [36], 
or mean changes in MMSE-scores by changes in serum vitamin B12 [37]. In 4 studies concentrations 
of vitamin B12 status markers were log-transformed [29, 32-34] and 1 study presented associations per 
standard deviation increase in serum vitamin B12 [30]. We requested corresponding authors to provide 
us with the regression coefficient (SE) for the interaction term (vitamin B12 status*time) including 
untransformed continuous serum/plasma vitamin B12 concentrations. One study already reported data 
in the desired format [31] and 3 authors [30, 33, 35] provided the data upon request.
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We requested authors of studies only providing data on MMSE-scores [29, 32-34, 36] to repeat the 
analyses with MMSE expressed as a z-score, one author provided us with the requested data [33]. 
Studies identified for domain-specific cognition addressed several cognitive domains, however, only for 
the domains executive function [30, 33, 38] and memory [30, 33, 35, 38] 3 or more comparable studies 
were available. Although studies were comparable, there was still variation with regard to the cognitive 
performance tests used, the frequency of cognitive performance testing, and statistical methods used 
to assess the association between executive function or memory and vitamin B12 status. Therefore we 
requested corresponding authors to provide us with the regression coefficient (SE) for the association 
between untransformed vitamin B12 status measured at baseline and cognitive performance test scores at 
follow-up expressed as z-scores. Four authors provided these data upon request [30, 33, 35, 39], enabling 
us to perform a meta-analysis for the domain memory. 
Statistical analyses
We calculated summary estimates of comparable studies using random effects meta-analysis. Applying 
the methods of DerSimonian and Laird, the between-study variance is estimated which is then used 
to modify the weights for calculating the summary estimate [40]. Heterogeneity between studies was 
evaluated using the I2 statistic, which expresses the percentage of variation attributable to between-study 
heterogeneity rather than chance [41]. All statistical analyses were performed using STATA version 11.0 
(College Station, TX), with statistical significance defined as a P-value <0.05.
ReSulTS
In total, we identified 5,913 potentially relevant papers, of which 5,003 papers were excluded based on 
title and abstract. Of the remaining 910 papers, 889 were excluded based on full texts, leaving 21 papers 
addressing the relation between vitamin B12 intake or status and cognitive function. Four additional 
papers were identified from the database alerts (Figure 1). From the 25 included studies, 2 RCTs and 
6 prospective cohort studies addressed the relation between vitamin B12 intake and cognitive function. 
Nineteen prospective cohort studies addressed the relation between vitamin B12 status, measured by 
serum/plasma vitamin B12 (n=17), MMA (n=3) or holo-TC (n=4) and cognitive function. 
vitamin B12 intake and cognitive function
Details on the studies addressing the relation between vitamin B12 intake and cognitive function are presented 
in Table 1. 
Three studies involving 5,254 elderly people were included in a meta-analysis pooling relative risks for incidence 
of AD (431 cases) during 3.9 to 9.3y follow-up per µg increase in vitamin B12 intake at baseline [19-21]. Cases of 
AD were diagnosed based on commonly used criteria [42, 43]. The summary estimate showed no association 
between vitamin B12 intake and incidence of AD (RR=0.99, 95% Confidence interval (CI): 0.99, 1.00) with no 
heterogeneity between studies (I2=0%, p=0.92)
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Studies on incident dementia [21] or global cognition assessed by MMSE [33, 44] or a compound z-score 
[28] did not show significant associations with vitamin B12 intake. One RCT [45] and 2 prospective cohort 
studies  [33, 38] addressed the association between vitamin B12 intake and domain-specific cognition. For the 
domain executive function the 2 prospective cohort studies found that higher vitamin B12 intakes at baseline 
were associated with a better cognitive performance after 3 or 6 years of follow-up [33, 38] whereas the RCT 
did not show beneficial effects of daily vitamin B12 supplementation [45]. For the domain memory results were 
largely inconsistent showing a positive [38], negative [45]  or no [33, 38] association. The cognitive domains 
speed and language were only addressed in single studies and no associations with vitamin B12 intake were 
observed  [33, 45].
vitamin B12 status and incident dementia or Ad
Table 2 presents details of the prospective cohort studies investigating the association between vitamin B12 status 
and incidence of dementia or AD. Dementia and AD were diagnosed based on similar criteria (dementia: [43, 
46-48]; AD: [42, 43, 49]). 
Four studies involving 2,630 elderly people (age range: 60-101 year) were included in a meta-analysis pooling 
relative risks for incidence of dementia (263 cases) during 2.4 to 4.5y follow-up per 50 pmol/l increase 
in serum/plasma vitamin B12 concentrations at baseline [22, 23, 26]. The summary estimate showed no 
association between serum/plasma vitamin B12 and incidence of dementia (RR=1.00, 95% CI: 0.98, 1.02) with 
little heterogeneity between studies (I2=9.1%, p=0.35) (Figure 2). Similar to this finding, Ravaglia et al. (2005) 
[24] reported that low serum vitamin B12 concentrations (≤250 pmol/l) did not significantly increase the risk 
of dementia. Although Kivipelto et al. (2009) [50] found no association between holo-TC as a continuous 
variable and risk of dementia, the third quartile of holo-TC was associated with a reduced risk of dementia.
Figure 2. Forest plot of association between serum/plasma vitamin B12 (50 pmol/l) and risk of dementia: Meta-
Analysis of 4 prospective cohort studies (n=2630, 263 cases). RR, relative risk; CI, confidence interval.
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Five studies reported on the association between vitamin B12 status (serum vitamin B12 n=3, holo-TC n=2) 
and incidence of AD. Studies on serum vitamin B12 showed no significant associations [24-26]. Higher 
baseline concentrations of holo-TC were significantly associated with a reduced risk of AD in one study [51]. 
These results were not in line with findings from Kivipelto et al (2009), reporting no significant association for 
holo-TC as a continuous variable. However, the latter study did report a reduced risk of AD associated with the 
third quartile of holo-TC concentrations.
vitamin B12 status and global cognition
For global cognition, we identified 4 prospective cohort studies on serum/plasma vitamin B12 and compound 
z-scores [27, 30, 31, 35], and 6 prospective cohort studies on serum/plasma vitamin B12 and MMSE-scores [29, 
30, 32, 33, 36, 37] (Table 3). 
From 4 cohort studies including 1,579 elderly people, we obtained the regression coefficient for associations 
between additional annual change in compound z-score [30, 31, 35] or MMSE z-score [33] and serum/plasma 
vitamin B12 concentrations (50 pmol/l). A pooled analysis of the results showed no overall association (β=0.00, 
95% CI: -0.00, 0.01), with moderate heterogeneity between studies (I2=42.6%, p=0.16) (Figure 3). In line with 
this finding, De Lau et al. (2009) [27] observed no association for plasma vitamin B12 with rate of cognitive 
decline during follow-up.
Figure 3. Forest plot of association between serum/plasma vitamin B12 (50 pmol/l) and additional rate of change 
in global cognition z-scores: Meta-Analysis of 4 Prospective Cohort Studies (n=1579).
CI, confidence interval.
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For MMSE-scores we did not have sufficient data available in the desired format to perform a meta-
analysis and therefore results are qualitatively described. In line with the finding from the pooled 
analysis, 3 studies showed that the additional rate of change in MMSE-score was not significantly 
associated with serum vitamin B12 concentrations [29, 30, 33]. Moreover, Eussen et al. (2002) [36], 
Kado et al. (2005) [34] and Kim et al. (2008) [37] reported no significant associations between serum/
plasma vitamin B12 concentrations and global cognition (Table 3). In contrast, Feng et al. (2009) [32] 
showed that higher serum vitamin B12 concentrations at baseline (natural log transformed, pmol/l) 
were significantly associated with better repeated MMSE-scores during follow-up. 
Longitudinal data on MMA and holo-TC in relation to global cognition scores were scarce. Clarke et al. 
(2007) [29] reported the additional change in MMSE-score during 10 y related to a doubling in MMA 
(μmol/l) and holo-TC concentrations (pmol/l) at baseline. A doubling of MMA concentrations 
was associated with about 60 percent faster rate of cognitive decline and a doubling of holo-TC 
concentrations was associated with a 40 percent slower rate of cognitive decline. In addition, Tangney 
et al. (2009) [31] reported that higher MMA concentrations (μmol/l) were associated with a more 
rapid deterioration of global cognition assessed with a compound z-score of 4 tests. De Lau et al. 
(2009) [27] observed no significant association for MMA or holo-TC with rate of cognitive decline 
during follow-up.
vitamin B12 status and domain specific cognition
Five prospective cohort studies investigated associations between serum/plasma vitamin B12 and 
memory (n=5), executive function (n=3), speed (n=1) and language (n=1) (Table 4). 
For the domain memory we pooled associations between memory z-scores at 3, 4, or 6 years follow-up 
and serum/plasma vitamin B12 concentrations at baseline (50 pmol/l) from 4 studies [30, 33, 35, 39] 
including 3,460 elderly people. The studies of Mooijaart et al. (2005) [30] and Tucker et al. (2005) 
[33] both included 2 memory scores (word list and word list recall at 30 min [30] or word list and 
backward-digit span[33]). Therefore we performed 2 meta-analyses, one with the word list scores 
and one with the other 2 memory scores, but for both analyses the overall associations were similar 
(β=0.01, 95% CI:-0.01, 0.03), with no evidence for heterogeneity between studies (I2=0.0%, p=0.99). 
In line with these results, La Rue et al. (1997) [38] reported that Spearman correlations between serum 
vitamin B12 at baseline and 3 different memory scores at 6 years follow-up were not significant (no data 
available).Associations between serum vitamin B12 concentrations at baseline and executive function 
at follow-up were assessed in 3 cohort studies [30, 33, 38]. La Rue et al. (1997) [38] and Mooijaart et 
al. (2005) [30] showed no significant associations, whereas Tucker et al. (2005) [33] observed that 
higher serum vitamin B12 concentrations (50 pmol/l) were associated with a better executive function 
score at 3 years follow-up. The cognitive domains language [33] and speed [30] were both assessed in 
single studies, but no associations with serum vitamin B12 were found. 
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Main findings
The available evidence from a limited number of RCTs and prospective cohort studies in elderly people 
does not support the hypothesis that vitamin B12 intake or status is related with dementia, AD or global 
cognition. For domain-specific cognition, some prospective cohort studies observed associations 
between vitamin B12 intake or serum vitamin B12 and executive function or memory, however, results 
were inconsistent. Significant associations were shown between MMA or holo-TC and risk of dementia 
or AD or global cognition scores indicating better cognitive function with better vitamin B12 status, 
but these findings originate from only 4 prospective cohort studies. Overall, these results suggest that 
current evidence on the relation of vitamin B12 intake or status with cognitive function does not suffice 
for being involved in deriving recommendations on vitamin B12 intake as the evidence-base for the 
presence of an association is limited and not supportive. 
Methodological considerations of this meta-analysis
Previous systematic reviews on the relation of vitamin B12 intake or status with cognitive function 
reported a large heterogeneity between studies, mainly with regard to cognitive outcomes, cut-off 
levels indicating low vitamin B12 status and data analyses [7-11]. This heterogeneity limited previous 
meta-analyses. A strength of our review is that we dealt with these sources of heterogeneity by defining 
4 clusters of cognitive outcomes that were separately reviewed: dementia, AD, global cognition and 
domain-specific cognition. The domain-specific outcomes were further categorized as measuring 
memory, executive function, speed or language to cover the large variation in cognitive performance 
tests used between studies. 
To overcome the variation in cut-off levels for low vitamin B12 status and to allow comparison 
and subsequent combination of individual studies, we expressed results of individual studies in a 
standardized format: Relative risk (binary outcomes) or regression coefficient (continuous outcomes) 
per change in untransformed unit of exposure. Most of the included studies reported results based 
on untransformed vitamin B12 concentrations whereas few studies reported results based on log-
transformed [32, 33] or square root transformed [22] units of exposure because the distribution 
of  serum vitamin B12 concentration within the study population was skewed. We chose to use 
untransformed data as there is no evidence to assume that the association between vitamin B12 and 
cognitive function is not continuous across the common range of exposure [52]. Meta-analyses of 
associations based on log-transformed data would probably not alter our conclusions as both results 
from studies using log-transformed data and those using untransformed data were similar.
A common concern in meta-analyses is statistical heterogeneity between studies. Among the meta-
analyses reported here, we only observed moderate statistical heterogeneity for the association 
between serum vitamin B12 and global cognition. We were not able to explain this heterogeneity 
with meta-regression due to the limited number of studies included, however potential sources of 
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heterogeneity are: age of the study populations (mean age 63-85 years), tests used to measure global 
cognition (MMSE, or compound z-score of 4-6 tests), duration of follow-up (3-10 years) and level of 
adjustment for confounders. Although most included studies adjusted for a wide range of confounders 
for cognitive function, residual confounding by other unmeasured or inadequately measured factors 
cannot be ruled out. 
As the quality of included studies determines the quality of the meta-analysis, we assessed the risk of 
bias for each study identified in our review. Five prospective cohort studies were evaluated as having a 
low risk of bias, as confounders were appropriately dealt with, measures of vitamin B12 intake or status 
were adequate and no other serious risks of bias were identified [21, 29, 32, 39, 51]. The other 20 
studies (2 RCTs and 18 prospective cohort studies) were evaluated as having moderate or high risk 
of bias as methods used for sequence generation or allocation concealment were unclear [44, 45], 
important risk factors were not evaluated for their confounding potential (ApoE-ɛ4 [19, 22, 23, 25, 
27, 28, 30, 31, 33-35, 37], vascular disease [20, 50], or data were not reported in sufficient detail to be 
used in meta-analysis [24, 26-28, 36-38]. Due to the limited number of studies included in the different 
meta-analyses, we were not able to study the effect of study quality on the pooled effect measures.
Reflection on our results and considerations for future research
Observational studies
Prospective cohorts studying associations between vitamin B12 intake and cognitive function were 
limited. This is likely to be related to difficulties in interpreting values on vitamin B12 intake in elderly 
people. Although intakes of vitamin B12 generally exceed the current recommended amounts, the 
prevalence of vitamin B12 deficiency among elderly people in Western countries is estimated to be 20 
percent [53]. The main cause for vitamin B12 deficiency in elderly people is food-bound malabsorption 
due to atrophic gastritis, a clinical condition accompanied by limited or absent secretion of gastric 
acid [54]. A study including elderly with this condition showed that plasma vitamin B12 levels were 
significantly correlated with vitamin B12 intake from supplements and fortified foods, but not with 
vitamin B12 intake from unfortified foods [55]. In addition intestinal absorption of vitamin B12 may be 
compromised by the use of acid lowering agents including proton-pump inhibitors and H2-blockers. 
These medicines are commonly used by elderly people, however available data on the association 
between vitamin B12 status and the use of these acid lowering agents is inconsistent [56, 57]. To deal 
with the potential issue of malabsorption the use of markers for vitamin B12 status is preferred over 
measures of vitamin B12 intake when studying associations with cognitive function in elderly people.
Prospective cohort studies on associations between vitamin B12 status and cognitive function mainly 
addressed serum/plasma vitamin B12 concentrations which is considered to be a less sensitive and 
specific marker of vitamin B12 status than MMA or holo-TC [14]. A recent study published after the 
end date of our search showed that higher holo-TC concentrations were related to better performance 
in executive function and psychomotor speed among non-demented elderly people [58]. Holo-TC 
was additionally associated with global cognition (MMSE) and had a borderline significant association 
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with verbal expression when including dementia subjects in the analyses. Supported by findings from 
studies with a case-control or cross-sectional design MMA and holo-TC seem to be more sensitive 
to global cognition and domain-specific cognitive performance than serum vitamin B12 [29, 31, 59, 
60] whereas results on incidence of AD were inconsistent [61-63]. However, more prospective cohort 
studies are needed to confirm these observations. 
RCTs
As shown in this review, the limited evidence from RCTs showed no effects of oral vitamin B12 
supplementation on cognitive performance. RCTs on the effects of intramuscular injections with 
vitamin B12 were excluded from this review as they do not reflect dietary intake of vitamin B12, however 
these trials did not provide evidence for a beneficial effect of supplementation on cognitive performance 
either [64-66]. Data from short-duration (<4 months) trials on the effect of vitamin B12 in combination 
with other B-vitamins (folic acid, vitamin B6) on cognitive performance tests did not show any 
effects [45, 67-70], whereas trials with a duration of 2 years did show a beneficial effect of B-vitamin 
supplementation on executive function/speed [71, 72]. However, de Jager et al. (2011) only observed 
a significant benefit in MCI patients with high homocysteine levels at baseline (≥11.3 µmol/l) [71]. 
Two trials including subjects with mild to moderate AD did not show an effect of 1.5-2 years B-vitamin 
supplementation on the rate of cognitive decline [73, 74]. More RCTs on the effect of vitamin B12 
on cognitive function are needed that are designed according to the recommendations from previous 
consensus meetings regarding sample sizes, selection of study populations, study duration and doses 
[52, 75-79].
Measures of cognitive function
Many different mechanisms have been suggested for the potential relation between vitamin B12 and 
cognitive performance as summarized by Smith and Refsum (2009)[52]. A commonly suggested 
mechanism is that a low vitamin B12 status compromises methylation reactions in the central nervous 
system. Besides, low-normal vitamin B12 status may affect the brain via elevated levels of homocysteine, 
raised concentrations of MMA or changes in cytokine concentrations. Neuro-imaging studies have 
shown that changes in brain structures and brain volume are associated with cognitive decline [80]. In 
addition, low-normal vitamin B12 status has been associated with loss of brain tissue (atrophy) [81-83] 
and damage to the white matter [27, 81] in healthy elderly people. A recent trial including patients 
with mild cognitive impairment showed a 30 percent lower rate of brain atrophy in participants after 2 
year supplementation with high doses of vitamin B6, folic acid and vitamin B12 as compared to placebo. 
In participants with elevated homocysteine levels, the rate of atrophy was even 53 percent lower after 
supplementation. The rate of atrophy was significantly inversely associated with change in vitamin 
B12 status as measured by serum vitamin B12 or holo-TC [84]. These data indicate that measures of 
brain atrophy alone or in combination with domain-specific tests may be more sensitive for examining 
associations between vitamin B12 intake or status and cognitive performance.
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ConCluSionS
Current evidence on the relation between vitamin B12 intake or status and cognitive function does not 
suffice for being involved in deriving recommendations on vitamin B12 intake as the evidence-base for 
the presence of an association is too narrow. Further studies should consider the selection of sensitive 
markers of vitamin B12 status (MMA and holo-TC) as a proxy for vitamin B12 intake, and measures of 
brain atrophy alone or in combination with domain-specific tests as cognitive outcomes. 
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ABSTRACT
Elevated homocysteine levels and low vitamin B12 and folate levels have been associated with 
deteriorated bone health. This systematic literature review with dose-response meta-analyses 
summarizes the available scientific evidence on associations of vitamin B12, folate and homocysteine 
status with fractures and bone mineral density (BMD). 
Twenty-seven eligible cross-sectional (n=14) and prospective (n=13) observational studies and one 
RCT were identified. Meta-analysis on four prospective studies including 7475 people showed a modest 
decrease in fracture risk of 4% per 50 pmol/L increase in vitamin B12 levels, which was borderline 
significant (RR=0.96, 95% CI = 0.92 to 1.00). Meta-analysis of eight studies including 11511 people 
showed an increased fracture risk of 4% per µmol/l increase in homocysteine concentration (RR=1.04, 
95% CI = 1.02 to 1.07). We could not draw a conclusion regarding folate levels and fracture risk, as too 
few studies investigated this association. Meta-analyses regarding vitamin B12, folate and homocysteine 
levels and BMD were possible in female populations only and  showed no associations. Results from 
studies regarding BMD that could not be included in the meta-analyses were not univocal.
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inTRoduCTion 
Osteoporosis is a chronic, multifactorial disorder which is characterized by low bone mass and 
microarchitectural deterioration of bone tissue [1]. Its major consequence is fractures. Especially hip 
fractures are frequently associated with institutionalization and increased mortality, and thus with an 
increased social and economic burden. This burden is expected to increase substantially in Europe in 
the coming decades due to a rise in life expectancy [2]. 
Elevated homocysteine concentrations and low vitamin B12 and folate status have been associated in 
several studies with lower bone mineral density (BMD) and higher fracture risk in elderly [3-11]. 
An elevated plasma homocysteine level (>15µmol/l)  is prevalent in 30-50% of people older than 
60 years [12-14].  The cause is multifactorial; a combination of environmental and genetic factors, 
nutrition, lifestyle and hormonal factors [15]. Vitamin B12 and folate are major determinants of 
homocysteine metabolism [16, 17], and supplementation with vitamin B12 and folic acid has been 
shown to be effective in normalizing homocysteine levels [18, 19]. Reversing elevated homocysteine 
levels through folic acid and vitamin B12 supplementation could theoretically prevent  the problem of 
impaired bone health and osteoporosis. However, at present, no consensus is reached on the magnitude 
of the association between vitamin B12, folate, homocysteine and bone health nor on the possible effect 
of vitamin B12 and folate supplementation on bone health.
Up until now one systematic review including a meta-analysis summarized the evidence on 
homocysteine and fracture risk, showing that higher homocysteine levels significantly increase the risk 
of fracture [20]. No meta-analyses are known on the topic of folate and vitamin B12 in relation to bone 
health. The purpose of this article is to provide a systematic overview, where possible including pooled 
estimates of the dose –response association, of the scientific evidence available from randomized 
controlled trials (RCTs), prospective cohort and cross-sectional studies addressing vitamin B12, folate 
and homocysteine levels in association with bone health, i.e. fracture risk and BMD, in adults and 
elderly people. 
Methods
This systematic review with dose-response meta-analyses was conducted within the scope of the 
EURRECA (European Micronutrient Recommendations Aligned) Network of Excellence (http://
www.eurreca.org) [21].  We followed a standardized methodology which is described in short below.
Search strategy and selection of articles
We conducted systematic literature searches for 1) vitamin B12 2) folate and 3) homocysteine. The 
electronic databases MEDLINE, EMBASE and Cochrane Library Central were searched, using 
search terms in ‘MeSH’ terms and ‘title’ and ‘abstract’ on: study designs in humans, vitamin B12, folate, 
homocysteine, and intake or status. The full search strategy is shown in Appendix I. 
To be able to use the same search to identify publications on other health related outcomes both in 
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adults and elderly and in younger population groups, no terms were added to limit the search to health 
outcome or study population. Moreover, by using a broad search we expected a more complete retrieval 
of relevant publications. In this review only the results on vitamin B12, folate and homocysteine status 
(i.e. biomarkers measured in serum or plasma) in relation to bone health indicators (fracture risk and 
BMD) are presented. In addition to the search, reference lists of 10 review articles were checked to 
identify potentially relevant references that were not identified with the multi-database search. The 
search was not limited by language. This review contains studies up to July 2012.
We selected articles in two steps. The first selection step included screening for title and abstract by 
three independent investigators ( JvW, ED, SB). In the second selection step, full texts of the selected 
abstracts were evaluated on basis of predefined inclusion criteria by four investigators ( JvW, ED, AS, 
MP). 
For the purpose of alignment and quality control 10% of the references in each selection step was 
screened and selected in duplicate by two investigators independently. Results were compared and 
discrepancies were resolved by unanimous consensus among all investigators. 
Studies were eligible for inclusion if they were conducted in apparently healthy human subjects aged 
≥18 y. Furthermore, studies had to report fracture incidence, fracture risk or bone mineral density 
(BMD) as a health outcome and had to report baseline data on the outcome measure. 
Observational studies were included if they 1) had a prospective cohort, nested case-control or cross-
sectional design, and 2) addressed serum/plasma concentration of markers indicating vitamin B12 
status (serum/plasma vitamin B12, methylmalonic acid (MMA) or holotranscobalamin (holoTC)), 
folate status (serum/plasma folate or erythrocyte folate), or homocysteine status (serum/plasma 
homocysteine). Intervention studies were included if they 1) had a randomized controlled trial 
design, 2) studied the effects of vitamin B12 or folic acid supplements, fortified foods or micronutrient 
intake from natural food sources and included a placebo or untreated comparison group, and 3) had a 
minimum intervention duration of six months.
Data extraction and statistical analysis
We extracted data for each of the identified studies on population characteristics, study design, 
assessment of vitamin B12, folate and homocysteine status and fracture risk or bone mineral density. 
Opportunities for meta-analysis were evaluated based on comparability of health outcome and status 
marker. If less than three comparable studies were available, results were qualitatively described. If three 
or more comparable studies were available, the results of these individual studies were expressed in 
a standardized format to allow comparison in the form of a continuous dose-response meta-analysis 
that pools the regression coefficient (β) (SE) from multiple adjusted models. We chose to express 
association measures for serum/plasma vitamin B12 per 50 pmol/L. When βs were not reported in the 
original article, we transformed Relative Risk (RR), Hazard Ratio (HR) or Odds Ratio (OR) to βs, 
using a standardized method [22]. The transformations to obtain βs and SEs and statistical analyses were 
performed using R statistics version 2.9.2 (www.R-project.org), with statistical significance defined as 
p<0.05. HR and OR were considered as RR because the outcome was relatively rare.. If articles reported 
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insufficient data (missing data, inconsistencies or any other uncertainties), we contacted corresponding 
authors for additional information. 
We calculated summary estimates of comparable studies using random effects meta-analysis. Applying 
the methods of DerSimonian and Laird, the between study variance was estimated which was used to 
modify the weights for calculating the summary estimate [23]. Residual heterogeneity between studies 
was evaluated using Q-statistic and I2 statistic. 
In total, from 3 searches we identified 11837 potentially relevant articles, of which 9835 articles were 
excluded based on title and abstract. Of the remaining 2002 articles, 1961 articles were excluded based 
on full texts, leaving 41 articles. As the searches were partly overlapping, and some articles addressed 
more than one association this resulted in 20 unique articles, 19 observational and 1 intervention. A 
search update on July 2nd, 2012 resulted in an additional 8 observational studies, which makes a total of 
28 included articles. All addressed the association between vitamin B12, folate or homocysteine status, 
and fracture risk or BMD. The flow diagram of the process of screening and selection is shown in Figure 1.
 
Figure 1. Flow diagram of screening and selection.
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ReSulTS
fractures 
Vitamin B12
Four longitudinal observational studies [3, 24-26], including 7475 elderly people with 3 to 16 years of 
follow-up and a total of 458 cases addressed the association between serum/plasma vitamin B12 and 
fracture (Table 1). Pooled analysis of the association between 50 pmol/L increase in plasma/serum B12 
and change in fracture risk showed an inverse association (RR= 0.96, 95% CI= 0.92 to 1.00) with no 
heterogeneity between studies (I2= 0%, p= 0.84) (Figure 2). This indicates that a vitamin B12 increase 
of 50 pmol/L tends to decrease the risk of fracture with 4%. 
	  
Figure 2. Forest plot of vitamine B12 status - fracture risk
Folate 
Three longitudinal observational studies examined the association between plasma folate and fractures 
[24-26] (Table 2). One study showed that women, but not men, with plasma folate in the lowest 
quartile had a higher fracture risk (HR 2.40, 95% CI 1.50 to 3.84) compared to the highest (reference) 
quartile (p for trend <0.001) [24]. Ravaglia et al. (2005) showed a significant association between low 
folate status and fracture risk when folate was analyzed as a dichotomous variable (lowest quartile of 
folate status vs other 3 quartiles), but when analyzed as a continuous variable, no significant association 
was observed [26]. One study did not observe an association [25]. 
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Homocysteine 
Eleven longitudinal observational studies examined the association between homocysteine status and 
fracture incidence [3-5, 25-29] (Table 3). A meta-analysis of eight studies, including 11511 elderly 
people with 3 to 12.6 years of follow up and 1353 cases, showed a significantly increased fracture risk 
with increasing plasma homocysteine (µmol/L) (summary estimate RR 1.04, (95% CI: 1.02 to 1.07). 
Heterogeneity between studies was large (I2=60.57%, p=0.0002) (Figure 3). When hip fractures (3 
studies; [24, 28, 29]) and total fractures (5 studies; [3, 26, 27, 30, 31]) were analyzed separately, the 
relation remained significant, 1.06 (95% CI: 1.03 to 1.08, I2=0.00%, p=0.72) and 1.04 (95% CI: 1.00 to 
1.08, I2=65.02%, p=0.011).  
	  
Figure 3. Forest plot of homocysteine status - fracture risk
Three studies that were not included in the meta-analysis also showed significant associations between 
homocysteine levels and fracture risk. These studies were not included because the necessary data 
could not be retrieved from the articles; either homocysteine levels were log-transformed [4, 5] or data 
were not shown on population homocysteine status [25]. Regardless the type of analysis, women and 
men in the highest homocysteine quartile had a 1.7 to 3.8 higher RR or HR than those in the lowest or 
the lowest three quartiles [4, 5, 25].        
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Bone Mineral density 
In the studies included in this review BMD was measured at various sites in the body (e.g. lumbar 
spine, femoral neck, radius, hip, total body). As BMD differs per site in the body, we pooled results 
per biomarker (serum/plasma vitamin B12, folate and homocysteine) and per site for the three sites 
generally measured (FN, LS or total hip), thus resulting in 9 meta-analyses. Betas of the individual 
studies are shown in Table 1, 2, and 3. The studies included in the meta-analyses took only women 
into account. Only five studies regarding BMD included a male population [6, 7, 10, 32, 33], and 
these studies were not comparable quantitatively because differences in the presentation of results or 
differences in the measured BMD sites.
Vitamin B12
Pooled analysis showed no association between serum/plasma vitamin B12 levels and BMD in women; 
FN: β=0.00, 95% CI: -0.13 to 0.14, I2=0.00%, p=0.4018 [9, 34, 35]; LS: β=-2.25, 95% CI: -7.98 to 
3.49, I2=99.47%, p<0.0001 [9, 34-36]; total hip β=-2.23, 95% CI: -10.38 to 5.92, I2=97.71%, p=0.0001 
[34-37].  The studies that could not be included in the meta-analyses showed diverse results; in six out 
of eight studies low serum/plasma vitamin B12 was significantly associated with low BMD at at least 
one site [6, 7, 11, 32, 33, 38]. Two studies did not observe an association between vitamin B12 status 
and BMD [39, 40]. Morris et al. addressed MMA levels as well as a marker for vitamin B12 status, and 
observed a lower BMD with higher serum MMA concentrations [7].
Folate 
Pooled analysis showed no association between serum/plasma folate and BMD in women; FN: β=0.00, 
95% CI: -0.03 to 0.03, I2=0.00%, p=0.8810 [9, 34, 35]; LS: β=0.01, 95% CI: 0.00 to 0.01, I2=0.00%, 
p=0.7674 [9, 34-36]; total hip: β=0.00, 95% CI: 0.00 to 0.01, I2=78.47%, p=0.0003 [10, 34-37]. 
From the studies that could not be compared in a meta-analysis, three studies showed significant 
associations between folate status and BMD or change in BMD over time [8, 10, 39]. Five studies did 
not observe an association between folate status and BMD [7, 33, 38, 40, 41].
Homocysteine
Pooled analyses showed no association between serum/plasma homocysteine levels and BMD in 
women; FN: β=-0.01, 95% CI: -0.04 to 0.02, I2=31.48%, p=0.2116 [9, 27, 34, 35]; LS: β=-0.01, 95% CI: 
-0.08 to 0.05, I2=98.44%, p<0.0001 [9, 27, 34-36]; total hip: β=-0.03, 95% CI: -0.08 to 0.02, I2=99.87%, 
p<0.0001 [10, 27, 34-37]. The studies that could not be pooled showed diverse results. In five studies 
a high homocysteine level was significantly associated with low BMD or change in BMD over time 
at at least one site [7, 29, 31, 38, 41]. Three studies did not observe a significant association between 
homocysteine status and BMD or change in BMD [8, 39, 40]. 
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Intervention studies:
Up until now, only one RCT (N=47) which met our inclusion criteria studied the efficacy of B-vitamin 
supplementation on BMD [42]. This study shows some evidence that BMD may be increased with 
high doses of B-vitamin supplementation in people with hyperhomocysteinemia (tHcy >15µmol/L). 
However, this outcome was only found in a sub-analysis of 8 hyperhomocysteinemic subjects. [42].
diSCuSSion
Our meta-analyses showed a significant association of homocysteine levels with fracture risk, a weak 
though significant inverse association of vitamin B12 levels with fracture risk. We could not draw a 
conclusion regarding folate levels and fracture risk, as too few studies investigated this association. 
Meta-analyses regarding vitamin B12, folate and homocysteine levels and BMD in women found no 
associations. Results from studies regarding BMD that could not be included in the meta-analyses are 
not univocal.
 
To our knowledge this systematic review with meta-analyses is the most extensive systematic review 
on the association of vitamin B12, folate and homocysteine with bone health until now. Previous non-
systematic literature reviews on the association between folate, vitamin B12 and homocysteine with 
bone health reported similar results, i.e. conflicting evidence with suggestions towards the association of 
homocysteine levels with fracture [43-45]. These reviews did not report a systematic literatures search 
strategy and did not provide a quantitative cumulative result. In our review the most recent published 
articles have been taken into account. The search strategy we used was systematic and extensive, and we 
used well-defined in- and exclusion criteria. 
One recent systematic review included a meta-analysis on the association between tHcy and fractures 
[20]. This meta-analysis is different in design than ours, as it is not a dose-response meta-analysis. 
To overcome the variation in cut-off levels for low vitamin B12 and folate status, high homocysteine 
status, and to allow comparison and subsequent combination of individual studies in the performed 
meta-analyses, we expressed results of individual studies in a standardized format. We assumed a linear, 
continuous dose-response association between markers of vitamin B12 and folate with fracture rather 
than a threshold effect. This assumption is generally used in meta-analyses. Furthermore, in some of the 
key articles addressing the association of homocysteine levels with fractures this association is present 
[4, 5]. 
A common concern in meta-analyses is heterogeneity between studies. In our meta- analyses we 
experienced various levels of statistical heterogeneity (no heterogeneity to large heterogeneity). 
The heterogeneity may be explained by the differences in mean age of the study populations (41-78 
years), differences in mean status of vitamin B12 (190-549 pmol/L), folate (5.2-24.9 nmol/L) and 
homocysteine (9.3-16.5 µmol/L), differences in sex distribution of the study populations, duration 
of follow up (3-16 years) and level of adjustment for confounders. Although most included studies 
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adjusted for a wide range of confounders for fracture risk or BMD, residual confounding by other 
unmeasured or inadequately measured factors cannot be ruled out. For example, low vitamin D status 
is a risk factor for fracture [46]. From the studies included in our meta-analyses for fracture  three out 
of nine adjusted for vitamin D status [24, 25, 27]. Outcomes do not seem to differ between studies that 
corrected for vitamin D status and studies that did not. Homocysteine levels are increased with renal 
dysfunction, often measured by serum or urine creatinine levels. Five out of eight studies in the meta-
analysis regarding homocysteine and fracture risk corrected for creatinine levels [3, 24, 26, 27, 29], and 
outcomes did not seem to differ.     
As almost all studies were performed in countries without mandatory folate fortification, or were 
performed before the fortification era in the USA and Australia, we do not consider folate fortification 
as a source of heterogeneity in our review.
The majority of studies included were longitudinal and cross-sectional observational studies. We 
could only include one intervention study, which had a very small study population (N=47). One 
intervention study which found a beneficial effect of vitamin B12 and folic acid supplementation on 
fracture risk could not be included in our systematic review, because this study investigated a population 
of hemiplegic patients following stroke [47]. The generalizability of these findings is confined to a 
highly selective patient population with a high percentage of vitamin D deficiency and a high fracture 
risk. As evidence from intervention studies is lacking, currently no causal effect between vitamin B12, 
folate and homocysteine levels and bone health can be established. Consequently, it is yet unknown 
whether extra vitamin B12 and folate intake through supplementation could reverse the observed 
negative effects of vitamin B12 and folate deficiency and elevated homocysteine levels. Further evidence 
from an intervention study is expected soon, as a large intervention study on the effect of vitamin B12 
and folic acid supplementation on fracture risk, BMD and bone turnover markers is currently carried 
out with results expected in 2013 [48]. 
As the quality of included studies determines the quality of the review and meta-analysis, we assessed 
the overall risk of bias of each individual study using standardized procedures largely based on guidance 
from the Cochrane Collaboration [49], resulting in one of the following judgments: low, moderate or 
high risk of bias. Twenty out of the 28 included studies were evaluated as having moderate (n=15) or 
high risk (n=5) of bias. These studies did take one or more of the predefined confounders into account, 
i.e. age, sex, smoking, physical activity and body weight, or the study was funded or co-funded by a 
commercial organization. Due to the limited number of studies included in the meta-analyses, we were 
not able to study the effect of the overall risk of bias, nor of its single components on the pooled effect 
measures. There seems to be no difference in the outcomes of studies with low risk of bias compared 
to studies with moderate or high risk of bias, and we therefore assume that the quality of the included 
studies had no effect on the outcome of this review.
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The intake of folate and vitamin B12 are a determinant of folate, vitamin B12 and homocysteine status. 
To deal with  potential malabsorption of vitamin B12 [50] and reduced bioavailability of folate [51], the 
use of biomarkers for vitamin B12 and folate status is preferred over measures of intake when studying 
associations with bone health in elderly people. 
In studies addressing folate status, serum or plasma folate was measured, which is considered as an 
appropriate marker for folate status in epidemiological studies [52]. Homocysteine is a non-specific 
marker for both folate and vitamin B12 status [53], which makes it a relevant biomarker in this review. 
Regarding the metabolic interactions between vitamin B12, folate and homocysteine combined with 
the variety in data presented in the studies, we were not able to investigate the possibility that a low 
vitamin B12 or folate status in combination with a high homocysteine level might result in a higher 
fracture risk in comparison to a low vitamin B12 or folate status or homocysteine level alone. In most 
studies regarding vitamin B12 status, status was assessed with serum or plasma vitamin B12. Other, more 
sensitive markers for vitamin B12 deficiency, like MMA and HoloTC [54], were addressed only in a few 
studies. We could therefore not draw conclusions about the association between these biomarkers and 
outcomes on bone health.
There are several suggested mechanisms for the association between vitamin B12, folate, homocysteine 
and bone health. Homocysteine may interfere with collagen cross-linking. Cross-links are important 
for the stability and strength of the collagen network. Interference in cross-link formation would cause 
an altered bone matrix, resulting in more fragile bones [55]. As collagen cross-links do not alter BMD, 
this may explain why a more convincing result is found regarding fractures than BMD, as suggested 
for example by Van Meurs et al. (2004). Vitamin B12 deficiency has been associated with impaired 
functional maturation of osteoblasts [56]. Some in vitro studies support the hypothesis of a possible 
favorable effect of vitamin B12 supplementation, although results are equivocal. Vitamin B12 has been 
shown to stimulate osteoblast proliferation and alkaline phosphatase activity [57] but Herrmann et 
al. were not able to show any significant and consistent effect of vitamin B12 or folic acid on osteoblast 
activity [58]. Recent publications show evidence of osteoclast stimulation in the presence of high 
homocysteine and low vitamin B12 concentrations [59-61]. Vitamin B12 and folate are not the only 
B-vitamins involved in the homocysteine metabolism. Various micronutrients, such as vitamin B2 
(riboflavin), vitamin B6 (pyridoxine) and choline also affect homocysteine levels [16, 17, 62], and 
may consequently affect bone health. Given that vitamin B12 and folate are the main factors influencing 
homocysteine levels, and therefore the primary focus in a homocysteine lowering intervention [63], 
our review focused on vitamin B12, folate and homocysteine. 
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ConSideRATionS foR fuTuRe ReSeARCH And 
ConCluSionS
The mechanisms involved in the association between biomarkers of B-vitamins and bone health are still 
unclear and therefore more fundamental research is required to establish the potential mechanisms. 
Subsequently, both observational and intervention studies should preferably not focus on just one 
biomarker in relation to the homocysteine metabolism, but take a biomarker profile into account, 
including serum/ plasma vitamin B12, MMA, HoloTC, folate and homocysteine levels. Evidence is 
needed from well designed, large intervention studies to establish a causal relationship between markers 
of B-vitamins and bone health.
This systematic review with meta-analyses shows that elevated homocysteine levels are associated with 
increased fracture risk. Vitamin B12 status may be associated with fracture risk and evidence for an 
association between folate status and fracture risk is scarce. Vitamin B12, folate and homocysteine levels 
are probably not associated with BMD, but results are not univocal.
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ABSTRACT
introduction
Elevated homocysteine levels and low levels of vitamin B12 and folate have been suggested to be 
modifiable risk factors for cognitive decline in elderly. Our aim was to evaluate the cross-sectional 
association of levels of homocysteine, folate, and vitamin B12 biomarkers (total B12, holotranscobalamin 
(holoTC) and methylmalonic acid (MMA)) with cognitive function in specific cognitive domains in 
Dutch elderly. 
Methods
Data were collected from 2919 elderly (≥ 65 years) participating in the B-PROOF study. A cognitive 
test battery was used covering four cognitive domains: attention and working memory (n=848), 
information processing speed (n=837), executive function (n=824) and episodic memory (n=2848). 
Concentrations of vitamin B12, holoTC, homocysteine, MMA and folate were measured and a vitamin 
B12 biomarker combination score, the ‘wellness score’, was calculated. Multivariable regression analysis 
was used to assess the association between biomarker status and cognitive function.
Results
After adjustment for age, sex, smoking status, alcohol intake, education, GDS depression score and 
creatinine, levels of homocysteine (β= -0.009), folate (β= 0.002), MMA (β= -0.163) and the wellness 
score (β= 0.048) were significantly associated with the domain of episodic memory. Additionally, 
homocysteine (β= -0.015) and the wellness score (β= 0.103) were significantly associated with the 
domain information processing speed. No associations were observed of vitamin B12 nor holoTC 
with cognitive function in any domain. CONCLUSION: Levels of homocysteine, MMA, folate and 
a combination score of vitamin B12 biomarkers are associated with the domains episodic memory and 
information processing speed. Observations are in line with other observational studies. 
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inTRoduCTion
In general, cognitive functioning decreases with age. This decrease includes normal, age-related 
cognitive decline, but also more rapid cognitive decline, leading to cognitive impairment, and dementia 
or Alzheimer’s disease. Insight in aspects that are associated with development and progression of 
cognitive decline may help to identify risk factors and potential therapies. Elevated homocysteine levels 
and low levels of vitamin B12 and folate have been suggested to be modifiable risk factors for cognitive 
decline [1]. However, intervention studies investigating the effect of vitamin B12 and/ or folic acid 
supplementation show contradictory results [2, 3].  
Two major factors complicate a good comparison between studies on vitamin B12 status and cognitive 
function and may therefore contribute to the discrepancy in findings: the use of different biomarkers 
for vitamin B12 status and the large variety in tests that are used to determine cognitive function.
Research on vitamin B12 status and cognitive function focused mainly on total vitamin B12 (total B12) 
levels. The association of levels of holotranscobalamin (holoTC) and the metabolite methylmalonic 
acid (MMA) with cognitive functioning has been studied in less detail, although these have been 
suggested as sensitive markers for vitamin B12 status [4, 5]. A novel approach for evaluating vitamin B12 
status is combining four biomarkers of vitamin B12 status (total B12, holoTC, MMA and homocysteine) 
into a single variable, the so-called ‘wellness score’[6].
In many studies, the Mini-Mental State Examination (MMSE) is used to determine cognitive 
function. This test however is mainly developed as a screening instrument to alert for dementia and 
is not distinctive to diagnose mild or isolated cognitive deficits. The ability of the MMSE to reveal 
associations between exposure and cognitive function depends furthermore on the prevalence of low 
scores in the population [7]. Neuropsychological testing by the use of more specific cognitive tests, 
covering different cognitive domains, is therefore preferred to determine cognitive functioning [8]. 
There is however lack of a generally accepted standard test battery, which complicates comparison 
between studies [9]. 
In this study, we cross-sectionally explored the association of levels of homocysteine, folate, vitamin 
B12, HoloTC, MMA and the wellness score with domain-specific cognitive functioning in Dutch elderly 
participating in the B-PROOF study. 
MeTHodS
participants
In this cross-sectional study, baseline data of the B-PROOF study (B-vitamins for the PRevention Of 
Osteoporotic Fractures) were used. The B-PROOF study is an intervention study which investigates 
the effect of vitamin B12 and folic acid supplementation on fracture risk in a general elderly population 
(≥65 years) with an elevated homocysteine level (≥12 µmol/l). The study population and the design of 
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the study have been described elsewhere in detail [10]. The study has been carried out in three study 
centers in The Netherlands; Erasmus MC (EMC, Rotterdam), VU University Medical Center (VUmc, 
Amsterdam) and Wageningen University (WU, Wageningen). Elderly people living in the areas of these 
three study centers were invited to participate. Participants were excluded if they recently (≤ 4 months) 
used intramuscular injections of vitamin B12 or folic acid supplements (>300 µg/ day), had serum 
creatinine levels >150 µmol/L, had plasma homocysteine concentrations >50 µmol/L, were diagnosed 
with cancer in the last five years or had mobility restrictions. The study started in August 2008 and 
all baseline measurements have been completed in March 2011. After checking medical history and 
supplement use, fasting blood samples were obtained at one of the research centers or at the homes of 
the elderly. Participants completed questionnaires regarding socio-demographic status, lifestyle and 
depressive symptoms. The questionnaires were checked with the participant to ensure that they were 
fully completed. Measurements were performed during a 1.5-2 hour session at the study center or at 
the participant’s home and consisted of cognitive tests, anthropometric measurements and physical 
performance tests. Self-reported medical history, including current alcohol and smoking habits were 
investigated by a questionnaire and were reviewed by one of the co-workers with the participant. 
Cognitive function and depression
We used the Mini-Mental State Examination (MMSE) as a descriptive measure for global cognitive 
performance [11]. An extensive cognitive test battery consisting of six standardized cognitive tests 
was used to address overall cognitive function as well as four specific domains: attention and working 
memory, information processing speed, executive function and episodic memory (Table 1). The first 
three domains were assessed in the subsample of WU (n=857), whereas the latter was assessed in all 
subjects (n=2919). 
Biochemical analysis 
Blood samples were obtained from participants in a fasted state or after a light breakfast in a standardized 
way and samples were kept frozen at -80°C until analysis. Plasma homocysteine was measured using the 
Architect i2000 RS analyser (VUmc, intra assay CV=2%, inter assay CV=4%), HPLC method (WU, 
intra assay CV=3.1%, inter assay CV=5.9%) or LC-MS/MS method (EMC, intra assay CV=5.5% 
at 14.1 μmol/L, inter assay CV=1.4% at 13.7 μmol/L). According to a cross-calibration, outcomes 
of the three centres did not differ significantly. Serum vitamin B12 and folate were determined with 
electrochemiluminescence immunoassay (Elecsys 2010, Roche, Almere, The Netherlands) (intra 
assay CV vitamin B12 5.1% at 125 pmol/L and 2.9% at 753 pmol/L; intra assay CV folate: 5.9% at 5.7 
nmol/L and 2.8% at 23.4 nmol/L)[12]. Serum holoTC was determined by the Abbott AxSYM analyser 
(Abbott Diagnostics, Hoofddorp, The Netherlands)  (CV <8% at 20, 40 and 80 pmol/L) [13]. Serum 
MMA was determined using LC-MS/MS (CV = 6.7%, 5.0% and 5.0% at 0.15, 0.36 and 0.65 µmol/L. 
respectively). Serum creatinine was determined enzymatically with the colorimetric Roche CREA 
plus assay (intra assay CV=2%). DNA was isolated from buffy coats to determine MTHFR C677T 
genotype using the Illumina Omni-express array. 
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Education level was computed from self-reported highest education and classified into three levels of 
secondary education: <5 years (low), 5-8 years (middle) and >8 years (high). Depression  was assessed 
with the 15-item Geriatric Depression Scale, where a score ≥5 points indicated risk of depression [14]. 
Smoking (never, former, and current smoker) and alcohol consumption (none, light, moderate, and 
excessive) were based on self-report. Classification of alcohol use was based on the number of days per 
week alcohol was consumed and the number of drinks per time [15]. MTHFR C677T genotype was 
divided into two groups: either 677TT or 677CT and 677CC genotype.
Table 1. Schematic division of cognitive tests into cognitive domains [60-63] 
Cognitive test Domain Description Score
Mini Mental State 
Examination 
(MMSE)
Global measure of 
cognitive function
Questions and tasks which provide 
a brief overview of basic cognitive 
skills. 
Number of correct 
answers (max. 30)
Symbol Digit 
Modalities Test 
(SDMT)
Information processing 
speeda
Translate symbols into numbers 
using a key within limited time 
(1,5 minute).
Number of correct 
translations.
Letter Fluency Test Executive Functionb
Generation of words starting with 
specific letters within a limited 
time (1 minute).
Number of correct 
words produced.
Trail Making Test 
A / B
(TMT)
Information Processing 
Speed and Executive 
Function
Connect an alternating sequence of 
numbers in ascending order. 
Score is based on 
time required.
Digit Span Test 
forward/ backward
Attention and Working 
Memoryc
Repeating progressively longer 
series of digits,
forward/ backward.
Number of correct 
recalls forward + 
backward
Word Learning Test 
(WLT) Episodic Memory
d
Reproduce words of a list which is 
read aloud. Delayed recall: 
recall after 15-20min.
Number of correct 
reproduced words 
Stroop Color Word 
Test
Information Processing 
Speed and Executive 
Function
Part I and II: Read names of colors 
and colored blocks, Part III: Name 
color of ink, instead of reading the 
conflicting word. 
Score is based on 
time required for 
part III.
a This domain involves psychomotor speed, perceptual organization and visual scanning abilities. 
b This domain involves cognitive flexibility: the ability to plan, organize, error correction and manage multiple 
tasks simultaneously. 
c Short term working memory and attention are required to manage information and carry out a complex task. 
d Long term memory that includes delayed recall and recognition memory.
Statistical analysis
Crude cognitive test scores were transformed into a standardized z-score (z-score = [test score 
– mean test score] / SD). A composite score for every domain was calculated by averaging the 
z-scores of tests covering that domain: Attention and Working Memory = (Z  Digit Span-forward + 
Z Digit Span-backward) / 2; Executive function = (Z Letter Fluency-mean letters) + (-Z StroopIII/ 
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((StroopI+StroopII)/ 2)) + (-Z Trail making B/ Trail making A) / 3; Information processing speed = 
(-Z SDMT nr. correct) + (-Z Trailmaking A) + ((-Z StroopI+StroopII)/ 2) / 3; Episodic Memory = (Z 
WLT total 1-5 + Z WLT delayed – trial 5 + Z WLT recognition total) / 3. A composite score for overall 
cognitive function was calculated by averaging the z-scores of each cognitive test for subjects who 
completed all six cognitive tests. For the Stroop Test and the Trail Making test time was the reported 
variable, a higher test score indicated more time needed to perform the test. Z-scores for these tests 
were therefore inverted. In case participants did not complete a test, no z-score could be calculated, 
resulting in slightly different numbers per cognitive domain.
For each participant, vitamin B12 status was expressed as a wellness score (w), calculated according 
to the formula: w = log10 (holoTCnormalized * B12normalized) – log10 (MMAnormalized * Hcynormalized)[6].  The 
normalized values are the individual values expressed relative to the median value of our study 
population. A wellness score of -<0.5 is considered as ‘transitional’ or subclinically deficient, a 
score of <-1.5 as deficient. Continuous variables were expressed as mean ± SD, or as median (IQR) 
for not normally distributed data. One extreme outlier of MMA (11.1 µmol/L) was excluded from 
analyses considering MMA and the wellness score. The Mann-Whitney U test was used to compare 
homocysteine levels among the different MTHFR genotypes. Multivariate linear regression was used 
to describe the association between vitamin B12 status and overall and domain-specific cognition, 
based on their biological relevance and their contribution to a change in the regression coefficient of 
the variable of interest of at least 10% the analysis was adjusted for age, sex, smoking status, alcohol 
intake, education level, depressive symptoms and creatinine level. An interaction term was added to the 
multivariate regression model to test for interaction between vitamin B12 status and MTHFR genotype.
Statistical significance was defined as p<0.05 and all tests were two-sided. Statistical analyses were 
performed using SAS statistical software version 9.2 (SAS institute Inc., Cary, NC, USA).
ReSulTS
Mean age was 74.1 ± 6.6 years and 50% of the population was men. Two hundred (200) participants 
(7%) showed depressive symptoms based on a GDS score ≥ 5. Median homocysteine level was 14.4 
µmol/L (13.0 – 16.6). Median homocysteine levels were significantly higher in the MTHFR 677TT 
group compared to the MTHFR 677CC/CT group (14.9 µmol/L and 14.3 µmol/L respectively, p 
<0.001). Median total B12 was 266 pmol/L (208 - 342), holoTC  64.0 pmol/L (46.0 - 85.0), MMA 0.23 
(0.18 - 0.30) and folate 18.7 (14.8 - 24.0) (Table 2). The distribution of the wellness score was skewed 
to the left ranging from -2.79 to 0.71 (Figure 1). The proportion of participants with a wellness score 
of -0.5 (transitional) and <-1.5 (deficient) was 17% and 2%, respectively. Median MMSE score was 28 
(IQR 27-29). Mean scores of the six cognitive tests are shown in Table 3. 
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Figure 1. Distribution of the wellness score (n=2879). wellness  = log10( holoTC/64.0  *  B12/266.4 )  - 
log10(MMA/0.23 *  Hcy/14.4 )
Associations between biomarkers and cognitive function
Table 3 shows the crude and adjusted multivariate linear regression analyses for the vitamin B12 
biomarkers, folate and the wellness score, with domain-specific and overall cognitive function. In 
the crude regression models significant associations were observed for homocysteine and folate with 
overall cognitive function; for homocysteine with attention and working memory; for vitamin B12, 
homocysteine, MMA, and the wellness score with information processing speed; homocysteine and 
the wellness score with executive function; and for homocysteine, MMA,   and the wellness score with 
episodic memory. 
After adjusting for age, sex, smoking status, alcohol intake, education level depressive symptoms and 
creatinine level, associations remained significant for homocysteine and wellness score with information 
processing speed (b = -0.015 (SE 0.007) and b = 0.103 (SE 0.048), respectively), and homocysteine, 
MMA, folate and the wellness score with the domain episodic memory (b = -0009 (SE 0.004), b = 
-0.163 (SE 0.057), b = 0.002 (SE 0.001) and b = 0.048 (se 0.024), respectively). No associations were 
observed of total B12 and holoTC with any cognitive domain in the adjusted models. There was no 
significant interaction between the vitamin B12 biomarkers and the MTHFR genotype observed in the 
regression models.
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Table 2. Characteristics of the Dutch study population
Characteristic (n=2919) Value1
Demographic measures 
Age (y) 74.1 ± 6.6
Men 1459 (50)
Education 
Low 1545 (53)
Middle 615 (21)
High 757 (26)
Health measures 
Weight (kg) 77.9 ± 13.3
Height (cm) 169.3 ± 9.3
Smoking status
          Current smoker 281 (10)
          Former smoker 1649 (56)
          Never smoker 989 (34)
Alcohol intake
          Light 1835 (70)
         Moderate 715 (27)
         Excessive 77 (3)
Depressive symptoms (GDS ≥5) 200 (6.9)
Biochemical measures
Plasma Hcy (µmol/L) 14.4 (13.0 - 16.6)
Serum MMA (µmol/L) 0.23 (0.18 - 0.30)
Serum folic acid (nmol/L) 18.7 (14.8 - 24.0)
Serum vitamin B12 (pmol/L) 266 (208 - 342)
Serum holoTC (pmol/L) 64 (46 - 85)
MTHFR genotype
 677 CC 1200 (45.6)
 677 CT 1085 (41.2)
 677 TT 348 (13.2)
Cognitive measures 
MMSE score (max. 30 points) 28 (27 - 29)
Episodic Memory
RAVLT
Immediate recall (max. 75 words) 36.4 ± 10.1
Delayed recall (max. 15 words) 7.0 ± 3.0
Delayed recognition (max. 30 words) 27.8 ± 2.4
Attention and Working Memory*
Digit Span
Forward (max. 16 points) 8.1 ± 1.7
Backward (max. 14 points) 5.9 ± 1.8
Information Processing Speed*
TMT (Part A, sec.) † 45.2 ± 18.5
Stroop ([Part 1 + Part 2] / 2, sec.) † 59.0 ± 12.0
SDMT (nr. of correct items) 46.1 ± 9.6
Executive Function*
Letter Fluency Test (nr. of correct items) 36.4 ± 11.3
TMT (Part B / Part A) † 2.4 ± 0.8
Stroop Test (Part 3 / [Part 1 + Part 2 / 2]) † 2.0 ± 0.5 
GDS, Geriatric Depression Scale; MTHFR, Methylenetetrahydrofolate Reductase; Hcy, homocysteine; holoTC, holotranscobalamin; 
MMA, methylmalonic acid; MMSE, Mini-Mental State Examination; RAVLT, Rey Auditory Verbal Learning Test; SDMT, Symbol Digit 
Modality Test; TMT, Trail Making Test. 
1 Values are presented as mean ± SD, number (%) or median (IQR) * Determined in a subsample of WU (n=857)    † Higher scores 
indicate more time needed to complete the tests, i.e. poorer performance 
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diSCuSSion
We assessed the association of biomarkers of vitamin B12 and folate status with domain-specific cognitive 
function in Dutch elderly in this cross-sectional study. All markers, except for total B12 and holoTC were 
associated with the domain episodic memory. Additionally, homocysteine and the wellness score were 
significantly associated with the domain information processing speed. 
We observed an association of homocysteine, folate and MMA with cognitive function, but not for 
total B12 itself. A similar pattern is shown in several observational studies; total B12 is not associated with 
cognitive function, but levels of folate, MMA and homocysteine are [16-19]. Although some studies 
also show an association of total B12 with cognitive function in addition to homocysteine, MMA and 
folate [20-22], these findings may suggest that cognitive performance is not sensitive to changes in total 
B12 status, possibly because levels of total B12 do not adequately reflect vitamin B12 status. It is therefore 
suggested that studies investigating vitamin B12 status in relation with cognitive function should 
include holoTC or MMA as sensitive markers for vitamin B12 status [3]. In our study, levels of holoTC 
were not associated with cognitive function in any domain, in contrast with other studies, in which a 
significant association was observed [23-25]. HoloTC however, is not yet widely studied in association 
with cognitive function. We observed associations of MMA specifically with the domain episodic 
memory, as was observed in other observational studies [23, 26, 27]. Many cross-sectional studies 
have shown an inverse association between homocysteine levels and cognitive function and dementia, 
well summarized in several systematic reviews [1, 28, 29]. Several studies observed similar associations 
in the domain information processing speed [17, 30-35]. Longitudinal studies observed associations 
between homocysteine levels and cognitive decline [21, 24, 25, 31, 36-39], usually measured with a 
decline in MMSE score.  
Levels of folate have been associated with cognitive function in many observational studies summarized 
in two reviews [1, 29]. More specifically, in our study, the association was mainly present in the domain 
episodic memory. This association is also prevalent among other observational studies [21, 30, 32], 
although in other studies this association was not observed [17, 35], mainly due to insufficient variation 
in folate status or overreliance on immediate versus delayed recall [29].
Besides investigating associations of separate biomarkers with cognitive function, we also combined 
four biomarkers of vitamin B12 status (total B12, MMA, holoTC and homocysteine) into a single variable: 
the ‘wellness score’. To the best of our knowledge, our study is the first to investigate the wellness score 
in association with domain-specific cognitive testing. One cross-sectional study used this model with 
MMSE score as an outcome measure, showing that a lower wellness score was associated with cognitive 
impairment, defined by an MMSE score <22 [40]. Although holoTC and MMA are suggested to be 
better biomarkers than total B12 and homocysteine [6, 13, 41], the four biomarkers are counted equally 
in the wellness score levels. Another point of consideration when using the wellness score are the 
normal values used to normalize the values of the biomarkers in the formula. In our study, we used 
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median values of our study population as normal values. We chose to do so, because our population 
consists of elderly with an elevated homocysteine level. The distribution of vitamin B12 biomarkers may 
therefore differ from general elderly populations. However, a comparison of results between studies 
will still limited when future studies will also use their own median values.
Although observational evidence of associations of homocysteine, vitamin B12 and folate with cognitive 
function and cognitive decline is abundant, evidence from randomized controlled trials (RCTs) 
is limited and does not support a beneficial effect of vitamin B12 and folic acid supplementation, as 
summarized in several systematic reviews [2, 3, 42-45]. One of the main reasons for the absence of a 
treatment effect might be the heterogeneity existing among studies, for example on dose and duration 
of B-vitamin supplementation, sample size and cognitive test battery. 
A particular strength of our study is that we used a broad cognitive test battery which contained both 
easy and more difficult tests. Furthermore, each cognitive domain was represented by at least two 
cognitive tests, by clustering the scores into compound scores which improved the robustness of the 
underlying cognitive tests. All cognitive tests used in our study were sensitive tests and previously 
studied for test-retest reliability and validity [46]. Because the cognitive test scores in our study have 
been standardized, the magnitude of the beta-coefficients can be compared across all models. This 
shows that the association of homocysteine, MMA and the wellness score with cognitive function is 
mainly present within the domains Information Processing Speed and Episodic Memory. The reason 
that we observed significant associations within these domains might be because cognitive speed and 
memory are components of fluid abilities which tend to change more when ageing [47], combined 
with differences in sensitivity of the cognitive tests corresponding to each domain. 
Recently, some studies regarding B-vitamins and cognitive function focused on brain structure, 
especially brain atrophy and white matter hyper intensities, as measured with Magnetic Resonance 
Imaging (MRI). This approach is promising as this measure is objective, and not prone to short term 
fluctuations, practice effects and intra/inter rater variability as may be the case for cognitive tests. Cross-
sectional and longitudinal associations have been observed for homocysteine and B-vitamin levels 
with brain structure measurements [26, 48-50], and an intervention study showed positive effects of 
B-vitamin supplementation on the rate of brain atrophy in elderly with Mild Cognitive Impairment 
(MCI) [51, 52].  
In contrast to the MRI study, our study population has a relatively high cognitive condition, as shown 
by a median MMSE score of 28. Participants in the B-PROOF study were furthermore included on 
basis of an elevated plasma homocysteine level and therefore our results cannot be directly extrapolated 
to the whole elderly population. On the other hand, during screening we observed that 49% of the 
potential participants had plasma homocysteine levels ≥12 µmol/L, indicating that our results may 
apply to a large part of the elderly population. The range of homocysteine levels is quite small; 95% of 
our population had a homocysteine level between 12.0 and 22.3 µmol/L. Due to the relatively good 
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cognitive condition and the limited range of homocysteine levels in our study population we may have 
observed a smaller effect size than we would have observed when including participants with a larger 
range of both cognitive function and homocysteine levels. 
We observed that homocysteine levels were significantly higher among participants with the 677TT 
MTHFR genotype compared to the combined 677CC and 677CT genotype. This is in line with our 
expectations, since the MTHFR enzyme is involved in the conversion of homocysteine to methionine 
and the 677TT allele encodes an enzyme with reduced activity [53, 54]; individuals who are homozygote 
for this polymorphism show about 25% higher homocysteine levels compared to individuals with the 
CC genotype [55]. In our study population the prevalence of the MTHFR 677TT polymorphism was 
13% (n=348). The limited sample size of the TT polymorphism population could be an explanation of 
the absence of an interaction between MTHFR genotype and cognitive function. Nevertheless, our 
results are in agreement with three other studies that did not observe an association between MTHFR 
genotype and cognitive function [56-58].
Since our data are cross-sectional, we cannot exclude reverse causality. It is possible that factors causing 
brain dysfunction and cognitive decline are also responsible for the elevation of homocysteine levels. 
There are several biological mechanisms explaining why high levels of homocysteine and low levels of 
vitamin B12 and folate affect cognitive function. First, homocysteine may be neurotoxic. Furthermore, 
low levels of folate and vitamin B12 lead to low levels of S-adenosyl methionine, which impairs 
methylation reactions important to the maintenance of brain tissue [28]. Additionally, an elevated 
homocysteine level, due to its suggested cause of atherosclerosis, might cause brain atrophy and white 
matter hyperintensities, which are likely to increase the risk of vascular dementia [51, 59]. 
In summary, we observed an association of homocysteine, folate and a marker of vitamin B12 status, 
MMA with cognitive functioning in the domains episodic memory and information processing speed.
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ABSTRACT
importance
In the coming decades, the number of fractures is expected to rise substantially. An elevated plasma 
homocysteine level is a risk factor for osteoporotic fractures. Supplementation with vitamin B12 and folic 
acid lowers homocysteine levels and may therefore contribute to fracture prevention. 
objective 
To determine whether vitamin B12 and folic acid supplementation reduces osteoporotic fracture incidence in 
hyperhomocysteinemic elderly.
design, settings and patients B-proof
Is a multi-center, double-blind, randomized, placebo-controlled trial in the Netherlands, in which 2,919 
participants aged ≥65 years with elevated homocysteine levels (12-50 μmol/L) were included. 
intervention 
Participants were assigned to daily 500 μg vitamin B12 and 400 μg folic acid or placebo supplementation for 
two years. Both tablets also contained 600 IU vitamin D3. 
Main outcome Measure
Primary endpoint was time-to-first osteoporotic fracture. Data were analyzed according to the intention-to-treat principle, 
using Cox proportional-hazards models. Stratified analyses were conducted if pre-specified covariates interacted 
significantly with treatment. Second, per-protocol analyses were performed, including only compliant participants.
Results
Osteoporotic fractures occurred in 61 persons (4.2%) in the intervention group compared with 75 (5.1%) 
in placebo. Osteoporotic fracture risk was not significantly different between groups in the intention-to-
treat analyses (Hazard Ratio (HR)=0.84, 95% CI 0.58-1.22) or per-protocol analyses (HR=0.82, 95% CI 
0.55-1.22). For persons >80 years, in per-protocol analyses, osteoporotic fracture risk was 72% lower in 
the intervention group compared with placebo (HR=0.28, 95% CI 0.10-0.74). Analyses on fractures of any 
type showed similar results. Mortality did not differ between groups. Sixty-three vs. 42 participants in the 
intervention and placebo group, respectively, reported incident cancer (HR=1.55, 95% CI 1.04-2.30).
Conclusions and relevance 
Combined vitamin B12/folic acid supplementation had no effect on osteoporotic fracture incidence in this 
elderly population. Stratified analyses suggested a beneficial effect on osteoporotic fracture prevention in 
persons >80 years who were compliant with supplement use. However, treatment was also associated with 
increased cancer risk, although this possible adverse effect should be interpreted with caution. In conclusion, 
vitamin B12 and folic acid supplementation cannot be recommended at present for fracture prevention in 
elderly people.
Trial registration 
ClinicalTrials.gov (NCT00696414).
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inTRoduCTion
Osteoporosis is a chronic, multifactorial disorder, characterized by low bone mass and micro-
architectural deterioration of bone tissue with fractures as a major consequence [1]. Fractures lead 
to pain, impairment in physical and social functioning, loss of quality of life and an increased risk of 
mortality [2]. Because of further ageing of the population, the number of fractures and their socio-
economic burden is expected to rise substantially in the coming decades [3]. An elevated circulating 
plasma homocysteine (Hcy) concentration has been identified as an independent risk factor for 
osteoporotic fractures in observational studies [4-10], a finding that is consistent with meta-analyses 
[11, 12] and mechanistic studies [13, 14]. 
Elevated Hcy concentrations (≥15µmol/L) are prevalent in 30-50% in persons >65y [15, 16]. Treatment 
with vitamin B12 and folic acid, both playing a central role in the Hcy metabolism [17], is effective in 
normalizing Hcy concentrations [18, 19]. Two randomized controlled trials investigated the effect of 
B-vitamin supplementation on fracture risk [20, 21]. Among stroke survivors, a large protective effect 
of 2 year supplementation of 1.5 mg vitamin B12 and 5 mg folic acid was observed on hip fracture risk 
in the trial of Sato et al. [20]. However, in the HOPE-2 trial no effect of 5y supplementation of 1 mg 
vitamin B12, 2.5 mg folic acid and 50 mg vitamin B6 was observed on fracture incidence among persons 
with high cardiovascular risk [21]. Given the conflicting results and low generalizability to the general 
older population, further investigation is needed. 
We conducted the B-vitamins for the PRevention Of Osteoporotic Fractures (B-PROOF) study to 
assess the efficacy and effectiveness of two year oral supplementation with 500 µg vitamin B12 and 400 
µg folic acid in the prevention of osteoporotic fractures in Dutch elderly people with elevated plasma 
Hcy concentrations. 
MeTHodS
Study design and population
B-PROOF is a randomized, placebo-controlled, double-blind multi-center trial, of which the design 
and methods have been described in detail previously [22]. In brief, we included 2,919 participants 
aged ≥65y with elevated Hcy levels (12-50 µmol/L). Exclusion criteria were a serum creatinine level 
≥150 µmol/l, cancer diagnosis in the past 5 years and severe immobility (being bedridden or using a 
wheelchair permanently). Participants were enrolled from September 2008 till March 2011 and were 
randomized to receive daily either an oral vitamin tablet containing 500 µg B12 and 400 µg folic acid 
or a placebo tablet. Tablets in both treatment arms contained 600 IU vitamin D3 to ensure a normal 
vitamin D status [23]. Randomization was stratified for study center, sex, age (65-80y, >80y) and level 
of Hcy (12-18 µmol/L, >18 µmol/L). The intervention period comprised two years. As planned at the 
start of the study [22], to increase power, participants who finished their intervention more than one 
year before the end of the study (n=678) were invited to extend their participation with one year. In 
total, 393 participants agreed and extended their participation. At baseline and 2y follow-up, a broad 
set of measurements was performed. The Medical Ethics Committee of Wageningen UR approved 
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the study protocol and the Medical Ethics Committees of Erasmus MC and VU University Medical 
Center (VUmc) gave approval for local feasibility. All participants gave written informed consent. The 
B-PROOF study is registered with the Netherlands Trial Register (NTR1333) and with ClinicalTrials.
gov (NCT00696414).
Baseline characteristics
Height and weight were measured and information on demographic factors, lifestyle characteristics, 
medication use and medical history were obtained using a questionnaire. Anti-osteoporotic 
medication use was registered and included the use of bisphosphonates, strontium-ranelate, selective 
estrogen-receptor modulators, estrogens, androgens, denosumab or teriparatide. Plasma Hcy and 
serum creatinine, as well as the C677T polymorphism in the methylenetetrahydrofolate reductase 
(MTHFR) gene (rs1801133) were determined [22]. For Hcy, levels after two years of intervention 
were measured as well. In addition, baseline serum vitamin B12 and folate were determined using 
immunoelectrochemiluminescence assay (Elecsys 2010, Roche, Almere, the Netherlands). Serum 
holotranscobalamin (holoTC) was determined by the AxSYM analyser (Abbott Diagnostics, 
Hoofddorp, the Netherlands) and serum methylmalonic acid (MMA) was measured by LC-MS/MS.
fracture assessment
Fractures were reported by the participants on a study calendar which was returned every three months 
during the intervention period. Additionally, participants were asked for the occurrence of fractures at 
the follow-up measurement using a structured questionnaire. Subjects who dropped out of the study, 
who refused, or were unable to complete the follow-up measurements were contacted around the end 
of the follow-up period to obtain information on incident fractures. In case this was not successful, a 
participant was regarded as lost to follow-up, and date of last contact was recorded. Date, type and cause 
of fracture were recorded. All reported fractures were verified with the participants’ general practitioner 
or hospital. Fractures were classified as osteoporotic or non-osteoporotic. Osteoporotic fractures were 
defined as all fractures except for head, hand, finger, foot or toe fractures, fractures caused by traffic 
accidents and fractures caused by cancer [24].
Compliance
Every six months, new tablets were sent to the participants and they were requested to return any 
remaining tablets. A subject was defined as compliant when at least 80% of the tablets had been taken 
during the intervention period, as indicated by the returned tablets.
Adverse events
Hospital admissions and other adverse events were recorded by the participants on the study calendars. 
In addition, all events reported to the study team by phone or otherwise were recorded. All ill-health 
related conditions reported by participants were considered as adverse events. In case participants 
reported a cancer diagnosis of any type, except for non-melanoma skin cancer, they were excluded 
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from further tablet use. At the end of the intervention period, participants were asked whether they had 
been diagnosed with cancer during the trial. Reported cases of cancer, except for non-melanoma skin 
cancer, were verified with the participants’ general practitioner or hospital.
Statistical analyses
Statistical analyses were performed before the treatment code was revealed. The primary analysis was 
based on the intention-to-treat (ITT) principle (adjusted model), including all subjects who agreed to 
start the treatment and completed the baseline measurements. Baseline characteristics of the treatment 
groups were compared with Chi-square tests for categorical data and unpaired Student’s t-tests for 
continuous data. Non-parametric tests were applied if the distribution was skewed. Difference between 
the treatment groups in change of Hcy after two years was tested with an unpaired Student’s t-test.
The primary outcome was time-to-first osteoporotic fracture, while time-to-first fracture of any type was 
considered a secondary outcome. Time-to-event data were analyzed using the Kaplan-Meier approach 
and the log-rank test. Hazard ratios (HR) and 95% confidence intervals (95%CI) were calculated with 
the use of crude and adjusted Cox proportional-hazards models. Individual time of follow-up was 
calculated as the time until the first fracture (osteoporotic or any type), end of intervention period, date 
of lost-to-follow-up, or death, whichever came first. 
Additionally, pre-specified per-protocol (PP) analyses were performed, including only data from 
subjects who were compliant to the study protocol. For drop-outs, the time until drop-out was used 
in these analyses.
The difference in number of persons who reported at least one adverse event between treatment groups 
was tested using Chi-square. For time-to-cancer, post-hoc analyses were performed following the same 
approach as the fracture analyses. Additionally, sensitivity-analyses were done including cancer cases 
that could not be fully verified, and this was repeated excluding relapse cancer cases.
For all outcomes, interaction with treatment was tested for the pre-specified covariates sex, baseline age 
below and above 80y, plasma Hcy below and above 18 µmol/l, MTHFR C677T genotype and for study 
center. In case of significant interaction (p<0.1), stratified analyses were performed. 
Statistical significance was set at α=0.05. Data were analyzed using IBM SPSS Statistics 20 (SPSS Inc., 
Chicago, Illinois).
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ReSulTS
Characteristics of the participants
Analyses included 2,919 participants (Figure 1) (49.9% men, mean age=74.1y, median plasma 
Hcy concentration=14.4 µmol/L). At baseline, no significant differences between the intervention 
(n=1,461) and placebo (n=1,458) group were observed, except for a 3% higher holoTC level in the 
intervention group (p=0.03) (Table 1). Baseline anti-osteoporotic medication use was similar in the 
two groups (Table 1), as were numbers of new users of these medicines during the intervention period 
(4.2% in the intervention vs. 4.4% in the placebo group, p=0.78). Mean change in Hcy levels was -4.4 
µmol/L in the intervention vs. -0.2 µmol/L in the placebo group (p<0.01) (Table 2).
	   Blood sampling eligible 
participants 
N=6,242 
Randomized 
N=3,027 
Allocated to the intervention group (n=1,516) 
• Received  allocated intervention (n=1461) 
• Did not receive allocated intervention  (n=55) 
(withdrew before starting the intervention)  
Allocated to the placebo group  (n=1,511) 
• Received  allocated intervention (n=1458) 
• Did not receive allocated intervention  (n=53) 
(withdrew before starting the intervention)  
 
Lost to follow-up after drop-out 
(n=69) 
Included in the intention to treat 
analyses 
(n=1,461) 
Included in the intention to treat 
analyses 
(n=1,458) 
Excluded: 
• Not meeting inclusion criteria 
(n=3,172) 
• Declined to participate (n=43) 
Drop-out (n=200) 
Deceased (n=26) 
No longer motivated or personal event 
(n=40) 
No longer capable, too burdensome (n=92) 
Perceived side effects ( n=13) 
Reason unknown (n=29) 
Drop-out (n=222) 
Deceased ( n=16) 
No longer motivated or personal event 
(n=42) 
No longer capable, too burdensome (n=118) 
Perceived side effects (n=14) 
Reason unknown (n=32) 
Lost to follow-up after drop-out 
(n=55) 
Figure 1. Screening, randomization and follow-up in the B-PROOF study
Note: the number of participants that dropped out because they deceased does not equal the total number of deceased 
participants; some participants (n=37) dropped out for other reasons and deceased after drop-out (Intention-to-treat). 
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Table 1. Baseline characteristics of the B-PROOF study population (n=2919)
Placebo group
(N=1,458)
Intervention group
(N=1,461)
Age (y)a 74.2 (6.4) 74.0 (6.6)
Sex (% women)b 49.7 50.4
Study centerb
WUR (%)
VUmc (%)
EMC (%)
29.6
26.8
43.6
29.2
26.4
44.4
History of fracture (% yes)b,c 42.9 41.3
Height (cm)a 169.2 (9.3) 169.4 (9.4)
Weight (kg)a 77.8 (13.3) 77.9 (13.3)
Current smoker (%)b 9.7 9.5
Alcohol use b
Light (%) 66.8 68.0
Moderate (%) 29.0 28.5
Excessive (%) 4.2 3.5
Physical activity (min/day)c 131 [86-193] 126 [81-190]
Educationb 
Low (%)
Intermediate (%)
High (%)
53.6
21.1
25.4
52.4
21.1
26.5
B12 and/or folic acid supplement use (% yes)
b,c 15.8 15.3
Vitamin D supplement use (% yes)b,c 19.7 18.3
Osteoporotic medication use (% yes)b,c 7.1% 7.8%
Biochemical analyses:
Homocysteine (µmol/L)d 14.5 [13.0-16.7] 14.3 [13.0-16.5]
Vitamin B12 (pmol/L)
d 266 [204-343] 267 [213-341]
Folate (nmol/L)d 18.9 [14.8-24.5] 18.8 [14.9-24.7]
Methylmalonic acid (µmol/L)d 0.23 [0.18-0.31] 0.22 [0.18-0.30]
Holotranscobalamin (pmol/L)d 63.0 [45.0-84.0] 65.0 [48.0-86.0]*
MTHFR C677Tb
   CC (%)
   CT (%)
   TT (%)
44.2
42.7
13.1
45.6
41.6
12.9
Creatinine (µmol/L)a 84.1 (18.0) 83.9 (18.6)
MTHFR=Methylenetetrahydrofolate reductase, WUR=Wageningen UR, VUmc=VU University Medical 
Center, EMC=Erasmus MC. * for P < 0.05. a Presented as mean (standard deviation), difference tested using 
t-test. b Presented as percentages, differences tested using Chi-squared test. c Data based on self-report. 
d Presented as median [interquartile range], differences tested using Mann-Whitney U test.
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primary endpoint: osteoporotic fractures
In the ITT analyses, 52 persons sustained a total of 61 osteoporotic fractures (fracture rate=2.0/100 
person-y) in the intervention group vs. 61 persons with 75 osteoporotic fractures (fracture rate=2.5/100 
person-y) in the placebo group (incidence rate ratio=0.80, 95%CI=0.55-1.16). Two fractures could not 
be verified, and were considered as non-case. Time-to-first osteoporotic fracture was not significantly 
different between the intervention and placebo group (log-rank p=0.40). Cox proportional-hazard 
models adjusted for age, sex, study center, baseline plasma Hcy, and serum holoTC showed that persons 
in the intervention group did not have a significantly lower probability to sustain an osteoporotic fracture 
than persons in the placebo group (HR=0.84, 95%CI 0.58-1.22) (Figure 2A, Table 3). Interactions of 
treatment group with age, sex, Hcy concentration, study center, and MTHFR C677T genotype were 
not significant. 
PP analysis was performed among 2,661 compliant participants, including 91.4% of participants 
in the intervention group vs. 90.9% of the placebo group. Fracture rates are presented in Table 3. 
Multivariable Cox proportional-hazard models did not show a significantly different osteoporotic 
fracture risk between the intervention group and placebo group (HR=0.82, 95%CI 0.55-1.22) (Table 
3). A significant interaction effect with age was observed (p=0.02). Persons >80y in the intervention 
group had a 72% lower probability of sustaining an osteoporotic fracture (HR=0.28, 95%CI 0.10-0.74) 
compared with the placebo group (Table 3). The number needed to treat was 25 (for two years).
Secondary endpoint: Any type of fractures
The rate of fractures of any type in the intervention group vs. the placebo group was 2.6/100 person-y 
vs. 3.1/100 person-y, respectively. No significant effect of the intervention in both the ITT and the PP 
were observed (HR=0.83, 95%CI 0.59-1.16 and HR=0.80, 95%CI 0.56-1.15, respectively) (Figure 2B, 
Table 3). Again, interaction with age was observed in the PP analysis (p=0.02). Persons >80y in the 
intervention group had a 74% lower probability of a fracture of any type (HR=0.26, 95%CI=0.10-0.71) 
compared with placebo. Specific types of fractures are shown in eTable 1.
Adverse events
Mortality did not differ between the intervention and placebo group (n=37 vs. n=42 respectively, 
p=0.57, ITT). In the total number of adverse events, no difference was observed between treatment 
groups (p=0.84). However, 63 participants in the intervention group and 42 participants in the placebo 
group reported a new, subsequently verified diagnosis of cancer during the intervention period (Chi-
square p=0.04). The HR was 1.55 (95%CI 1.04-2.30) (ITT, Table 3, Figure 2C). Verification of cancer 
diagnosis was not possible in 13 cases. PP analyses (Table 3) and sensitivity analyses (data not shown) 
provided similar results. 
Interaction effects with age (p=0.09), sex (p=0.09) and study center (p=0.09) were observed (ITT). 
Corresponding subgroup analyses revealed that the effect was more pronounced in participants aged 
>80y, more in women, and more in the VUmc study center, which recruited more women and persons 
>80y (Table 3). Differences mainly appeared for colorectal cancer (14 in intervention group vs. 5 in 
placebo) and other gastro-intestinal cancers (7 vs. 1, respectively).
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Figure 2. Time-to- a) first osteoporotic fracture, b) first fracture of any type.
a.
b.
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Figure 2. c) cancer diagnosis, adjusted for age, sex, study center, plasma homocysteine and serum 
holotranscobalamin, derived from Cox proportional-hazards analysis (Intention-to-treat)
diSCuSSion
Daily supplementation of 500 µg vitamin B12 and 400 µg folic acid – in addition to 600 IU vitamin D3 - 
for 2 years did not significantly reduce osteoporotic fracture risk in elderly aged ≥65y with an elevated 
plasma Hcy level. Pre-specified interactions with subsequent subgroup analysis suggested an almost 
4-fold reduction of fractures among those aged >80y who were compliant in taking the supplement. 
Mortality did not differ between treatment groups over the two year intervention period. However, 
supplementation was associated with a higher cancer incidence, especially colorectal and other gastro-
intestinal cancers. 
Compared to the Sato trial [20] (a strong treatment effect on fractures) and the HOPE-2 trial [21] 
(no treatment effect), differences in study design and population with B-PROOF should be noted. 
Regarding baseline health status, the Sato trial included a very specific, high fracture risk population 
consisting of post-ischemic stroke, hemiplegic patients. HOPE-2 included participants with a history 
of vascular disease, while B-PROOF included participants primarily based on elevated Hcy levels. 
Also, median Hcy levels differed substantially between the studies: 19.9 µmol/L in the Sato trial, 11.5 
µmol/L in the HOPE-2 trial, and 14.4 µmol/L in B-PROOF. In addition, dietary patterns, presence of 
fortified food and/or supplement use might contribute to differences between the populations. 
c.
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Mean age did not differ substantially between the studies. Whereas sex distribution was similar 
between Sato et al. and B-PROOF (53% vs. 50% women), fewer women participated in HOPE-2 
(28%). However, we did not find evidence for an interaction between sex and treatment in our study. 
Comparison of dose and duration across the three trials indicates that higher supplementation dose 
and longer study duration did not result in more favorable outcomes, therefore not explaining the 
differences in results. Concluding, in the Sato trial, Hcy levels were higher and the general health status 
of the participants was worse, resulting in a higher a priori fracture risk than for participants in HOPE-2 
and B-PROOF. 
The fact that the age-specific effect was observed in the PP analyses and not in the ITT analyses 
suggests a true treatment effect. It is known that Hcy levels increase with age, and therefore baseline 
homocysteine levels or change in homocysteine levels might provide a possible explanation for the 
results. On the one hand, we did not observe significant interaction of baseline Hcy level (below and 
above 18 µmol/L) with treatment. Interestingly, on the other hand, Hcy levels appeared to decrease 
more in compliant persons >80y compared with persons <80y (Table 2, post-hoc analysis), especially 
when taking into account the changes over time as shown by the placebo group.
The observation of a significantly higher cancer incidence in the intervention group than in the control 
group was unexpected. It is important to note that B-PROOF was not designed to study cancer as a 
primary outcome. The limited follow-up time of 2 years, for instance, does not allow firm conclusions 
about cancer development and long-term cancer risk. The results of the present trial differ from the 
B-Vitamin Treatment Trialists’ collaboration meta-analysis of 13 trials, involving 49,621 individuals, 
which reported that allocation to folic acid had no significant effects on overall cancer incidence (1904 
in the folic acid group vs 1809 in the control group, rate ratio (RR) 1.06, 95%CI 0.99-1.13), or on 
cancer incidence at any site [25]. This meta-analysis, primarily involving participants at high risk of 
cardiovascular disease, tested the effect of a mean daily dose of folic acid of 2 mg (range 0.5-5 mg) for 
an average duration of 5.2 years [25]. These findings were consistent with two previous meta-analyses 
(RR 1.05, 95% CI 0.99-1.11 and RR 1.07, 95% CI 1.00-1.14) [26, 27]. The higher cancer risks observed 
in the B-PROOF trial may reflect the effects of chance as they were based on only 105 incident cancer 
events compared with 3713 cancer events in the B-Vitamin Treatment Trialists’ collaboration meta-
analysis [25]. 
The dose of folic acid provided in B-PROOF (400 µg) was relatively low and well below the tolerable 
upper intake level for folic acid of 1 mg per day in Europe [28]. In addition, no national mandatory folic 
acid food fortification exists in the Netherlands. Subgroup analysis in two of the three meta-analyses on 
this potential side-effect showed that increased risk of cancer was mainly seen in low-dose (≤1mg/day) 
supplementation rather than in high-dose supplementation, while a dose-response effect was absent 
[26, 27]. However, it should be noted that the low-dose trials all had doses above ours (ranging from 0.5 
to 1.0 mg) and in addition, dose-related effects were absent in the third meta-analysis[25]. 
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Regarding vitamin B12 and vitamin D3, to date, little is known about the possible relation between 
vitamin B12 and cancer risk or the interaction between folic acid, B12 and/or vitamin D3 and cancer risk.
Folate is required for DNA-synthesis and DNA-methylation, processes which are also important in 
cancer initiation and progression. It has been hypothesized that folic acid prevents against the initiation 
of cancer, while it enhances growth and progression of established neoplastic cells [29]. As shown 
in Figure 2C, the curves for cancer incidence diverge shortly after the start of the intervention. This 
fits with the hypothesis of an effect on cancer progression, rather than cancer induction. This idea is 
supported by the observation that the effect on cancer incidence in our study was most pronounced in 
persons aged >80y, among whom the presence of latent cancer is speculated to be more likely. The fact 
that our study population was older (mean age 74y) than the populations in the three meta-analyses 
(mean population ages ranging from 26y to 69y [27]) may therefore also explain the higher overall HR 
observed in our study. Further research into the effects of folic acid on cancer progression is warranted, 
especially in the oldest-old.
The major strengths of B-PROOF are its double-blind randomized placebo-controlled design, and 
the use of clinical endpoints. It is the first trial primarily designed to study the effect of B-vitamin 
supplementation on fracture prevention in an elderly population with mildly elevated Hcy levels. 
Another strength is the high compliance with the allocated treatment. 
Both the occurrence of a fracture and the diagnosis of cancer were based on self-report, which could be 
regarded as a limitation. However, structured questionnaires were used and the diagnoses were verified 
with the participant’s general practitioner or hospital. Potential underreporting is expected to be non-
differential for treatment groups. In addition, it should be noted that multiple statistical tests have been 
performed. Although they were pre-specified, the occurrence of false-positive findings cannot be ruled 
out.
In conclusion, an overall effect of supplementation of vitamin B12 and folic acid in reducing fracture 
risk in elderly with elevated Hcy levels was not observed in B-PROOF. However, stratified analyses 
suggested a reduced fracture risk in elderly aged >80y who were compliant in taking the supplement. 
On the other hand,  supplementation of vitamin B12 and folic acid was also associated with higher cancer 
risk, although these results should be treated with caution as they have not been observed in meta-
analyses of previously available trials with folic acid. Hence, vitamin B12 and folic acid supplementation 
cannot be recommended for fracture prevention. 
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Apendix
Appendix eTable 1. Total number of fractures during the intervention period per fracture type according to 
treatment group and age category
Placebo group Intervention group
Total 
sample 
(N=1,458)
Age ≤80y 
(N=1,205)
Age >80y 
(N=253)
Total 
sample 
(N=1,461)
Age ≤80y 
(N=1,220)
Age >80y 
(N=241)
Head 5 5 0 2 2 0
Arm 11 8 3 13 10 3
Elbow 1 1 0 0 0 0
Wrist 12 8 4 16 14 2
Hand 4 4 0 2 2 0
Fingers 1 1 0 4 3 1
Rib 11 7 4 13 13 0
Vertebra 15 8 7 7 3 4
Pelvis 6 0 6 1 0 1
Hip 13 8 5 8 5 3
Leg 5 2 3 2 0 2
Ankle 7 7 0 6 5 1
Foot 3 3 0 3 3 0
Toe 0 0 0 2 2 0
Total 94 62 32 79 62 17
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This thesis addresses the association of homocysteine, vitamin B12 and folate levels with cognitive 
function and bone health, two health outcomes of major importance for the elderly. These associations 
were studied using existing available scientific literature and cross-sectional observations in the 
B-PROOF study population at baseline. Additionally, the association between vitamin B12 intake and 
vitamin B12 biomarkers was studied. The effect of 2-year vitamin B12 and folic acid supplementation on 
fracture risk was assessed in the B-PROOF study, a randomized controlled trial (RCT). In this final 
chapter, a reflection is given on the findings in this thesis and suggestions are made for further research.
MAin findingS
Table 1 summarizes the findings from Chapter 2 to 7. Findings are presented in the context of a model 
which links dietary intake to biomarkers of nutritional status and subsequently to health outcomes. In 
general, it is shown that vitamin B12 intake is associated with vitamin B12 biomarker status. Furthermore, 
observational associations are shown between biomarker status and the health outcomes cognitive 
function and bone health. The intervention study showed prudently positive effects of vitamin B12 
and folic acid supplementation on bone health in the subgroup of elderly aged >80 years who were 
compliant to the study supplement. However, these benefits should be weighed against potential risks. 
MeTHodologiCAl ConSideRATionS 
A combination of study designs was used in this thesis to obtain more insight in the role of homocysteine, 
vitamin B12 and folate levels in cognitive function and bone health: an intervention study, cross-
sectional observational studies and systematic reviews with meta-analyses. 
The proof of the pudding is in the eating: the B-pRoof study
After a systematic review and meta-analysis of intervention studies, an RCT is seen as a source of the 
highest level of evidence in research, including nutritional research [1]. In general, evidence from 
RCTs, such as the B-PROOF study, is needed to establish a causal relationship between exposure 
and outcome. In addition, adhering to the intention-to-treat principle in the analysis of the outcomes 
confirms the efficacy of a given intervention in a targeted population. In other words, the proof of the 
pudding is in the eating. Therefore, the B-PROOF study was envisaged to make a valuable contribution 
to the research field of homocysteine and related B-vitamins and their relation with bone health.
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The B-PROOF study was our focus in three chapters (Chapter 3, 6 & 7). The B-PROOF study population 
involved elderly aged 65 years and older with an elevated homocysteine level (≥12.0 µmol/L). With 
this population we assumed to have recruited an appropriate study population for our intervention, 
since both an advanced age and an elevated homocysteine level are risk factors for fractures [2, 3]. 
On both age and homocysteine levels, however, we had to make concessions to our original inclusion 
criteria (age ≥ 70 years and tHcy ≥ 15 µmol/L, see Chapter 2) to facilitate recruitment of participants, 
otherwise it would not have been possible to include almost 3000 participants in the timeframe set 
for our research. Although we expected that in our study population still enough fractures would 
occur based on current fracture rates in the Netherlands, altering these inclusion criteria might have 
contributed to a dilution of the treatment effect in our study population. 
yet another cross-sectional study, been there, done that?
With the extensive baseline data of the B-PROOF study we were able to investigate cross-sectionally 
vitamin B12 biomarker status (Chapter 3) and cognitive function (Chapter 6). A major drawback 
of cross-sectional studies is, as repeatedly mentioned, the inability to establish a causal relationship 
between exposure and outcome. Cross-sectional studies are therefore mainly hypothesis-generating. 
There are already many observational studies on the association of homocysteine, vitamin B12 and 
folate status with cognitive function and also the association between vitamin B12 intake and status is 
far from unexplored. What have we contributed with these two cross-sectional studies? The answer 
lies in the extensive baseline assessments we performed on: vitamin B12 and folate intake, biomarker 
status and health outcomes, in this case cognitive function. Although the observational evidence seems 
abundant, comparability among studies is still rather low. Regarding the association between intake 
and status and among status markers (Chapter 3), there are only a few studies which studied all main 
four biomarkers of vitamin B12 status (total B12, holoTC, MMA and tHcy). Providing information on 
levels of the four biomarkers and their mutual associations in such a large, relatively general elderly 
population contributes  to the knowledge in this field of research. 
The majority of evidence for the association between nutrient status and cognitive function emerges 
from studies using the MMSE as a single measure for cognitive function. We combined information 
on the four biomarkers for B12, plus folate with a detailed measure on cognitive function divided in 
cognitive domains, again contributing to the knowledge in this research field. Herewith we adhere to 
our own suggestion in Chapter 4 to include MMA and holoTC as sensitive markers in research on 
vitamin B12 and cognitive function. 
The icing on the evidence cake: systematic reviews with meta-analyses
We included two systematic reviews with meta-analyses in this thesis (Chapter 4 & 5). A major strength 
of these systematic reviews is that we included only studies which were performed in generally healthy 
populations. This enables us to extrapolate the findings from these reviews. Chapter 4 describes the 
association of vitamin B12 intake and status with cognitive function; homocysteine and folate were left 
aside in this chapter. For this thesis it would have been more appropriate to include these biomarkers as 
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well, but this single-nutrient approach fitted in the scope and organization of the EURRECA network, 
in which our systematic review took place [4]. Associations of folate with various health outcomes were 
considered separate from vitamin B12, and homocysteine was not investigated, because of its lack of 
specificity for vitamin B12 deficiency [5]. In general our observations from chapter 6 are in line with our 
findings in the systematic review regarding cognitive function (Chapter 4). Total B12 is not associated 
with cognitive function, where more sensitive biomarkers like MMA are associated. However, we did 
not observe an association with holoTC. Additionally, although we did not consider homocysteine and 
folate in Chapter 4, findings are in line with existing literature; showing a stronger association of folate 
and homocysteine with cognitive function than total B12.
The review in Chapter 5 regarding bone health describes predominantly observational studies and only 
one intervention study, since the available intervention studies about vitamin B12, folic acid and bone 
health did not consider generally healthy populations [6, 7], which was a prerequisite for inclusion. 
Nonetheless, this review provides an extensive overview about the observational evidence in the 
association of levels of homocysteine, vitamin B12 and folate with fracture risk and BMD. 
wHAT you See iS wHAT you geT? ConSideRATionS 
RegARding THe endpoinTS in THiS THeSiS
We addressed two age-related health endpoints in this thesis: bone health and cognitive function. 
Furthermore, we evaluated levels of vitamin B12 biomarkers as both exposure (Chapter 4, 5 & 6) and 
outcome (Chapter 3). 
B-vitamins: biomarkers 
As mentioned in Chapter 3, there is no consensus about the best biomarker or biomarkers and 
accompanying cut-off values to determine vitamin B12 deficiency. This complicates the interpretation 
of results and the comparison with results of different studies. Currently, the general idea is that a 
combination of at least two biomarkers, preferably a circulating biomarker (total B12 or holoTC) and a 
functional biomarker (MMA or homocysteine) reflects vitamin B12 status better than the use of only 
one biomarker [8, 9]. 
A recent study of Bailey et al. emphasizes the difficulty of establishing a cut-off value for vitamin B12 
deficiency and shows a continuous model of MMA levels against total B12 levels, comparable to our 
model as shown in Chapter 3 [10]. The authors have modeled levels of MMA against levels of total B12 
with different mathematical models to establish an inflection using data of 12,683 adult participants of 
the NHANES 1999-2004 study. They conclude that the inflection was dependent on the used model, 
and that the use of one cut-off point for vitamin B12 deficiency is challenged by the presence of 3 distinct 
slopes. The presence of 3 slopes is in line with our findings, although the change points were different 
from ours: 126 and 287 pmol/L vs. 220 and 330 pmol/L in our data. Bailey et al. however, used a model 
with 2 knots, where we used a model with 5 knots, since this model had a better fit to our data than 
models with less knots. 
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Bailey et al. distinguished 3 groups according to total B12 status: a clearly vitamin B12 deficient group 
(total B12 <126 pmol/L), an adequate vitamin B12 group (total B12 >287 pmol/L) and a large (~33% 
of the participants) group with an intermediate vitamin B12 status. This intermediate group represents 
subclinical vitamin B12 deficiency, a suboptimal vitamin B12 status occurring long before classical clinical 
vitamin B12 deficiency is determined. The models shown in the study of Bailey et al. and in Chapter 
3 acknowledge that the use of a single cut-off value for vitamin B12 deficiency does not distinguish 
the severely deficient group from the subclinical deficient group. The clinical relevance of subclinical 
vitamin B12 deficiency is not generally established and needs further attention to investigate the impact 
of this metabolic state on health in especially elderly people. Although many observational studies 
show negative health outcomes associated with vitamin B12 levels in the subclinical deficiency range, 
the effect of vitamin B12 supplementation on improving health outcomes is not established [11, 12]. All 
in all, it is clear that total B12 levels below 287-330 pmol/L deserve further attention in research.
The wellness score- which combines several markers for vitamin B12 status, as described in Chapter 
6- may be an interesting approach in evaluating vitamin B12 status as it considers four biomarkers at 
the same time, which might reflect vitamin B12 status better than the level of one or two biomarkers. 
However, the used formula, in which all biomarkers are given the same weight and the use of reference 
values, could be questioned; correlations between biomarkers differ and levels of biomarkers vary 
per study. The implementation of different reference values in other studies jeopardizes comparison 
between studies. Furthermore, the costs of analyzing all four biomarkers are considerable and may be 
avoided when agreement is reached on cut-off values for vitamin B12 deficiency. Thus, the use of the 
wellness score seems promising, but has not been well established yet. 
As described in Chapter 3, we observed a saturation of vitamin B12 biomarkers with dietary vitamin B12 
intakes around 5 µg, which is well above the current Dutch RDA of 2.8 µg/day for adults and elderly. 
This might suggest that the current RDA for vitamin B12 is too low, at least for elderly, as also proposed 
in other studies: a cross-sectional study investigating dietary vitamin B12 intake and levels of biomarkers 
in a population of postmenopausal women [13, 14] and a systematic review regarding daily vitamin B12 
losses and vitamin B12 bioavailability [15]. An increased need for dietary vitamin B12 may be due to the 
fact that many elderly have a reduced ability to absorb vitamin B12 from food as a result from gastric 
atrophy [16, 17]. However, more research is needed to confirm these observations.
Cognitive function
As mentioned earlier, the Mini Mental State Examination (MMSE) is widely used in research regarding 
nutritional status and cognitive function. This test however is mainly meant as a screening instrument 
to alert for dementia and is not distinctive to mild or isolated cognitive deficits. The ability of the 
MMSE to reveal associations between exposure and cognitive function depends furthermore on the 
prevalence of low scores in the population [18]. We measured cognitive function with an extensive 
test battery, and constructed cognitive domains, which is an acknowledged way to investigate cognitive 
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function. However, the use of the many available tests in research to measure cognitive function 
complicates comparison of study results. To overcome this practical problem, experts in cognitive 
testing should propose transparently and objectively a small set of outcomes which could be used in 
trials on cognitive outcomes, as suggested, among others, by Dangour and Allen [19]. Furthermore, 
the use of computerized tests for the assessment of short term effects on domains like attention may be 
considered, as they are able to capture short times with great accuracy. The use of magnetic resonance 
imaging (MRI) is promising in the research of B-vitamins and cognitive function. This technique can 
reveal associations between biomarker status and brain structure, and outcomes could be combined 
with performance on cognitive tests. MRI measurements may give more insight in the mechanisms 
by which elevated homocysteine levels and low levels of vitamin B12 and folate interfere with cognitive 
function, since effects on specific regions in the brain could be studied that are key components to 
the process of cognitive decline and dementia. There are several mechanisms suggested in literature as 
described in the Introduction, Chapter 4 and Chapter 6, in short: Hypomethylation as a result of low 
vitamin B12 and folate levels and elevated homocysteine levels causes myelin damage and disturbed 
neurotransmitter metabolism [20], homocysteine is suggested to be neurotoxic [21], high levels of 
homocysteine could cause structural vascular changes in the brain [22], leading to brain atrophy and 
white matter hyperintensities [23, 24] and high levels of MMA may also induce neurological damage 
[25]. 
“The toe bone is connected to the foot bone”, fractures and other weaknesses 
In the B-PROOF study osteoporotic fracture incidence, a clinical endpoint with high public health 
relevance, was our primary outcome. The occurrence of a fracture is in most cases the first clinical 
sign of the presence of osteoporosis. We considered all fractures osteoporotic, except for the head/ 
hand/ finger/ foot/ toe fractures and fractures caused by traffic accidents. The distinction between an 
osteoporotic fracture and a non-osteoporotic fracture may be arbitrary, as not every fracture indicates 
osteoporosis and osteoporosis does not always lead to a fracture. In the B-PROOF study we observed 
no difference in the effect of vitamin B12 and folic acid supplementation on osteoporotic fractures and 
fractures of any type. 
Another indicator of osteoporosis is low bone mineral density (BMD). Contradictory, it hypothesized 
that elevated homocysteine levels affect bone strength without altering BMD, by interfering 
with collagen cross-linking [26]. The absence of an association of homocysteine, vitamin B12 and 
folate with BMD in the meta-analyses in Chapter 5 and in other observational studies support the 
collagen cross-link theory. In this light, the use of new techniques, such as high resolution peripheral 
quantitative computed tomography (hr-pQCT), may provide more insight in the mechanism by which 
homocysteine, vitamin B12 and folate affect bone health, since this method measures not only BMD, but 
also assesses bone micro structure and bone strength [27].    
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The rate of bone formation and bone resorption in the skeleton can be assessed by measuring 
biochemical bone turnover markers in plasma or serum. High homocysteine levels and low levels of 
vitamin B12 and folate were associated with increased bone resorption and decreased bone formation in 
several studies [28-31]. Intervention studies with B-vitamin supplementation did not observe effects on 
bone turnover markers [32-37]. It should be noted that, although measurements are relatively easy and 
non-invasive, the value of measuring bone turnover markers is yet to be established, since there is little 
consensus about which markers should be used. The International Osteoporosis Foundation therefore 
recently recommended that a marker of bone formation (serum procollagen type I N propeptide, 
s-PINP) and a marker of bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) are 
used as reference analytes for bone turnover markers in clinical studies [38]. Moreover, levels of bone 
turnover markers cannot be interpreted straightforwardly and possible treatment-induced changes are 
not fully understood yet. 
It is furthermore suggested that homocysteine could affect bone health via decreased methylation 
capacity, since methylation is important for gene expression. Decreased methylation capacity is 
reflected by a lower ratio between S-adenosylmethionine (SAM) and S-adenosyl homocysteine 
(SAH). A lower SAM/SAH ratio has been shown to be correlated with lower bone strength in rats 
[39]. In the Rotterdam study, in elderly women, lower methylation capacity was associated with lower 
BMD, but not with an increased fracture risk [40]. Furthermore, fracture risk may also be affected 
by elevated homocysteine levels via poor physical performance, since this association is observed in 
several observational studies [41-43]. Within the B-PROOF study, physical performance and handgrip 
strength were indeed inversely associated with homocysteine levels, but only in women [44]. We do 
not have an explanation for the sex-specificity of this effect, but this interaction of physical performance 
with sex has been observed in another study as well [43].  
Consider the endpoints bone health and cognitive function and the conclusions emerging from our 
systematic reviews in Chapter 4 and 5, an intervention study such as the B-PROOF study is a logical 
next step. An intervention study could reveal whether B-vitamin supplementation is indeed the panacea 
it is suggested to be in observational studies.
B-pRoof, one of A kind
The B-PROOF study is the first RCT in a general elderly population investigating the effect of vitamin 
B12 and folic acid on fracture risk as a primary outcome. The only two other RCTs regarding this topic 
are inconclusive: the study of Sato et al. observed a large treatment effect in Japanese post stroke 
hemiplegia patients [6] and the HOPE-2 trial did not observe a treatment effect in a Western population 
with a high cardiovascular risk from countries with and without mandatory folic acid fortification [7] 
(Chapter 7).  
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The absence of a significant treatment effect in our study could have various reasons. First of all, it is 
possible that there is no effect of vitamin B12 and folic acid supplementation on fracture risk. It has been 
postulated, provoked by inconclusive findings from homocysteine lowering trials, that not an elevated 
homocysteine level itself is deleterious, but that it is a biomarker for ‘something else’, for example a 
low general nutritional status, well-phrased by Raisz as homocysteine being a ‘culprit or innocent 
bystander’ [45]. 
We observed a strong treatment effect in participants aged 80 years and older who were compliant to 
the study supplementation. This finding suggests that vitamin B12 and folic acid supplementation is 
genuinely beneficial for fracture prevention in elderly with an elevated homocysteine level. What could 
then have contributed to the absence of a significant overall effect? 
It could be possible that the study duration was not long enough. The intervention period was two 
years, with a one year extension for a subgroup consisting of almost 400 participants. In interventions 
on the effect vitamin D on fracture risk however, study duration ranged from 12 to 60 months [46]. 
Comparable sample size calculations and outcome estimations have been used in the vitamin D 
supplementation study of Chapuy et al. [47] which showed a significant fracture incidence reduction 
after 18 months of follow-up. Furthermore, Sato et al. achieved beneficial results after intervening for 
two years [6]. In addition, the treatment effect observed in elderly aged >80 years in the B-PROOF 
study suggests that a two year intervention is long enough.  
It is very well plausible that the study population was not sensitive enough. We observed less fractures 
than expected based on fracture incidence in Dutch elderly. It might be that our study population, 
except from having an elevated homocysteine level, is healthier than a random sample of Dutch elderly 
aged 65 years and older. This possible selection bias could be due to the fact that people who are willing 
to participate in a two year intervention study are the healthier part of the general population. People 
who beforehand perceive an intervention study as too burdensome and are therefore not willing to 
participate might be the people who have a higher a priori fracture risk and would theoretically benefit 
more from an intervention study such as the B-PROOF study. In addition, although homocysteine levels 
were elevated, the range was relatively small: 95% of our population had a homocysteine level between 
12.0 and 22.3 µmol/L. Regarding earlier observational evidence on associations of homocysteine levels 
with fracture risk [3, 48], it could well be that a threshold-effect exists. In both studies the association 
was present in the highest quartile of homocysteine levels compared to the lowest quartile [48] or 
lowest 3 quartiles combined [3]. Mean homocysteine levels in the highest quartile were in both 
studies higher than our median homocysteine level: 20.8 µmol/L (men) and 18.6 µmol/L (women) 
[48]; in the study of Van Meurs et al. quartiles were defined in a sex-specific and age-specific manner 
for five-year categories, mean values per quartile are therefore not provided in the article, but since 
mean homocysteine level ranged from 11.9 to 15.9 µmol/L in the total cohorts investigated and were 
higher in older age groups [3], one could but conclude that the highest quartile included people with 
homocysteine levels above our range of homocysteine levels.      
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The observation that in the intervention group more participants reported cancer incidence than in 
the control group was against our expectations, as meta-analyses, including up to 50,000 participants 
did not show negative effects of folic acid supplementation on cancer incidence [49-51]. We are still 
refining our analyses and we can neither confirm nor deny that the supplementation of vitamin B12 and 
folic acid had a negative effect on cancer progression in our study population. We should note however, 
that we observed no difference in mortality between the intervention groups.
The ambiguous role of folate, and especially synthetic folic acid in cancer development, and more 
specifically colorectal cancer development, has been topic of research in the last decade and there seems 
to be a dual role of folic acid in cancer: it may protect against the initiation of cancer, but facilitate the 
growth of neoplastic cells [52], questioning the value of folic acid supplementation.
When we designed our intervention study we chose a folic acid dose well below the safe upper level of 
1 mg. In the B-PROOF study we included vitamin B12 in the supplement because of its homocysteine-
lowering capacity, the generally low vitamin B12 status in elderly and the positive results from the Sato 
trial. The duration of our intervention, i.e., two years, is a time span very limited for a possible initiation, 
development and discovery of a cancer, especially colorectal cancer. It is therefore more plausible that 
folic acid supplementation in our study might have accelerated growth of already present tumors, but 
in this stage we can only speculate. 
Although folic acid is highly effective in lowering homocysteine levels, focusing on ways to lower 
homocysteine levels without the use of folic acid, such as supplementation with vitamin B6, B12 and 
possibly B2 might have more positive health effects, although further research is warranted.
In general, RCTs are needed to provide an evidence base for nutrient recommendations, which is still 
scarce in the case of homocysteine, vitamin B12 and folic acid in relation to bone health and cognitive 
function. 
Besides our speculations about the absence of an overall treatment effect in the B-PROOF study one 
could furthermore cautiously question the possibility that the absence of a significant health effect 
from homocysteine lowering trials is inherent in such a trial. The difficulty of obtaining evidence from 
RCTs in nutrition research has been acknowledged before, in general [53] and for homocysteine 
lowering RCTs [54]. Blumberg et al. emphasized why nutritional interventions are different from drug 
interventions, from which the need for evidence-based proof originates, the most important being: I) 
medical interventions are designed to cure a disease not produced by their absence, while nutrients 
prevent dysfunction that would result from an inadequate intake; II) drug effects can be tested against 
a non-exposed group, whereas it is impossible or unethical to attempt a zero intake group for nutrients; 
III) drug effects are generally expected to be large and with a limited scope of action, where nutrient 
effects are smaller, mainly within the range of biological variability and have a wide range of biochemical 
functions [53]. These differences complicate the establishment of evidence from RCTs that a nutrient 
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affects a health outcome. In addition, one has to take the specific shortcomings of homocysteine 
lowering RCTs in account, i.e., although there seems to be a linear association, the possibility that 
homocysteine levels are not elevated enough to show a treatment effect; a too short intervention 
period; the contrast between intervention and placebo group being too small (as point II mentioned 
above) and the potential adverse effects of folic acid [55]. Taken together these considerations it is very 
well plausible that the characteristics of the RCT study design itself contribute to the null findings in 
homocysteine lowering trials. We should therefore not ignore the vast body of observational research 
evidence regarding homocysteine, vitamin B12 and folate.
lost in translation? where are we and where are we going to? implications and 
outlook
We can conclude from the results of this thesis that further research is necessary, but what will be the 
next steps in research regarding homocysteine, vitamin B12 and folate in association with bone health 
and cognitive function? 
To start with, the B-PROOF study is a source of very relevant information. Besides the outcomes and 
associations described in this thesis, many other measurements were performed. Serum and plasma 
samples are available for further analysis of biomarkers, for example levels of vitamin B2 and B6, or 
metabolites in the homocysteine metabolism. Genetic aspects beyond the consideration of a single 
SNP, such as common genetic polymorphisms for homocysteine levels [56] could be studied in 
relation to fracture incidence. 
With respect to bone health, we measured, besides fracture incidence, physical performance, fall 
incidence and BMD, the latter in a subsample. Associations of homocysteine with these outcomes and 
the effect of vitamin B12 and folic acid supplementation could be investigated. In addition, plasma/
serum samples could be used for the determination of bone turnover markers. This would provide 
insight in levels of bone turnover markers in elderly and in changes in bone turnover markers induced 
by B-vitamin supplementation. Regarding cognitive function, the effect of 2-year supplementation 
of vitamin B12 and folic acid will be studied. We furthermore performed brain MRI measurements 
in 225 participants at the end of the intervention, which enables us to investigate differences in brain 
measures between participants in the intervention and placebo group. Last but not least, it would be 
highly relevant to follow the B-PROOF participants over a longer period regarding the occurrence 
of malignancies. Supplementation of a combination of 400 µg folic acid and 500 µg vitamin B12, as 
supplemented in the B-PROOF study, is currently not recommended for elderly, awaiting further 
analysis of our data.
In this thesis, we have considered bone health and cognitive function as two separate health outcomes, 
which is common in research investigating associations between exposures and health outcomes. 
Nevertheless, these health outcomes are intertwined, since physical performance affects cognitive 
function and vice versa. 
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A suggestion could be to combine these and other health outcomes related to homocysteine, vitamin 
B12 and folate into a ‘global health index’. Such a suggestion for the use of global indices as a primary 
health outcome in nutrition research has been proposed by Heaney [57]. Heaney acknowledges the 
association of a single nutrient with many health outcomes. A global index combining these health 
outcomes could improve power to detect differences that are relatively small, but summed up may 
be relevant and detectable. Although this approach clearly needs further substantiation, combining 
physical and cognitive performance into a single health outcome would be an interesting next step in 
research regarding homocysteine, vitamin B12 and folate status and health in elderly people. 
To conclude this thesis, our literature reviews and observational data confirm an association of 
levels of homocysteine, vitamin B12 and folate with cognitive function and fracture risk in elderly. 
Supplementation with vitamin B12 and folic acid did not lower the risk of fracture in the total study 
population. Though beneficial effects on fracture incidence emerged from elderly aged >80 years, these 
benefits should be weighed against potential risks.
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SAMenvATTing
Een verhoogd homocysteine gehalte in het bloed blijkt een risicofactor te zijn voor onder andere hart- en 
vaatzieken, cognitieve achteruitgang en fracturen. Omdat vitamine B12 en foliumzuur het homocysteine 
gehalte verlagen, zou suppletie met vitamine B12 en foliumzuur het risico op deze verschillende leeftijd 
gerelateerde aandoeningen kunnen verlagen en dientengevolge van substantieel belang kunnen zijn 
voor de volksgezondheid. 
Dit proefschrift richt zich op twee gezondheidsuitkomsten die in de wetenschappelijke literatuur vaak 
worden geassocieerd met een verhoogd homocysteine gehalte en lage gehaltes aan vitamine B12 en 
foliumzuur, namelijk: osteoporose en cognitieve achteruitgang bij ouderen. 
De inhoud van dit proefschrift is voornamelijk gebaseerd op het B-PROOF onderzoek. Het 
B-PROOF onderzoek is een grote, gerandomiseerde, dubbelblinde interventiestudie, uitgevoerd in 
drie verschillende onderzoekscentra: Wageningen University, Wageningen, VU medisch centrum, 
Amsterdam en Erasmus medisch centrum, Rotterdam. Het B-PROOF onderzoek is opgezet om het 
effect te onderzoeken van suppletie van vitamine B12 en foliumzuur gedurende twee jaar op het risico 
op fracturen bij ouderen (65 jaar en ouder) met een verhoogd homocysteine gehalte (≥12 µmol/L). 
Verder is de beschikbare wetenschappelijke literatuur over de associatie van vitamine B12, foliumzuur en 
homocysteine met cognitief functioneren en botgezondheid systematisch beschreven en waar mogelijk 
kwantitatief vergeleken in een meta analyse om een overzicht te geven van de beschikbare informatie. 
Deze reviews zijn geschreven in de context van het EURRECA (EURopean RECcomendations 
Alligned) Netwerk. Het EURRECA netwerk had als doel de methoden voor het afleiden van aanbevolen 
hoeveelheden voor micronutriënten binnen Europa te harmoniseren. Hierbij werd speciale aandacht 
gegeven aan aanbevelingen voor kwetsbare populatiegroepen zoals oudere mensen.
De opzet van het B-PROOF onderzoek is uitgebreid beschreven in Hoofdstuk 2. Bij aanvang van 
de studie zijn bloedmonsters verzameld en hebben de deelnemers (N=2919) vragenlijsten ingevuld 
over hun gezondheid en leefstijl. Verder ondergingen de deelnemers een uitgebreide screening met 
metingen op het gebied van antropometrie, cognitief functioneren en fysiek functioneren. Dit heeft 
geresulteerd in een uitgebreide dataset die is gebruikt om verschillende cross-sectionele associaties te 
beschrijven. 
In hoofdstuk 3 is bij aanvang van de B-PROOF studie in een subgroep van de onderzoekspopulatie 
de associatie onderzocht van de inname van vitamine B12 met 4 biomerkers voor vitamine B12 status 
(serum B12, holotranscobalamine (holoTC), methylmalonzuur (MMA) en homocysteine).  Serum B12 
en holoTC zijn zogenaamde circulatie biomerkers, die een directe weergave zijn van de vitamine B12 
status. MMA en homocysteine zijn zogenaamde metabole biomerkers, waarbij een verhoogde status 
een indicatie is voor een vitamine B12 tekort. Wij zagen dat een tweemaal zo hoge inname van vitamine 
B12 was geassocieerd met een 9% hogere serum B12 status, een 15% hogere holoTC status, een 9% lagere 
MMA status, en een 2% lagere homocysteine status. De biomerkers leken verzadigd bij een vitamine 
B12 inname boven de 5 microgram per dag; dat wil zeggen, de status veranderde niet boven een inname 
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van 5 microgram per dag. Verder bleek de status van de verschillende biomerkers met elkaar samen te 
hangen: de status van MMA en homocysteine zijn hoger bij serum B12 waarden lager dan 330 pmol/L 
en bij holoTC waarden lager dan 100 pmol/L, met een sterke verhoging bij serum B12 en holoTC 
waarden onder de, respectievelijk, 220 en 50 pmol/L. Deze waarden geven een aanwijzing vanaf welke 
biomerker waarden er mogelijk sprake is van een vitamine B12 tekort.
Het systematische literatuuronderzoek in Hoofdstuk 4 liet geen, of inconsistente associaties zien van 
vitamine B12 inname met cognitief functioneren. Verder bleek serum vitamine B12 niet geassocieerd 
te zijn met het risico op dementie, globaal cognitief functioneren of geheugen. Studies die MMA en 
HoloTC als biomarker onderzochten, rapporteerden significante associaties met dementie, de ziekte 
van Alzheimer en globaal cognitief functioneren. 
De meta-analyse van de beschikbare wetenschappelijke literatuur, beschreven in hoofdstuk 5, liet zien 
dat serum/plasma vitamine B12 (per 50 pmol/L) net niet significant geassocieerd was met een lager 
risico op fracturen (RR=0.96, 95% CI = 0.92-1.00) en dat homocysteine significant was geassocieerd 
met een hoger risico op fracturen (RR=1.04, 95% CI = 1.02-1.07). Meta-analyses naar de associatie 
tussen vitamine B12, foliumzuur, homocysteine en botdichtheid (BMD) lieten geen significante 
associatie zien. 
In hoofdstuk 6 is de associatie bekeken van de eerder genoemde vitamine B12 biomerkers en foliumzuur 
met cognitief functioneren bij aanvang van de B-PROOF studie. Serum B12 en holoTC waarden waren 
in geen enkel cognitief domein geassocieerd met het cognitief functioneren. De homocysteine status 
(β= -0.009), foliumzuur status (β= 0.002), MMA status (β= -0.163) en de ‘wellness-score’ – een 
combinatiescore voor vitamine B12 biomerkers – (β= 0.048) waren significant geassocieerd met het 
domein ‘episodisch geheugen’. Verder waren homocysteine status (β= -0.015) en de wellness-score (β= 
0.103) significant geassocieerd met het domein ‘snelheid van informatieverwerking’. 
Hoofdstuk 7 beschrijft het resultaat van het B-PROOF onderzoek. Dagelijkse suppletie van 400 
microgram foliumzuur en 500 microgram vitamine B12 gedurende twee jaar verlaagde het risico op 
fracturen niet in de algemene B-PROOF populatie (HR=0.84, 95% CI = 0.58-1.22) (intention-to-
treat). Subgroup-analyse (per-protocol) in ouderen ouder dan 80 jaar liet wel een significant lager 
risico op fracturen zien in de interventiegroep ten opzichte van de placebogroep (HR=0.28, 95% 
CI 0.10-0.74). In de interventie groep bleek de incidentie van kanker hoger dan in de placebogroep 
(HR=1.55, 95% CI = 1.04-2.30) en hoewel dit mogelijk een toevalsbevinding is, kan op basis van dit 
resultaat de mogelijkheid van een (versnelde) kankergroei als negatieve bijwerking van de vitamine B12 
en foliumzuur suppletie niet uitgesloten worden. 
De conclusie van het onderzoek in dit proefschrift is dat zowel de observationele data als het 
systematische literatuuronderzoek een associatie bevestigen van homocysteine, vitamine B12 en 
foliumzuur status met cognitief functioneren en risico op fracturen in ouderen. Suppletie met vitamine 
B12 en foliumzuur verlaagde het risico op fracturen echter niet in de algemene B-PROOF populatie. 
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Na 5 jaar hard werken is er een eind gekomen aan mijn promotieonderzoek! Voor alle proefschriften 
geldt natuurlijk dat de promovendus het werk niet alleen heeft gedaan, en in het kader van een groot 
interventie onderzoek als B-PROOF geldt dit al helemaal. De artikelen in dit boekje zijn eigenlijk maar 
een klein deel van werk wat ik de afgelopen jaren heb uitgevoerd. De meeste tijd en energie heb ik de 
afgelopen jaren besteed aan het uitvoeren van het B-PROOF onderzoek.  
Dank aan mijn begeleiders, Lisette en Rosalie! Dank dat jullie me vrij lieten in mijn aanpak van 
B-PROOF en richting gaven aan mijn schrijfsels. Ik heb me wel eens zorgen gemaakt of het allemaal wel 
zou lukken met B-PROOF, maar jullie hebben het keer op keer weer mogelijk gemaakt om B-PROOF 
te verlengen en uit te breiden. Lisette, dank voor je rustige en bedachtzame aanpak en dat ik op stap kon 
naar verschillende congressen, het motiveerde me en gaf me inspiratie om door te gaan. Rosalie, dank 
voor alles! Ik heb veel van je geleerd en ik vind het heel bijzonder hoe je altijd weer zorgt dat alles op de 
één of andere manier weer op z’n pootjes terecht komt.
Graag wil ik alle deelnemers van het B-PROOF onderzoek hartelijk bedanken voor hun deelname 
aan het onderzoek! Zonder u is het uitvoeren van belangrijk voedingsonderzoek niet mogelijk en ik 
waardeer uw enthousiaste en inzet bij uw deelname dan ook ontzettend.  
Graag wil ik Dr. Arie Kies en Professor Edith Feskens bedanken voor het plaatsnemen in mijn 
promotiecommissie. I would like to show my gratitude to Dr Sandra Iuliano and Professor Helga 
Resfum for coming all the way to the Netherlands to be part of the thesis committee!
Het B-PROOF team in Wageningen: allereerst Miranda, wat hebben we een werk verzet! Toen we 
begonnen konden we ons niet voorstellen dat het project ooit af zou komen...Dank voor al je inzet, het 
perfect regelen van alle bloedafnames en een fijne collega zijn. Paulette en Elske: dank! Verderop meer. 
Nikita, wat zouden we zonder je moeten... ogenschijnlijk relaxed pak je alles op wat er langs komt, je 
regelt alles en kan daarnaast de allerlekkerste cheesecake bakken ☺! Pauline, Anouk (Vaes), Agnes, 
Livia, Moniek, Jidi, jullie bijdrage was groot, dank! Studenten en tijdelijke medewerkers: Maëlle, 
Linde, Astrid, Dagmar, Martijn, Suzanne, Nasim, Carina, Jalien, Daniëlle, Ettje, Annelies, Rosa, Josje, 
Martine, Anouk (Halfweeg), Aafke, Marleen, Nienke, Annaleen, Annemarthe, Desirée, Dorien, Priya, 
Saimi, Anouk (Blom), Sofie en Rianne dank voor alle metingen, gestickerde buisjes, verwerkte post, 
telefoontjes, vragenlijsten invoeren, archiveren, sorteren etc... 
B-PROOF collega’s van het Vumc en Erasmus MC. Wat een project! Het was ontzettend leuk en 
leerzaam om te zien hoe verschillende teams met heel verschillende karakters samen zo’n groot project 
kunnen uitvoeren. Mede-aio’s Karin Swart en Anke Enneman: wauw! Wat hebben we constructief 
geschreven en geanalyseerd aan het ‘hoofdartikel’, het resultaat mag er wezen! We trekken al 5 jaar 
samen op en vormen een goed team-op-afstand. De andere aio’s, Suzanne van Dijk, Annelies Ham, 
Evelien Sohl, dank voor de constructieve samenwerking! Sandra Smits en Sadaf Oliai Araghi voor jullie 
interesse en samenwerking. Natasja van Schoor, Nathalie van der Velde, Paul Lips, André Uitterlinden: 
Bedankt voor de constructieve samenwerking en jullie input in mijn manuscripten, Carola Zillikens, 
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Joyce van Meurs, Hans Brug, Robert de Jonge: bedankt voor het meeschrijven aan een aantal van mijn 
artikelen.
Roy Kessels van UMC St. Radboud: bedankt voor de samenwerking op het gebied van cognitief 
functioneren. Op de één of andere manier schoof ‘het cognitie artikel’ steeds verder naar achteren in 
mijn planning, maar nu is het toch echt bijna af! 
Het lab van de afdeling Humane Voeding: Nhien, Tineke, Marlies, dank voor het analyseren van de 
eindeloze stroom aan B-PROOF samples! Paul, dank voor je hulp bij het interpreteren van cross-
calibraties, cv’s, afwijkende uitslagen, etc. Anita, dank voor de organisatie rondom de bloedafnames 
en bestellingen van diverse producten. Jantien, dank voor het screenen van alle binnengekomen 
aanmeldingen.
Lucy, Diana en Christof, bedankt voor alle bloedafnames! Daarnaast: Lucy, dank je wel voor je immer 
positieve blik en eindeloze lijst met deelnemers die je hebt ingepland voor de bloedafnames.
Karin (Borgonjen) en Corine  dank voor de randomisatie, het bewaken en onthullen van de 
behandelcodes en de opzet van de FFQ’s. Ook Saskia wil ik hiervoor bedanken. Els, bedankt voor alle 
bestelde broodjes, kaas, koffie en je geduld met al die onderzoeken die door elkaar lopen en niet altijd 
alles even netjes communiceren…  
Het secretariaat: Karen, Gabriëlle, Jacqueline, Jasmijn, Lous, Cornelia, Gea, Marie, dank voor  jullie 
hulp! Het uitsorteren van de enorme hoeveelheden binnenkomende post, het doorgeven van alle 
verdwaalde telefoontjes, en dat ik altijd kon binnenlopen voor een vraag of praatje.
Alex Griffioen: dank voor het ontwerpen van het B-PROOF logo, de folders en de website! Hanneke 
van Bladel: dank voor het leesbaar maken van de tekst van de informatiefolder en het deelnemerboekje.
Dione: Dank je wel voor het netjes houden van wervingsbestanden, voor je geduldige uitleg van 
Teleform, de wervingsmails, etc.  Jan Harryvan, dank voor je hulp bij diverse zaken en de prachtige 
foto’s! 
Michel Heusinkveld van de postkamer: dank voor het verwerken van de karrenvrachten (letterlijk!) 
B-PROOF post. 
Dank voor de medewerkers van de receptie van het Biotechnion voor het opvangen van verdwaalde 
deelnemers en het doorgeven van enorme bergen post.
Paul Smeets, dank voor het opstarten van de MRI-metingen. Wie weet wat voor moois daar nog uit 
gaat komen!
Ondine, dank je wel voor je tijd en interesse. Ik kon vaak bij je binnenlopen voor allerhande vragen. Met 
de MRI metingen ben je toch ook een beetje bij B-PROOF betrokken geraakt. 
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Janette: wat hebben we veel besproken! Het is alweer lang geleden dat ik bij je aanklopte met de vraag 
waar ik een weegschaal vandaan zou kunnen halen… Wat heb je me veel geleerd over het onderzoek 
doen en je ervaringen bij Alpha Omega, dank je wel! Fijn dat ik altijd even binnen kon lopen. Ook voor 
je hulp bij het schrijven van het analyseplan. Marianne, hiervoor ook dank aan jou!
Carla: we leerden elkaar kennen toen je interim coördinator bij B-PROOF werd. Ik heb veel van je 
geleerd en bewonder je gestructureerde, rustige aanpak. Dank je wel voor alles!
Naast B-PROOF heb ik ook nog aan het EURRECA project gewerkt. Ik heb hier ontzettend veel 
van geleerd over Europese samenwerking, meta-analyses en aanbevelingen. Pieter, Lisette, Adriënne 
Rosalie, Esmée, Carla, Olga, dank jullie wel voor de fijne samenwerking. Olga en Carla, dank voor 
jullie geduld bij de meta-analyse. Het had wat voeten in aarde, maar uiteindelijk is het een mooi paper 
geworden.  Thank you international EURRECA colleagues! It was a pleasure to attend the EURRECA 
weeks and to discuss with you the issues regarding meta-analyses. 
Eerste verdieping, voor zover nog niet genoemd: Elise, Victoire, Lisette, Truus, Coraline, Wieke, Linda, 
Dieuwertje, Marieke, Bianca, Sjoukje, Lisette, Renate, Fränzel, Anne (Wijlens). Dank voor alles! Het 
is fijn op ‘de eerste’. Vera, Diederik, Sanne, Pleunie, Akke, Cecile, Rianne, Nicole, Sandra (Crispim) en 
andere collega-aio’s: het was gezellig! 
Ik had eigenlijk minstens 5 paranimfen moeten hebben, maar daar was geen ruimte voor op het podium, 
helaas... Michael, het was gezellig en ik heb veel van je geleerd! wat timmer jij hard aan de weg! Respect 
voor hoe je constructief en gefocust met je onderzoek bezig bent, en daarnaast is het ook hartstikke 
gezellig om bij te praten en biertjes met je te drinken ☺. Esmée, Dr Doets, we hebben heel wat gezellige 
reisjes gemaakt, en je vond altijd tijd om even bij te kletsen. Wat bewonder ik je aanpak! Jouw naam 
staat vooraan in hoofdstuk vier en jij hebt hier ook verreweg het meeste voor gedaan. Fijn dat het in mijn 
boekje mag staan. Ik hoop dat we elkaar, nu we geen collega’s meer zijn toch nog regelmatig blijven zien. 
Elske, mijn SAS-goeroe ☺, dank je wel voor al je hulp, statistische adviezen, gezelligheid, kopjes thee 
en nuchtere kijk... Vanaf het begin dat je bij B-PROOF betrokken bent ben je van onschatbare waarde... 
onderschat je inbreng niet! Je bent een echte wetenschapper met oog voor detail en je wilt altijd weten 
hoe het werkt... Ik heb ontzettend veel van je geleerd. En dan mijn paranimfen: Anne, na 5 jaar ‘roomies’ 
te zijn geweest mis ik je behoorlijk – Mike is natuurlijk een goede vervanging, maar we hebben lief en 
leed gedeeld en ik vind het fantastisch dat je naast me staat op het podium. Paulette, wat fijn dat je er 
bent! Je hebt zo veel voor B-PROOF gedaan, al die metingen, planningen,  deelnemers te woord staan, 
kapotte BUA apparaten, studenten begeleiden etc, etc. en daarnaast was je een supergezellige collega, 
mijn dank is heel groot! Wie weet gaan we nog eens P&J clinical trial services oprichten ☺. 
Marius van Dokkum en de uitgever Art Unlimited, hartelijk dank voor het beschikbaar stellen van de 
prachtige afbeelding op de omslag! 
Het zou best kunnen dat ik een aantal personen vergeten ben te noemen, daarvoor alvast excuses en 
natuurlijk hartelijk dank voor je bijdrage aan B-PROOF en/of mijn proefschrift!
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Lieve vrienden en familie. Wieteke en Kars, Steph en Michiel, Marleen & Wietse, Willem en Els, Joost, 
Ans en Jasja (dank voor het maken van het metabolisme figuur!), Boudewijn en Marieke, Daniëlle en 
Jobbe, Markus, Sjoerd, Marta, Cathelijne, Robert en Gwen, Laura en Jan, Janneke en Enrico, Merel, 
oud-huisgenoten (en ‘aanhang’) van de Strijdkeet en anderen.  En alle bijbehorend kindjes die er de 
afgelopen jaren zijn bijgekomen… Wat fijn om jullie om me heen te hebben!    
Teus en Joke, dank voor de fijne bezoekjes en jullie interesse. Het is altijd gezellig om bij jullie langs te 
gaan. Mathieu en Mun Mun, ik kijk uit naar ons volgende weerzien. 
Lieve Albertdien en Johan, al bijna 33 jaar hebben jullie interesse in wat ik doe en wat me bezighoud. 
Jullie voelen feilloos aan als ik wel wat hulp kan gebruiken. Ik herinner me bijvoorbeeld wiskunde 
huiswerk en een afstudeerverslag bijvoorbeeld... En recent hebben jullie ingesprongen met oppassen, 
zodat ik nog even hard kon doorwerken. Jullie zijn fantastisch!
Rients, Renske, Tijn en Roos (en …?). Wat een schatten zijn jullie! Fijn dat jullie er zijn… En Rients, 
mijn werkstuk is nu echt af, wanneer komt die van jou? ;-)
Lieve Pap en Mam, wat zal ik zeggen… Dank jullie wel voor alles! Jullie hebben altijd het volste 
vertrouwen in mijn kunnen en staan achter mijn keuzes. Fijn dat ik altijd bij jullie terecht kan. Daarnaast 
genieten jullie heerlijk mee van de mooie dingen in ons leven, wat geweldig!
Lieve Linde, jij bent het mooiste wat me in de afgelopen jaren is overkomen. Ik vind het fantastisch om 
jouw mama te zijn en ik geniet er ontzettend van om jou de wereld te zien ontdekken.
En dan Walter, mijn lief… zou er dan nu, na bijna 8 jaar promotiestress wat rust in ons huisje neerdalen? 
Ik betwijfel het… We leven het leven wel! En wat is er de afgelopen jaren veel gebeurd… Dank je wel 
voor alles, voor je liefde, begrip en geduld, je oneindige vertrouwen in mijn kunnen, dat je altijd met een 
paar woorden me weer de goede richting op wijst, dat je zo veel hebt opgevangen in dit laatste drukke 
jaar, dat je zo’n fantastische papa voor Linde bent en dat je bij me bent. Ik kijk uit naar onze toekomst 
samen!    
Janneke
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